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ABSTRACT 
From the standpoint of public health, the purpose of chemical health risk 
assessment is to protect the susceptible individuals and to set up an action threshold against 
chemical hazards. Chemical toxicity is usually associated with toxicokinetics (absorption, 
distribution, metabolism, and excretion). One of the critical challenges in human health 
risk assessment is to address the inter-individual variability in metabolism and toxicity of 
chemicals. The inter-individual differences may be due to sex, genetics, dietary habits, 
and disease states. We hypothesized that the inter-individual variability in genetics and 
disease states could affect the xenobiotic metabolism, which in turn has pronounced 
impacts on individual susceptibility toward chemical exposures. Herein, we use two 
structurally similar chlorinated chemicals, trichloroethylene (TCE) and 
tetrachloroethylene (PCE), as model compounds. Organ-specific toxicities of TCE and 
PCE have been linked to their respective oxidative and glutathione (GSH) conjugation 
metabolism; however, little is known regarding GSH conjugation metabolism at target 
organs (i.e., liver and kidney) due to the lack of sensitive analytical assays. In this 
dissertation, we successfully developed two LC-MS/MS methods for simultaneous 
detection of GSH conjugation metabolites in multiple mouse tissues for TCE and. With 
these validated methods, we advanced our knowledge in metabolism and toxicity of TCE 
and PCE from several aspects. First, our data show that the default uncertainty factor of 
3.16 for the toxicokinetic variability of TCE GSH conjugation metabolites is inadequate 
to protect 99% of the population for organ-specific toxicity mediated by DCVG, DCVC, 
ii
iii 
and NAcDCVC. Second, we found that nonalcoholic fatty liver disease states can also 
influence the kidney metabolism and toxicity of PCE. Third, our results demonstrate that 
the oxidative enzyme, cytochrome P450 2E1, can alter not only the oxidative but also the 
GSH conjugative metabolism, which in turn have pronounced impacts on the organ-
specific toxicity of TCE and PCE. Finally, we observed that the one-atom replacement of 
chlorine can substantially affect the oxidative and GSH conjugative metabolism of TCE 
and PCE. Collectively, this doctoral dissertation advances our understanding of 
metabolism and toxicity of TCE and PCE, and provides data for more refined health risk 
assessment of TCE and PCE. 
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CHAPTER I 
INTRODUCTION 
1.1 Trichloroethylene (TCE) and tetrachloroethylene (PCE): Highlighted chemicals 
to be re-evaluated for their risks to environment and human health 
1.1.1 General use, sources of human and animal exposure 
Trichloroethylene (TCE) and tetrachloroethylene (PCE) are structurally-similar, 
chlorinated olefins that have been widely used in industrial applications, such as metal 
degreasing, dry cleaning, and chemical production (ATSDR, 2014;  ATSDR, 1997). The 
initial production of TCE for commercial uses in the USA can be traced back to 1925, 
with the increasing needs in vapor degreasing and dry cleaning industry. From the mid-
1950s, the use of TCE in dry cleaning has been replaced by PCE (IARC, 2014), although 
the current use of PCE in dry cleaning is also being phased out by the California EPA 
(EPA, 2017).  Even though the use of TCE and PCE has been reduced over decades, the 
environmental releases of these chlorinated olefins were approximately 2.22 million 
pounds for TCE and 0.8 million pounds for PCE in the USA in 2016, according to the 
EPA Toxic Release Inventory program (USEPA, 2018). Due to their high production 
volume and widespread use, both TCE and PCE are commonly found in ambient air, 
ground and drinking water (IARC, 2014), and frequently detected at the National Priority 
List sites in the United States (ATSDR, 2014;  ATSDR, 1997;  Fay and Mumtaz, 1996). 
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The exposure to TCE and PCE for the general population mainly occurs via inhalation 
or ingestion of drinking water (ATSDR, 2014;  ATSDR, 1997). Assuming an ambient 
TCE concentration range of 100-500 ppt and an adult breathing rate of 20 m3/day, the 
average daily intake of TCE through inhalation was estimated as 11-33 µg/day for the 
general population. The average daily intake of TCE through ingestion was 2-20 µg/day, 
assuming a concentration range of 2-7 ppb and total water consumption of 2 liters/day 
(ATSDR, 1997). On the other hand, the total daily intake of PCE was estimated in the 
range of 1.22 to 2.67 µg/body weight (bw) for the general population in Canada, where 
drinking water ingestion only account for a minor amount of the total exposure, estimated 
to be 0.002 to 0.06 μg/kg bw per day (CEPA, 1993). As indicated in 1999-2000 National 
Health and Nutrition Examination Survey (NHANES), the mean blood levels of these 
chlorinated olefins were 0.013 ng/mL in 290 subjects, with a detection rate of 11.6% for 
TCE, and 0.138 ng/mL in 276 subjects, with a detection rate of 77.3% for PCE (Jia et al., 
2012). In the most recent 2013-2014 NHANES, the mean blood levels of these chlorinated 
solvents were 0.010 ng/mL in 3103 subjects, with a detection rate of 0.6% for TCE, and 
0.05 ng/mL in 2970 subjects, with a detection rate of 7.4% for PCE (CDC, 2017). Besides, 
the detection rate of the urinary biomarker of TCE exposure, n-acetyl-s-(1, 2-
dichlorovinyl)-L-cysteine (NAcDCVC), was also extremely low (0.08%) with 2475 
subjects (CDC, 2017). The declines in the detection rates of TCE and PCE among the U.S. 
population demonstrate that the exposure of TCE and PCE to the general population had 
been substantially decreased, in line with the regulatory interventions. However, TCE and 
PCE remain to be environmental contaminants of high concerns at hazardous waste sites, 
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because that they show multi-organ toxicities in animals and humans, and that they are 
among the top 10 chemicals that EPA will evaluate for risks to human health under the 
new Frank R. Lautenberg Chemical Safety for the 21st Century Act (U.S. EPA, 2017).   
 
1.1.2 Potential health hazards of TCE and PCE to animals and humans 
TCE and PCE can pose both cancer and non-cancer hazards at multiple organs to 
humans and animals, as concluded by U.S. EPA (U.S. EPA, 2011b;  U.S. EPA, 2011c), 
IARC (IARC, 2014), and NTP (NTP, 2015). For cancer hazards, TCE was classified as a 
human carcinogen, based on the substantial evidence on kidney cancer and the limited 
evidence on non-Hodgkin lymphoma and liver cancer (Table 1.1). On the other hand, even 
though the carcinogenic evidence is sufficient in animals, there is no consistent 
epidemiologic data for the association between PCE and cancers. Therefore, PCE has been 
classified as a probable human carcinogen (Group 2A) by IARC.  
 
Table 1.1 Weight of evidence for the carcinogenicity of TCE and PCE at multiple 
organs  
  TCE PCE 
Target organ  Animal  Human  Animal  Human  
Liver  S L S N 
Kidney  S S L L 
Bladder N N N L 
Lung S N N L 
Immune system  L L S L 
Brain  N N L N 
Testis N N S N 
*S, Strong evidence; L, suggestive/limited evidence; N, no evidence 
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For non-cancer hazards, TCE exposure causes toxicities at multiple sites, such as liver, 
kidney, central nervous system, immune system, and male reproductive system(U.S. EPA, 
2011c). PCE exposure also induces toxicity at similar target sites, including liver, kidney, 
central nervous system, and developing fetus (U.S. EPA, 2011b). Despite both TCE and 
PCE can induce qualitatively-similar toxicities, the severity of these toxicities could be 
different. The toxicity and regulatory values for TCE and PCE are summarized in Table 
1.2, where TCE is considered more toxic than PCE in general.  
 
Table 1.2 Toxicity and regulatory values for TCE and PCE 
Institute, toxicity value TCE PCE 
EPA, oral slope factor 5×10-2 per mg/kg-day 2×10-3 per mg/kg-day 
EPA, inhalation unit risk 2×10-2 per ppm 2×10-3 per ppm 
EPA, RfD 5×10-4 mg/kg-day  6×10-3 mg/kg-day 
EPA, RfC 4×10-4 ppm 5.8×10-3 ppm 
ACGIH, TLV-TWA 10 ppm 25 ppm 
ATSDR, chronic inhalation 
MRLs 0.0004 ppm 0.04 ppm 
NIOSH-IDLH 1000 ppm 150m 
 
 
1.1.3 Target-organ metabolism and toxicity of TCE and PCE  
Upon absorption, both TCE and PCE can be metabolized through both oxidative and 
GSH conjugative pathways (Figure 1.1). For oxidative metabolism, both TCE and PCE 
are mainly oxidized by CYPs to form their respective epoxide intermediate and chloral 
hydrate (CH). These upstream metabolites can be further converted to several oxidative 
metabolites, where trichloroacetate (TCA) is thought to be the major oxidative metabolite 
of TCE and PCE. TCA is a known activator for peroxisome proliferator-activated receptor 
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α (PPARα), which may contribute to the liver carcinogenesis of TCE and PCE in mice 
(Corton, 2008). The other crucial oxidative metabolite, trichloroethanol (TCOH), is a 
TCE-specific metabolite that is formed through oxidation of TCE-epoxide to CH. TCOH 
can further conjugate with glucuronide via UDP-glucuronosyltransferases (UGTs) to 
generate TCOH-glucuronide conjugate (TCOG). These TCE-specific metabolites can be 
subject to enterohepatic recirculation and would be a significant source of TCA (Stenner 
et al., 1997). On the other hand, the subsequent oxidation of PCE-epoxide mainly occurs 
through trichloroacetyl chloride (TCAC), which further converts to the major metabolite 
TCA and minor metabolite DCA (Chiu et al., 2007).  
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Figure 1.1 Overview of the metabolic pathways of TCE and PCE (This figure is 
reprinted with permission from Oxford University Press, Luo et al., 2018 
(https://doi.org/10.1093/toxsci/kfy099 )). Upon absorption, TCE and PCE can either be 
oxidized via cytochrome P450s (CYPs) or conjugated with glutathione (GSH) via 
glutathione s-transferases (GSTs). Abbreviations: trichloroethylene, TCE; 
tetrachloroethylene, PCE; chloral hydrate, CH; trichloroethanol, TCOH; trichloroacetate, 
TCA; trichloroacetyl chloride, TCAC; trichloro-glucuronide conjugate, TCOG; 
dichloroacetate, DCA; S-(1,2-dichlorovinyl)-glutathione, DCVG; S-(1,2-dichlorovinyl)-
cysteine, DCVC; N-acetyl-S-(1,2-dichlorovinyl)-cysteine, NAcDCVC; S-(1,2,2-
trichlorovinyl)-glutathione, TCVG; S-(1,2,2-trichlorovinyl)-cysteine, TCVC; N-acetyl-
S-(1,2,2-trichlorovinyl)-cysteine, NAcTCVC; gamma-glutamyl transferase, GGT; 
dipeptidase, DP; n-acetyl transferase, NAT; flavin monooxygenase, FMO; cysteine 
conjugate beta-lyase, CCBL.  
 
 
In addition to the oxidative metabolism, both TCE and PCE can conjugate with 
glutathione (GSH) by glutathione-s-transferases (GSTs) to generate their respective 
dichloro- and trichloro- GSH conjugates (DCVG and TCVG), which can be further 
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metabolized by renal and hepatic gamma-glutamyl transferases (GGTs) and dipeptidases 
(DPs) to their corresponding cysteine conjugates (DCVC and TCVC). These cysteine 
conjugates are then either detoxified through n-acetylation by n-acetyltransferases (NATs) 
to NAcDCVC and NAcTCVC, or further bio-activated via cysteine conjugate β lyase 
(CCBL), Flavin-monooxygenase (FMO), or CYPs to form reactive species such as 
thioketenes and sulfoxides. These and other reactive species generated from GSH 
conjugation are thought to be significant contributors to the nephrotoxicity of TCE and 
PCE (Lash and Parker, 2001;  Lash et al., 2007;  Lash et al., 2003).      
Target-organ toxicity of TCE and PCE (i.e., liver and kidney toxicity) is thought to be 
determined by their target-organ metabolism in humans and animals. For instance, both 
TCE and PCE can induce liver tumors in mice. The hepatocarcinogenesis of TCE and PCE 
has been attributed to their oxidative metabolites, TCA and DCA, as they are known 
PPARα activators that may induce cell proliferation in mouse liver (Maloney and 
Waxman, 1999). Aside from TCA and DCA, T/PCE-epoxide, CH, and TCAC are 
proposed metabolites that contribute to liver toxicity and carcinogenicity of TCE and PCE 
(U.S. EPA, 2011b;  U.S. EPA, 2011c). CH is a known genotoxicant that can induce 
aneuploidy (Sbrana et al., 1993). Interestingly, TCOH--- the downstream metabolite 
comes from CH, is consistently detected in TCE-exposed but not in PCE-exposed humans 
and animals (Chiu, et al., 2007;  U.S. EPA, 2011b). On the other hand, reactive species 
generated from GSH conjugation pathway may contribute to kidney toxicity and 
carcinogenicity of TCE and PCE. Cell-based assays have demonstrated the genotoxicity 
(Dekant et al., 1986;  Vamvakas et al., 1989a;  Vamvakas et al., 1988;  Vamvakas et al., 
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1989b) and nephrotoxicity (Lash et al., 2001b) for DCVG/DCVG and TCVG/TCVC. 
With metabolic-activation by using kidney subcellular fractions, DCVG and DCVC 
further manifested enhanced genotoxic responses (Vamvakas, et al., 1988). The reactive 
sulfoxides derived from cysteine conjugates of TCE and PCE, DCVCSO and TCVCSO, 
showed a stronger mutagenic activity compared to DCVC and TCVC in the Ames 
Salmonella typhimurium TA100 strain (Irving and Elfarra, 2013). As the high expressions 
of GGTs and DPs (Fagerberg et al., 2014) in kidney, kidney toxicity of TCE and PCE has 
been attributed to cysteine conjugates of TCE and PCE, and their bio-activated species. 
However, most of the studies on cysteine conjugates of TCE and PCE were conducted in 
vitro. Further in vivo evidence would advance our knowledge on the development of TCE 
and PCE-induced kidney toxicity in humans and animals.  
The other hypothesis for TCE-induced kidney toxicity is through the formation of CH 
metabolite, TCOH, which has been shown to induce formic acid excretion, cell replication, 
protein accumulation and increased tubular regeneration in the cortex of rat kidney (Green 
et al., 2003). TCE also induces formic aciduria in F344 rats (Yaqoob et al., 2013) and 
C57BL/6OlaHsd mice (Lock et al., 2017). However, opposite result on TCOH and kidney 
toxicity was also reported (Yaqoob et al., 2014). Although TCOH alone does not 
sufficiently account for TCE-induced renal effects (U.S. EPA, 2011c), this TCE-specific 
metabolite may explain, at least in part, the stronger weight of evidence of kidney cancer 
for TCE compared to PCE.  Further studies are required to clarify the role of TCOH in 
developing the kidney toxicity of TCE.       
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1.2 Inter-individual variability in metabolism and toxicity of environmental 
toxicants: TCE and PCE as model compounds 
The purpose of chemical health risk assessment is to set up an action threshold against 
environmental and occupational exposures of chemicals. By setting up the action 
thresholds, we anticipate that most of the general population can be protected from the 
adverse responses of chemical exposures. Therefore, determining the susceptible 
individuals among the general population is critical to the health risk assessment of 
chemicals.  
The inter-individual differences in responses to pharmaceuticals (Cattaneo et al., 2016;  
Harrill et al., 2009;  Tracy et al., 2016) mainly arise from the differences in 
pharmacokinetics (i.e. absorption (AboulFotouh et al., 2018), distribution, metabolism 
(Shirasaka et al., 2016;  Tracy, et al., 2016), and excretion (Wijma et al., 2018)). Several 
factors, including genetics, sex, age, diet, tobacco smoking, chemical co-exposures, and 
pre-existing disease states (Thummel and Lin, 2014;  Zeise et al., 2013), may influence 
the pharmacokinetics of drugs and toxicokinetics (TKs) of environmental toxicants, which 
in turn further elicit differences in therapeutic responses and/or toxicities. In this 
dissertation, we will probe the inter-individual variability in genetics, enzyme expression, 
and disease state on TKs and TDs of environmental chemicals. 
The activity of enzymes from CYP family, the most important drug-metabolizing 
enzymes, showed a high degree of inter-individual variability (8-158 fold) in human liver 
from 27 individuals (Thummel and Lin, 2014). CYPs may reduce or enhance the toxicity 
of xenobiotic chemicals, depends on the mode of action for chemical toxicity. If the 
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chemical has direct toxicity (e.g., terfenadine (Kivisto et al., 1994)) and the P450-
generated product is less toxic, then CYP-mediated metabolism may reduce toxicity. On 
the other hand, if the chemical toxicity is exhibited through bio-activation to generate 
reactive species that can either (i) form covalent binding to macromolecules or (ii) 
interacts with molecular targets to cause toxicity, then CYP-mediated metabolism may 
enhance toxicity (Guengerich, 2001). Typical examples include hexane (Stclair et al., 
1988), butadiene (Goggin et al., 2009), and TCE and PCE (Cichocki et al., 2016). 
Considering the dual functions of CYPs in developing chemical toxicity, the inter-
individual variability in expression of CYPs is critical to identifying the susceptible 
individuals towards the exposures of xenobiotic chemicals. 
Different disease states may also alter the TKs of the xenobiotic chemicals, which in 
turn translate into the inter-individual variability in responses. Nonalcoholic fatty liver 
disease (NAFLD) represents a disease spectrum for a prevalent disease in developed 
countries. NAFLD initially presents as nonalcoholic fatty liver (NAFL) and can progress 
to nonalcoholic steatohepatitis (NASH), as characterized by hepatic inflammation, hepatic 
injury, and concomitant NAFL (Chalasani et al., 2012). NAFLD has been shown to alter 
the expression of transporter and metabolism genes in the liver (Cichocki et al., 2017a;  
Cichocki et al., 2017b;  Hardwick et al., 2014;  Uno et al., 2018), which can affect the 
delivered dose of xenobiotics to this organ and others. The different delivered doses may 
further alter target-organ toxicities of xenobiotics. 
As discussed above, TCE and PCE can induce multi-organ toxicities, which are 
associated with their respective oxidative and GSH conjugative metabolism. The multi-
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organ toxicity and the well-characterized metabolism make TCE and PCE the ideal 
compounds for studying inter-individual variability in metabolism and toxicity of 
environmental toxicants. In this dissertation, by using TCE and PCE as model compounds, 
we will address the effects of genetics, critical metabolic enzyme, and disease states on 
TKs and TDs of environmental toxicants.    
 
1.3 Current challenges in studying inter-individual variability in metabolism and 
toxicity of TCE and PCE  
Several challenges exist for the studies on inter-individual variability in metabolism 
and toxicity of TCE and PCE. First, little is known regarding PCE GSH conjugative 
metabolism in vivo due to lack of sensitive analytical assays. Second, even though 
analytical methods for simultaneous detection of DCVG and DCVC in mouse tissues do 
exist (Kim et al., 2009a;  Yoo et al., 2015a;  Yoo et al., 2015b), the inconsistency of 
extraction protocols has confounded cross-tissue comparison. In addition, the limited 
sensitivity of current analytical assay has hindered the characterization of inter-tissue and 
inter-strain variability in GSH conjugative metabolism of TCE. Third, despite the effects 
of NAFLD on liver metabolism and toxicity of PCE have been reported (Cichocki, et al., 
2017a;  Cichocki, et al., 2017b), little is known regarding the effects of NAFLD on kidney 
metabolism and toxicity of PCE. Forth, in vivo contribution and inter-species differences 
of CYP2E1 in TKs and TDs of TCE and PCE remains unclear. Even though previous 
studies have shown that both hepatotoxicity and production of oxidative metabolites were 
ameliorated in male CYP2E1 knockout (Cyp2e1(-/-)) mice (Kim and Ghanayem, 2006;  
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Ramdhan et al., 2008), the exact role of CYP2E1 in TCE TKs is not well understood. 
Besides, to the best of our knowledge, no study has examined the metabolism and toxicity 
of PCE in Cyp2e1(-/-) or humanized CYP2E1 (hCYP2E1) mice. At last but not least, 
though deemed to be similar based on chemical structures, the TKs of TCE and PCE, and 
their respective metabolites, have not been directly compared.     
 
1.4 Specific aims 
To expand our understanding regarding T/PCE GSH conjugative metabolism in vivo, 
we aim to develop LC-MS/MS methods for simultaneous detection of D/TCVG, D/TCVC, 
and NAcD/TCVC in multiple mouse tissues (Specific Aim 1&2). By these methods, our 
first goal is to fully characterize the inter-tissue and inter-strain variability in TCE GSH 
conjugative pathway and to derive the chemical-specific uncertainty factors for TK 
variability in mouse tissues (Specific Aim 2). Next, we would examine how extrinsic 
(diet-induced disease states, Specific Aim 3) and intrinsic factors (endogenous expression 
and activity of CYP2E1, Specific Aim 4) affect the metabolism and toxicity of 
xenobiotics, using TCE and PCE as model compounds. To fill in the data gap that lies in 
the similarities and differences between TCE and PCE, we further aim to compare their 
TKs with an identical study design (Specific Aim 5). 
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CHAPTER II  
 
SIMULTANEOUS DETECTION OF THE TETRACHLOROETHYLENE 
METABOLITES S-(1,2,2-TRICHLOROVINYL)GLUTATHIONE, S-(1,2,2-
TRICHLOROVINYL)-L-CYSTEINE, AND N-ACETYL-S-(1,2,2-
TRICHLOROVINYL)-L CYSTEINE1 
 
 
2.1 Overview 
Tetrachloroethylene (perchloroethylene; PCE) is a high-production volume 
chemical and a ubiquitous environmental contaminant that is hazardous to human health. 
Toxicity of PCE is mediated through oxidative and glutathione conjugation metabolites. 
The conjugation of PCE by glutathione-s-transferase to generate S-(1,2,2-trichlorovinyl) 
glutathione (TCVG), which is subsequently metabolized to form S-(1,2,2-trichlorovinyl)-
L-cysteine (TCVC) is of special importance to human health. Specifically, TCVC can be 
metabolized to N-acetyl-S-(1,2,2-trichlorovinyl)-L-cysteine (NAcTCVC) which is 
excreted through urine, or to electrophilic metabolites that are nephrotoxic and mutagenic. 
Little is known about toxicokinetics of TCVG, TCVC, and NAcTCVC as analytical 
methods for simultaneous determination of these metabolites in tissues have not yet been 
                                                 
1 The text of this chapter is an Author’s Original Manuscript of an article published by Taylor & Francis 
Group in the Journal of Toxicology and Environmental Health, Part A on 11 July 2017, available online: 
https://doi.org/10.1080/15287394.2017.1330585 
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reported. Hence, we aimed to develop an ultra-high performance liquid chromatography 
electrospray ionization tandem mass spectrometry-based method for analysis of TCVG, 
TCVC, and NAcTCVC in liver, kidney, serum, and urine. We show that the method is 
rapid, sensitive, robust, and selective for detection all three analytes in every tissue 
examined, with limits of detection ranging from 1.8-68.2 femtomoles on column, 
depending on the analyte and tissue matrix. We also demonstrated that this method can be 
applied to quantify levels of TCVG, TCVC, and NAcTCVC in tissues from mice treated 
with PCE (10 to 1000 mg/kg, orally) with limits of quantitation of 1-2.5 pmol/g in liver, 
1-10 pmol/g in kidney, 1-2.5 pmol/mL in serum, and 2.5-5 pmol/mL in urine. This method 
is useful for further characterization of the glutathione conjugative pathway of PCE in 
vivo and improved understanding of PCE toxicity. 
 
2.2 Introduction 
Tetrachloroethylene (perchloroethylene; PCE) is a high-production volume 
chlorinated olefin solvent with wide-ranging industrial applications, which include dry 
cleaning, metal degreasing, and chemical synthesis; however, the use of PCE in dry 
cleaning has been curtailing in the United States since 2006. Exposure to PCE is common 
in humans because PCE is difficult to remediate from contaminated sites and it is a 
ubiquitous contaminant of soil, ground and drinking water, and air (IARC, 2014). PCE is 
also one of the most commonly found contaminants at hazardous waste sites(National 
Research Council, 2010). Federal and international regulatory agencies are concerned 
about understanding PCE toxicity (IARC, 2014;  U.S. EPA, 2011b) and PCE is among the 
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first 10 chemicals that EPA will evaluate for risks to human health under the new Frank 
R. Lautenberg Chemical Safety for the 21st Century Act (U.S. EPA, 2017).  
In both rodents and humans, the liver and kidney are main target organs for cancer 
and non-cancer effects of PCE; however, few studies have examined PCE toxicity 
(Cichocki, et al., 2016;  Lash et al., 2002). The liver and kidney bioactivate PCE to 
reactive metabolites in situ through both oxidative and conjugative metabolic pathways 
(Guyton et al., 2014;  Lash and Parker, 2001). Oxidation of PCE yields trichloroacetate 
(TCA) as the primary metabolite and is thought to occur mostly via hepatic cytochrome 
P450s (Cichocki, et al., 2016). PCE is also conjugated with glutathione (GSH) via hepatic 
or renal glutathione-S-transferases (GSTs) to form S-(1,2,2-trichlorvinyl) glutathione 
(TCVG)(Dekant, 1993;  Lash and Parker, 2001). TCVG can be further metabolized in the 
kidney by gamma-glutamyl transferase (GGT) and dipeptidase to form S-(1,2,2-
trichlorovinyl)-L-cysteine (TCVC). TCVC can either be detoxified via N-
acetyltransferases to N-acetyl-S-(1,2,2-trichlorovinyl)-L-cysteine (NAcTCVC), 
bioactivated to 1,2,2-trichlorovinylthiol via cysteine conjugate β-lyase, or to TCVC 
sulfoxide via flavin-containing monoxygenase 3 and cytochrome P450s (Ripp et al., 
1997). Both 1,2,2-trichlorovinylthiol and TCVC sulfoxide can spontaneously form a 
reactive thioketene which can adduct to DNA and proteins(IARC, 2014). PCE metabolites 
from the GSH conjugation pathway are cytotoxic in vitro (Birner et al., 1997;  Irving and 
Elfarra, 2013;  Lash, et al., 2002)and nephrotoxic in vivo (Birner, et al., 1997;  Elfarra and 
Krause, 2007). They are also mutagenic (Irving and Elfarra, 2013;  Vamvakas, et al., 
1989a;  Vamvakas, et al., 1989b). Therefore, determining tissue-specific levels of these 
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metabolites is critical to establishing concentration-response relationships for PCE 
exposure and effects (Cichocki, et al., 2016). 
The quantification of TCVG in in vitro experiments using isolated rodent 
hepatocytes, renal cortical cells, and/or subcellular fractions has been described (Lash et 
al., 1998). The development of a method that can simultaneously detect TCVG, TCVC, 
and NAcTCVC in multiple tissues from animals and humans is hindered by their very low 
abundance as compared to oxidative metabolites of PCE (Chiu and Ginsberg, 2011). Still, 
characterization of the flux of PCE to nephrotoxic (TCVG, TCVC, or their distal 
metabolites) or n-acetylated (NAcTCVC) metabolites is needed to fill a critical data gap 
and improve public health assessments of PCE.  
To this end, a method for extraction and quantification of TCVG, TCVC, and 
NAcTCVC in multiple tissues was developed. Efficient extraction of these analytes was 
achieved by solid-phase extraction (SPE). By coupling reverse-phase ultra-high 
performance liquid chromatography (UPLC) to electrospray ionization tandem mass 
spectroscopy (MS/MS), levels of all three PCE conjugates were simultaneously quantified 
from a relatively small amount of biological material (50 mg or µL of tissue). This method 
proved to be sensitive, robust, and precise, and was utilized to quantify levels of TCVG, 
TCVC, and NAcTCVC in a series of studies in mice. This method will be useful for future 
animal and human studies. 
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2.3 Methods 
2.3.1 Chemicals 
2-amino-5-[(1-{[(13C)carboxy(13C)methyl](15N)amino}-1-oxo-3-
[(trichloroethenyl)sulfanyl]propan-2-yl)amino]-5-oxopentanoic acid (TCVG*, purity: 
90.4%),  2-(15N)amino-3-[(trichloroethenyl)sulfanyl](13C3)propanoic acid (TCVC*, 
purity: 97.5%), and 2-[acetyl(15N)amino]-3-[(trichloroethenyl)sulfanyl](13C3)propanoic 
acid (NAcTCVC*, purity: 99.0%) were used as internal standards (I.S.) for TCVG, TCVC, 
and NAcTCVC, respectively. TCVG (purity: 98.9%), TCVC (purity: 98.4%), and all 
stable isotopically-labeled I.S. were synthesized and provided by Dr. Avram Gold at the 
University of North Carolina, Chapel Hill, NC. Purity of the synthetized standards was 
determined using HPLC-UV/Vis (Thermo Fisher Scientific, Waltham, MA) detection in 
a full scan mode for the wavelength range from 190 to 600 nm followed by a detection at 
the wavelength set at 254 nm (Figure A-1). NAcTCVC (CAS:111348-61-9, reported 
purity: 99.7%) was obtained from Toronto Research Chemicals (Toronto, Canada). 
 
2.3.2 Animals and treatments 
Two studies were conducted to collect tissues for these experiments. Both used 
male C57BL/6J mice (6-8 weeks of age) from the Jackson Laboratory (Bar Harbor, ME). 
Animals were acclimated for 1 week before treatments. All animal treatments and 
procedures were approved by the Institutional Animal Care and Use Committee at Texas 
A&M University. 
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In the first study, mice were intragastrically dosed with 0, 100, 300, or 1000 mg/kg 
PCE (5 mL/kg in 5% alkamuls-EL620 in saline) via gavage (n=3/group). These doses 
were selected based on previous studies in mice that showed saturation of PCE oxidative 
metabolism at similar doses (Buben and O'Flaherty, 1985;  Philip et al., 2007); thus, we 
aimed to determine whether GSH conjugation metabolism of PCE might be also saturated 
at these doses. In addition, this dose range was used in a chronic cancer bioassay via oral 
exposure to PCE in mice (National Toxicology Program, 1977). Mice were euthanized 
two hours after gavage and blood and organs were snap-frozen for determination of 
metabolites. As no other study has examined PCE metabolism through the GSH pathway 
in vivo, we selected the two hour time point based on studies of toxicokinetics of the 
conjugative metabolites of trichloroethylene (Bradford et al., 2011;  Kim et al., 2009b;  
Yoo et al., 2015c), a chemical which is structurally similar to PCE.  
In the second study, to characterize the urinary excretion of the GSH conjugation 
metabolites of PCE, mice were intragastrically dosed with 10, 100, or 1000 mg/kg PCE in 
a vehicle detailed above and then housed in metabolic cages (Hatteras Instruments, Cary, 
North Carolina) for collection of urine into a chilled container over a 24 hr period (n=3 
per group).  
 
2.3.3 Tissue Processing  
Serum (50 µL) was thawed on ice, spiked with 10 pmoles of each internal standard, 
and then mixed with 100 µL of methanol to precipitate protein. The sample was then 
vortexed and centrifuged (14,000 g, 5 min, 4 oC). The supernatant was diluted with 850 
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μL of distilled deionized water prior to SPE. Liver or kidney (50 mg) was spiked with 10 
pmoles of each internal standard, and then homogenized in 200 µL of methanol and 200 
µL of chloroform using stainless steel beads in a Bead Ruptor 24 (Omni Inc, Kennesaw, 
GA) for 30 seconds at 4 m/s. Homogenates were centrifuged (10,000 g, 5 min, room 
temperature), the supernatant was vortexed with 1000 µL of water and centrifuged again 
(10,000 g, 5 min, room temperature). The supernatant was used for SPE (see below). Urine 
(50 μL) was spiked with 10 pmoles of each internal standard, and then mixed with 100 μL 
of methanol for protein precipitation. The sample was then vortexed and centrifuged 
(10,000 g, 5 min, room temperature). The supernatant was diluted with 350 μL of 
ammonium formate buffer (15 mM, pH=7) for direct LC-MS/MS analysis without the use 
of SPE. 
 
2.3.4 Solid Phase Extraction (SPE)  
Strata-X-AW (cat no. 8E-SO38-TGB, sorbent lot no. S308-0066; Phenomenex, 
Torrance, CA) 96-well SPE cartridges were used to trap the anionic analytes. Cartridges 
were conditioned with 600 µL acidified methanol (0.1% acetic acid, v:v) and equilibrated 
with UPLC-grade water (600 µL), no vacuum was applied to the SPE manifold and 
reagents were allowed to flow through via gravity. Samples were then loaded onto 
cartridges and washed with 300 µL water. Analytes were eluted with 300 µL basified 
methanol (pH 10.8 via NH4OH) under gravity; at the end of the procedure, gentle vacuum 
(650 mBa) was applied to capture as much sample as possible. The entire eluent was 
transferred to a 1.5 mL microcentrifuge tube and was taken to dryness in vacuo; typically, 
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an overnight drying was necessary in the vacuum concentrator at room temperature. The 
residue was reconstituted in 50 µL of water: methanol (80:20, v:v) containing 0.1% acetic 
acid and transferred to an autosampler vial. Samples were stored at or below -20oC prior 
to analysis. 
 
2.3.5 UPLC parameters  
Samples were maintained at 4oC in the auto-sample manager of a Waters Acquity 
H-class UPLC (Waters, Milford, MA) during analyses. Samples (10 µL) were 
automatically injected into the UPLC and were chromatographed on a ZORBAX SSHD 
Eclipse Plus C18 column (3.0x50 mm, 1.8 μm, cat no. 959757-302; Agilent, Santa Clara, 
CA) with a guard column (2.1x5 mm, 1.8 μm, cat no.821725-901; Agilent, Santa Clara, 
CA). For each sample analysis, initial chromatographic conditions were 80% solvent A 
(water with 0.1% formic acid) and 20% solvent B (methanol with 0.1% formic acid). 
Conditions were maintained from 0-1 min, then increased to 90% of solvent B by 3 mins, 
then to 98% of solvent B by 4 mins, then to 20% of solvent B by 4.2 mins. Then, 20% of 
solvent B was maintained until 7 mins to allow sufficient equilibration time prior to the 
next injection. Flow rate was maintained at 0.4 mL/min. Column temperature was 
controlled at 25oC.  
 
2.3.6 MS/MS parameters  
An Agilent 6470 triple-quadrupole mass-spectrometer was used for all analyses. 
To optimize the MS/MS parameters for each analyte, pure material was dissolved in 
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mobile phase and directly injected (column off-line) into the MS at the flow rate of 0.5 
mL/min (methanol:water, 50:50, v: v, containing 0.1% formic acid). The Optimizer Tool 
(MassHunter, ver. B.08.00) on the Agilent software was used to achieve optimization of 
the fragmentor, collision energy, cell accelerator voltage, and mass transition for each 
analyte (Table B-1). Capillary voltage, sheath gas pressure, sheath gas temperature, and 
capillary temperature were optimized manually along with real chromatographic condition 
(column in-line, Table B-2-5).  
 
2.3.7 Method Validation  
Matrix-matched calibration curves were prepared with serum, urine, liver, and 
kidney obtained from untreated mice. Blank serum (50 μl), urine (50 μl), liver (50 mg), or 
kidney (50 mg) was spiked with standards for TCVG, TCVC (both at 0, 0.25, 0.5, 1.25, 
2.5, 6.25, 18.75, and 31.25 pmoles), and NAcTCVC (0, 0.5, 1.25, 2.5, 6.25, 18.75, and 
31.25 pmoles). All standard solutions were also spiked with 10 pmoles of each internal 
standard. Quantitative analysis was achieved by using the peak area ratios of standards 
and internal standards.  
Selectivity of the method was determined by using tissues obtained from six 
different animals. Sensitivity was defined as a limit of detection (LOD, the concentration 
with signal to noise ratio of 3), and a lower limit of quantification (LLOQ, the lowest 
concentration to be quantifiable at 20% of precision and accuracy). Sample to sample 
carry-over effect, as well as inter-channel cross talk were tested by using the highest 
concentration in the calibration curve.  
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Intra-day precision and accuracy (six injections per matrix and concentration) were 
evaluated by using serum, urine, liver, and kidney obtained from untreated mice spiked 
with TCVG, TCVC (both at 0.25, 2.5, and 25 pmoles), and NAcTCVC (2.5 and 25 
pmoles). Inter-day precision and accuracy were further assessed in six consecutive days. 
Recovery (RE%), matrix effect (ME%), and process efficiency (PE%) were calculated as 
detailed elsewhere (Matuszewski et al., 2003).  
Freeze and thaw stability, short-term stability, long-term stability, and on-tray 
stability of TCVG, TCVC, and NAcTCVC were evaluated by comparing peak areas of 
extracted samples before and after each test condition. Three freeze-thaw cycles at -20oC 
were applied to test the freeze and thaw stability. Samples were placed at room 
temperature for 4 h to evaluate short-term stability. For long-term stability, samples were 
stored at -20oC for 30 days. On-tray stability was evaluated at 4oC for 6 h. Stability of 
stock solutions was evaluated after they were placed at room temperature for 6 h.  
 
2.3.8 Statistical analyses 
GraphPad Prism (ver. 5, GraphPad Software, La Jolla, CA) was used to conduct one-way 
ANOVA and post-hoc tests. A p-value of less than 0.05 was considered significant in all 
analyses. 
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2.4 Results and Discussion 
2.4.1 Product ion transitions and MS/MS parameters 
Product ion spectra of all standards were obtained in positive ion mode via direct 
injection without a column (Figure 2.1). The precursor ion (M+H)+ of TCVG is m/z 436, 
which is consistent with the chemical structure of TCVG and with previous report. 
Fragment ions of TCVG include m/z 307 by loss of trichloroethenyl moiety, m/z 290 by 
loss of γ-glutamyl moiety, and m/z 361 by loss of glycine moiety. The precursor ions for 
TCVC and NAcTCVC were determined experimentally. For TCVC, the precursor ion is 
m/z 250. Fragment ions of TCVC include m/z 233 by loss of an ammonium group, m/z 
203.8 by loss of a carboxyl group, and m/z 160.8 by loss of a trichloroethenylthiol group. 
The precursor ion of NAcTCVC is m/z 292. Fragment ions include m/z 232.9 by loss of 
an acetylamine group, m/z 250 by loss of an acetyl group, and m/z 203.9 by loss of an 
acetyl and a carboxyl group. The quantifier and qualifier ion transitions of each analyte 
are summarized in Table 2.1. 
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Figure 2.1 Product ion spectra of (A) TCVG (left) and TCVG* (right), (B) TCVC 
(left) and TCVC* (right), and (C) NAcTCVC (left) and NAcTCVC* (right). The 
precursor ion (M+H+) of TCVG is m/z 436. Fragment ions of TCVG include m/z 307 (-
C2Cl3), m/z 290 (-C5H9N2O3), and m/z 361(-C2H4NO2). (B) The precursor ion 
(M+H+) of TCVC is m/z 249.9. Fragment ions of TCVC include m/z 233 (-NH3), m/z 
203.8 (-COOH), and m/z 160.8 (-C2Cl3S). (C) The precursor ion of NAcTCVC is m/z 
291.9. Fragment ions include m/z 232.9 (-C2H4NO), m/z 250 (-C2H3O), and m/z 203.9 
(-C2H3O and –COOH). TCVG*, TCVC*, and NAcTCVC* share the identical 
fragmentation with their corresponding unlabeled standard. 
 
 
Considering the natural abundance of chlorine isotopes (35Cl, 37Cl), and the pattern 
of stable-isotope labelling of the all three internal standards, alternative ion transitions 
were selected to avoid cross-talk among channels. The ion transition of m/z 443→313.8, 
not m/z 439→310.1, was used as the quantifier of TCVG*. Likewise, m/z 295.9→235.8 
ion transition was selected as the quantifier of NAcTCVC* because of its unique 
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fragmentation (due to position of the stable-isotope labels) which can distinguish 
NAcTCVC* from NAcTCVC (m/z 295.9→236.8). There was no ion channel cross-talk 
effect observed for TCVC and TCVC*. 
To avoid the interference from matrices, matrix-specific mass transitions were 
used for quantification of each analyte (Table 2.1). In general, the most abundant mass 
transition of each compound was used as a quantifier. However, we observed interferences 
in quantifier channels of TCVC* (255.9→237.8) in serum. Therefore, we used m/z 
255.9→162.9 as the quantifier of TCVC* specifically in serum. The quantifiers listed in 
Table 1 show good selectivity of the method in liver, kidney, and urine. 
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Table 2.1 Quantifiers and qualifiers for analysis of TCVG, TCVG, and NAcTCVC 
in multiple tissue.  
Analytes Ion transition (m/z) Collision energy (V) Fragmentor (V) 
TCVG 436.0→306.8 13 118 
 436.0→203.9 25 118 
 438.0→308.8† 13 118 
TCVG* 443.0→313.8† 17 118 
 439.0→309.8 13 118 
TCVC 251.9→234.8† 9 90 
 249.9→160.8 21 90 
 249.9→232.8 9 90 
TCVC* 255.9→237.8† 9 90 
 255.9→162.9₸ 21 90 
NAcTCVC 291.9→249.8† 9 90 
 291.9→232.8 17 90 
 293.9→251.8 9 90 
NAcTCVC* 295.9→235.8† 9 90 
 295.9→253.8 17 90 
† Selected quantifier for analysis. ₸ Alternative quantifier of TCVC* in serum. Dwell 
time and cell accelerator voltage were set at 25 ms and 2 V. 
 
2.4.2 Ionization parameters 
Ionization parameters including capillary voltage, sheath gas temperature, drying 
gas temperature, and nebulizer gas pressure were optimized along with the 
chromatographic conditions. Given that efficient separation for TCVG, TCVC, and 
NAcTCVC was achieved, analytes were optimized individually. In the positive ion mode, 
the abundance of all three analytes was optimal with a capillary voltage of 3600V. Signal 
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variation increased when sheath gas temperature was above 350oC. Drying gas 
temperature was optimal at 300oC. The increased variation and signal depression likely 
resulted from thermolysis of precursor ions. Optimization of nebulizer gas pressure 
showed that TCVC and TCVG need higher gas pressure for ionization.  
 
2.4.3 Method validation 
Figure 2.2 shows representative chromatograms of the analytes. Peaks of TCVC 
and TCVC*, TCVG and TCVG*, and NAcTCVC and NAcTCVC* co-eluted at 3.28, 3.58, 
and 4.04 min, respectively for each pair. Matrix-matched calibration curves were 
constructed for serum, urine, liver, and kidney (Figure 2.3). Slopes of calibration curves 
were similar across different matrices (CV<5%), demonstrating no inter-tissue matrix 
effects when stable isotope-labeled internal standards are employed. No sample-to-sample 
carryover effect was observed for TCVC analysis across tissues (data not shown). TCVG 
and NAcTCVC showed minimal sample-to-sample carryover (TCVG <0.22 % and 
NAcTCVC <1% at 6.25 pmoles of each metabolite on column). 
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Figure 2.2 Representative LC-MS/MS chromatogram for (A) standards 
and (B) internal standards of TCVG, TCVC, and NAcTCVC in liver. 
The spiked amount on-column was 0.025 pmoles for TCVG and TCVC, 
0.05 pmoles for NAcTCVC, and 2 pmoles for TCVG*, TCVC*, and 
NAcTCVC*.  
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Figure 2.3 Matrix matched calibration curves for (A) TCVG, (B) TCVC, and (C) 
NAcTCVC. X axis, expected amount of spiked standards on column; y axis, peak area 
ratio of standard to internal standard. 
 
 
  
30 
 
The method described herein was highly sensitive for the analysis of TCVC, 
TCVG, and NAcTCVC across tissues and represents the first study to report on the method 
for TCVC in tissues (Table 2.2). As compared to previously published method for TCVG 
(Lash, et al., 1998), we show about 104 lower LOD. Even though the sensitivity of 
NAcTCVC detection was reduced by applying positive, versus negative, electrospray 
ionization to achieve higher sensitivity of TCVG and TCVC, the sensitivity for urinary 
analysis of NAcTCVC is still superior to previously published methods (Bartels, 1994;  
Birner et al., 1996;  Volkel et al., 1999). Interestingly, the LOD of NAcTCVC in serum is 
3-6 fold lower than that in other matrices, which probably results from the ion 
enhancement effect of NAcTCVC in serum (See below)
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Table 2.2 Comparative analysis of LODs for TCVG, TCVC, and NAcTCVC between tissues and studies. 
Reference Matrix Extraction method* Detect Method TCVG
† 
(fmole) 
TCVC 
(fmole) 
NAcTCVC 
(fmole) 
This study 
Liver 
LL-SPE 
LC-MS/MS 
4.5 22.7 31.3 
Kidney 4.2 68.2 17.8 
Serum PP-SPE 3.4 9.4 5.4 
Urine PP-Direct dilution 13.5 22 26.3 
Instrumental  
LOD₸  2.1 1.8 14 
Bartels et al., 1994 Urine LL and derivatization with methanolic HCl  NICI-GC-MS/MS N/R N/R 4 
Birner et al., 1996  Urine Derivatization with diethylether/diazomethane  GC-MS N/R N/R 60,000 
Lash et al., 1998 Hepatocyte Derivatization with 1-fluoro-2,4-dinitrobenzene HPLC-UV 50,000 N/R N/R 
Volkel et al., 1999 Urine LL and derivatization with methanolic BF3 
NICI-GC-MS N/R N/R 20 
† Limit of detection (LOD) is defined as the tested concentration with the signal-to-noise ratio equals to 3, and expressed with the 
on-column amount of analyte. N/R: Not reported. ₸ Instrumental LOD was tested in de-ionized water. *LL-SPE: liquid-liquid 
extraction coupled with SPE; PP-SPE: protein precipitation coupled with SP
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2.4.4 Extraction recovery and matrix effect 
Methanol:chloroform was selected as the homogenizing solution to standardize the 
extraction procedure in liver and kidney samples and because analyte recovery was 
significantly improved (Figure A-2). Serum was extracted by protein precipitation rather 
than liquid-liquid extraction to avoid sample loss. Urine was diluted with ammonium 
formate buffer to balance pH.  
Recoveries and matrix effects of TCVG, TCVC, and NAcTCVC varied at different 
tested concentrations and among tissues (Table B-6-9). The recovery of analytes was 
generally highest in urine and serum, and lowest in liver and kidney. Variability in 
recovery was observed, which may have been a consequence of experimental error in the 
liquid-liquid or solid-phase extraction steps, or may be a result of differential composition 
among matrices. Overall, there was negligible matrix effect, except in urine where we 
observed appreciable concentration-dependent ion suppression or enhancement (Table 
2.3). Despite these matrix effects, the use of stable isotope-labeled internal standards 
permitted accurate and precise quantitation (see below). 
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Liver Kidney Serum Urine 
TCVG TCVC NAcTCVC TCVG TCVC NAcTCVC TCVG TCVC NAcTCVC TCVG TCVC NAcTCVC 
RE(%)† 50 32 58 53 43 60 56 43 68 81 91 102 
ME(%) 115 100 91 107 102 85 90 94 110 126 91 105 
PE(%) 57 32 53 57 44 51 51 40 74 102 83 107 
Intra-day₸ Accuracy(%) -2.5 -0.1 +1.0 +11.5 +3.2 +6.5 +0.8 +1.3 +8.6 +1.2 +5.9 +4.9Precision(%) 5.5 3.4 11.6 9.8 6.9 10.0 6.1 2.9 10.8 5.4 10.9 19.9
Inter-day 
Accuracy(%) -3.2 -2.7 +0.5 -1.5 +2.3 -8.1 +4.9 -0.8 +2.2 +6.0 +5.0 +17.7
Precision(%) 10.3 1.7 9.0 2 3.3 8.3 6.9 5.4 6.7 4.7 18.0 7.6 
On-tray stability (%)* 102 ± 12 99 ± 6 104 ± 9 106 ± 1 105 ± 1 103 ± 1 102 ± 1 105 ± 1 104 ± 3 103 ± 3 101 ± 6 97 ± 11 
Short-term stability (%) 106 ± 7 106 ± 5 108 ± 6 102 ± 1 101 ± 1 102 ± 2 101 ± 1 102 ± 1 98 ± 2 99 ± 3 101 ± 3 99 ± 6 
Long-term stability (%) 98 ± 2 102 ± 3 114 ± 4 102 ± 2 101 ± 6 99 ± 2 100 ± 6 98 ± 2 99 ± 3 107 ± 6 53 ± 8 102 ± 85 
Freeze-thaw stability 
(%) 102 ± 2  98 ± 3 88 ± 3 98 ± 2 99 ± 6 101 ± 2 100 ± 6 102 ± 2 101 ± 3 94 ± 5 193 ±31 301 ± 396 
Table 2.3 Comparative analysis of method performance of TCVG, TCVC, and NAcTCVC in multiple tissues. †Method validation for analysis of 
TCVG, TCVC, and NAcTCVC was compared at level of 50 pmole/g tissue or mL serum across different tissues. Recovery (RE), matrix effect (ME), 
and process efficiency (PE) were determined from n=5. ₸ Inter-day (n=6) and intra-day (n=6) accuracy (%) are expressed as bias deviated from the 
nominal concentration. Precision (%) is expressed as relative standard deviation. * Results of stabilities are expressed in average ± standard deviation 
(n=3). 
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2.4.5 Inter- and intra-day accuracy and precision 
Inter-day accuracy and precision were further evaluated across six different days; 
intra-day accuracy and precision were assessed by using six biological replicates in the 
same day. Our results show that this method is accurate (bias <15%) and reliable 
(precision <15%) for analysis of TCVG, TCVC, and NAcTCVC in liver, kidney, and 
serum (Table 2.3). Urinary analysis of NAcTCVC exhibited slightly higher variability; 
however, it still passed the criteria for determining the LLOQ (accuracy and precision 
<20%). The inferior performance of NAcTCVC is not surprising because this method is 
operated in positive ion mode, which is optimized for TCVG and TCVC, but not for 
NAcTCVC. Also, some blank urine samples had background levels of NAcTCVC, which 
may also introduce the variability into urinary analysis of NAcTCVC.  
2.4.6 Analyte stability 
Stock solutions and extracted samples were evaluated with respect to the stability 
of TCVG, TCVC, and NAcTCVC under various storage conditions. Stock solutions were 
stable at room temperature for up to 6 hours (data not shown). Analytes were stable in 
liver, kidney, and serum when evaluated for the on-tray, short-term, long-term, and freeze-
thaw conditions (Table 2.3). Results in urine show that TCVC and NAcTCVC are unstable 
for long-term storage at -20oC or three freeze and thaw cycles. However, analytes in 
extracted urine samples are considered stable on-tray or for short-term storage. Thereby, 
long-term storage and repeated freeze and thaw cycles should be avoided for analysis of 
these analytes in urine samples. 
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2.4.7 Application to toxicokinetic profiling of PCE in vivo 
Next, we applied this method to quantitate TCVG, TCVC, and NAcTCVC in 
multiple tissues of PCE-exposed mice. First we conducted a study where mice were treated 
with a single dose of PCE (100, 300, or 1000 mg/kg) and euthanized 2 hrs after oral 
gavage. Tissue levels of analytes demonstrated a dose-dependent increase with ascending 
dose of PCE (Figure 2.4). Levels of all three metabolites varied across tissues in a 
metabolite-specific manner. For instance, in mice treated with 1000 mg/kg PCE, we found 
that TCVG level was 16.7-fold higher in liver as compared to that in kidney or serum. 
TCVC level in kidney was higher than that in liver (18.3-fold) or serum (2.1-fold). 
Likewise, NAcTCVC level in urine was higher than that in liver (1.7-fold), kidney (13.7-
fold), and serum (4.6-fold) (Figure 2.5A).  
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Figure 2.4 Dose-response relationships of (A) TCVG, (B) TCVC, and (C) 
NAcTCVC in liver, kidney, and serum of mice treated with PCE (n=3 for each dose 
as indicated in the inset). Data shown are group means with standard deviations. The 
significance of dose-response relationships in each tissue was tested by one-way 
ANOVA and post-hoc test for a linear trend (*p < 0.05). 
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Figure 2.5 Analysis of TCVG, TCVC, and NAcTCVC in urine of PCE-treated mice 
at (A) 2 hrs or (B) 24 hrs after dosing. Data shown are group means with standard 
deviations. The significance of the dose-response relationship was tested by one-way 
ANOVA and post-hoc test for a linear trend (*p < 0.05). 
The observed differences in metabolite levels across different tissues are consistent 
with PCE metabolism pathways. GSH conjugation of PCE and other chemicals 
predominantly occurs in liver because of the high activity of GSH S-transferases (Moron 
et al., 1979). Renal GGT and dipeptidase activity is responsible for high levels of TCVC 
in kidney (Griffith and Meister, 1979). Also, the reabsorption of cysteine S-conjugates, as 
demonstrated in rat kidney (Heuner et al., 1991) and LLC-PK1 cells (Schaeffer and 
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Stevens, 1987), and the deacetylation of NAcTCVC that is catalyzed by renal 
aminoacylase (Uttamsingh et al., 1998) can also contribute to the high levels of TCVC in 
kidney. Interestingly, we found large quantities of NAcTCVC in liver even though the 
activity of gamma-glutamyl transpeptidase is approximately one-fifth of that in kidney 
(Whitfield, 2001). Intrahepatic conversion of GSH conjugates to mercapturic acids by N-
acetyltransferase activity has been reported in rat and guinea pig livers (Hinchman et al., 
1991), which could account for the generation of NAcTCVC in liver. Further mechanistic 
investigation on the fate of PCE conjugative metabolites in vivo is possible using this 
method. 
Next, we quantified urinary levels of NAcTCVC in mice treated with PCE (10, 
100, or 1000 mg/kg) (Figure 2.5B). Our results demonstrate that NAcTCVC is a major 
conjugative metabolite (~98% of combined amount of TCVG, TCVC, and NAcTCVC) 
excreted in urine. This is not surprising because the renal transport systems favor 
reabsorption of amino acids, but excretion of mercapturates. Our method is able to profile 
urinary levels of NAcTCVC in mice treated with as little as 10 mg/kg PCE (46.8±9.1 
pmol/mLurine, approximately 100 pmoles total) using only 50 µL of sample volume. In a 
previous study, rats and humans exposed to 10 ppm PCE by inhalation for 6 h excreted 
(24 hr urine collection) ~500 pmol and 40 nmol of NAcTCVC, respectively (Volkel et al., 
1998). Therefore, our method should be sufficiently sensitive for detection of urinary 
NAcTCVC in PCE-exposed animals and humans. 
The sensitivity of our method also allowed us to demonstrate the linear dose-
dependent increase of NAcTCVC, which suggests that the conjugative metabolism of PCE 
remains unsaturated at doses up to 1000 mg/kg. Lack of saturation of the GSH conjugation 
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metabolism pathway of PCE is noteworthy because the oxidative metabolism is saturated 
above 100 mg/kg (Philip, et al., 2007) and may reflect the small overall flux of PCE 
through conjugation in mice. 
 
2.5 Conclusions  
Metabolism of PCE is qualitatively similar in humans and rodents, although 
quantitative differences do exist (Cichocki, et al., 2016). These quantitative differences in 
metabolism may be important for extrapolation of data derived from rodents to human 
health assessments for PCE. 
It is now assumed that flux of PCE through conjugative pathways is minimal as 
compared to oxidative pathways; these assumptions are largely based on the data for 
trichloroethylene and quantification of urinary NAcTCVC and oxidative PCE metabolites 
in PCE-exposed humans and laboratory rodents (Bartels, 1994;  Birner, et al., 1996;  
Volkel, et al., 1999). However, urinary NAcTCVC may represent only a fraction of the 
overall flux of PCE through GSH conjugation (IARC, 2014).  
Little is known about PCE conjugative metabolism in vivo due to the lack of a 
sensitive analytical assays; to our knowledge, no previously published method for analysis 
of multiple PCE conjugative metabolites exists. To address these critical gaps in our 
knowledge of PCE toxicity, we developed a rapid, sensitive, and robust UPLC-ESI+-
MS/MS method. For the first time, we provide quantitative data for levels of TCVG, 
TCVC, and NAcTCVC in multiple mouse tissues after exposure to PCE. We demonstrated 
that this method has a limit of quantitation of 1-2.5, 1-10, 1-2.5, and 2.5-5 pmol/mL in 
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liver, kidney, serum, and urine, respectively, while maintaining selectivity of the method 
and a short duration of analysis.  
We also demonstrated that successful quantitation of PCE GSH metabolites can 
be achieved in all tissues tested despite small amounts of starting material. TCVC and 
TCVG can be detected and quantified in animals that were dosed with 100 mg/kg or more 
of PCE, while NAcTCVC is quantifiable in the urine of animals that were dosed with as 
little as 10 mg/kg of PCE. The range of doses used in this study is well within the range 
of doses used in PCE rodent cancer bioassays and other animal studies. Thus, our method 
and data provide important information for interpreting the findings from cancer bioassays 
in rodents. In addition, it is important to note that this method may have utility for the 
internal dosimetry of conjugative metabolites in studies of occupational and even 
environmental exposures in humans because PBPK modeling shows that the PCE fraction 
conjugated via GSH pathway may be 100 to 1000 fold higher in humans than in mice 
(Chiu and Ginsberg, 2011).  
One important limitation of this method, however, is its focus on proximal 
metabolites of the GSH conjugation pathway and not on some of the more reactive and 
toxic downstream metabolites such as TCVC sulfoxide (Elfarra and Krause, 2007). Still, 
the method reported herein will be applicable to further toxicokinetic studies of PCE and 
inform human health assessments of this ubiquitous environmental toxicant. 
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CHAPTER III  
 
CHARACTERIZATION OF INTER-TISSUE AND INTER-STRAIN VARIABILITY 
OF TCE GLUTATHIONE CONJUGATION METABOLITES DCVG, DCVC, AND 
NACDCVC IN THE MOUSE2 
 
 
 
3.1 Overview 
Trichloroethylene (TCE) is a ubiquitous environmental toxicant that is a liver and 
kidney carcinogen. Conjugation of TCE with glutathione leads to formation of 
nepthrotoxic and mutagenic metabolites thought to be critical for kidney cancer; however, 
relatively little is known about their tissue levels because previous analytical methods for 
their detection lacked sensitivity. Here, an LC-MS/MS-based method for simultaneous 
detection of S-(1,2-dichlorovinyl)-glutathione (DCVG), S-(1,2-dichlorovinyl)-L-cysteine 
(DCVC), and N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine (NAcDCVC) in multiple mouse 
tissues was developed. This analytical method is rapid, sensitive (limits of detection 3-30 
fmol across metabolites and tissues), and robust to quantify all three metabolites in liver, 
kidney and serum. The method was used to characterize the inter-tissue and inter-strain 
variability in formation of conjugative metabolites of TCE. Single oral dose of TCE (24, 
240 or 800 mg/kg) was administered to male mice from 20 inbred strains of Collaborative 
                                                 
2 The text of this chapter is an Author’s Original Manuscript of an article published by Taylor & Francis 
Group in the Journal of Toxicology and Environmental Health, Part A on 30 November 2017, available 
online: https://doi.org/10.1080/15287394.2017.1408512 
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Cross. Inter-strain variability in the levels of DCVG, DCVC, and NAcDCVC (GSD=1.6-
2.9) was observed. Whereas NAcDCVC was distributed equally among analyzed tissues, 
the highest levels of DCVG were detected in liver and DCVC in kidney. It is concluded 
that inter-strain variability in conjugative metabolite formation of TCE can affect the 
susceptibility to adverse health effects and that this method can aid in filling the data gaps 
in the human health assessment of TCE.   
 
3.2 Introduction  
Trichloroethylene (TCE), a ubiquitous environmental toxicant, causes liver cancer 
in mice and kidney cancer in rats and humans (IARC, 2014;  U.S. EPA, 2011c). It remains 
a top ten priority chemical of concern to human health (U.S. EPA, 2017). Upon absorption, 
TCE is metabolized through cytochrome P450 oxidation and glutathione conjugation 
pathways in both rodents and humans (Lash et al., 2000). Glutathione conjugation of TCE 
occurs primarily via glutathione-S-transferases (GSTs) in liver to form DCVG. DCVG can 
be metabolized via liver or kidney gamma-glutamyl transferase and di-peptidase to 
generate DCVC, which is then further transformed into NAcDCVC via N-acetyl 
transferase. In addition, NAcDCVC can be deacetylated by acylase to regenerate DCVC. 
Aside from the N-acetylation, DCVC can be further metabolized by cysteine conjugate β-
lyase to form reactive thioketenes, or undergo sulfoxidation by flavin-containing 
monooxygenase to form a reactive DCVC-sulfoxide (Lash, et al., 2001b;  Sausen and 
Elfarra, 1990).  
Metabolites that are generated through both oxidation and glutathione conjugation 
pathways are thought to be involved in organ-specific toxicity of TCE (Cichocki, et al., 
  
43 
 
2016;  Lash et al., 2014). While the effects of the oxidative metabolites of TCE have been 
widely studied (Corton et al., 2014;  Rusyn et al., 2014), the metabolites from glutathione 
conjugation pathway receive less attention because of their low abundance and lack of 
sensitive analytical methods (Chiu et al., 2009). However, these metabolites are thought 
to be the cause of kidney cancer in rats and humans (Chiu et al., 2013;  Guha et al., 2012). 
Glutathione conjugation metabolites of TCE are cytotoxic in vitro and nephrotoxic in vivo; 
they are also mutagenic in bacterial and mammalian model systems (Chiu, et al., 2013;  
Dekant, 2003;  Guha, et al., 2012;  Irving and Elfarra, 2013;  Lash, et al., 2014;  Lash et 
al., 2001a;  Lash, et al., 2007;  Lash, et al., 2001b). Still, the relationship between tissue 
levels of glutathione conjugation metabolites of TCE and cancer remains unclear (Green 
et al., 1997;  Yoo, et al., 2015b).  
Previous studies examined the flux of TCE through glutathione conjugation 
pathway in tissues of TCE-exposed animals and humans (Bloemen et al., 2001;  Kim, et 
al., 2009a;  Lash et al., 1999;  Lash et al., 2006;  Yoo, et al., 2015a;  Yoo, et al., 2015b). 
The analytical techniques ranged from LC-UV, to GC-MS and LC-MS/MS, and detection 
limits varied from 25 to 50,000 fmoles for DCVG and DCVC. One study reported a 
method for NAcDCVC with a detection limit of 80 fmoles (Bloemen, et al., 2001). Most 
sensitive was the LC-MS/MS-based method for analysis of DCVG and DCVC in mouse 
tissues (Kim, et al., 2009a;  Yoo, et al., 2015a;  Yoo, et al., 2015b); however, extraction 
protocols inconsistency confounds cross-tissue comparisons.  
Because of the complexity of metabolism-related effects of TCE, inter-individual 
variability in pharmacokinetics can play a major role in the susceptibility to toxicity and 
tissue specificity (Chiu et al., 2006a). Our previous study in mice showed considerable 
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inter-strain variability in DCVG and DCVC in the liver (Bradford, et al., 2011); there was 
a greater than 10-fold inter-strain variability in flux of TCE metabolism through 
glutathione conjugation (Chiu et al., 2014). This study aimed to further characterize inter-
individual variability in TCE metabolism through glutathione conjugation, and to extend 
the quantitative estimates to other tissues. To achieve this, a sensitive analytical method 
for simultaneous detection of DCVG, DCVC, and NAcDCVC in various tissues was 
developed using ultra-high performance liquid chromatography coupled with triple 
quadruple tandem mass spectrometry (LC-MS/MS). Furthermore, the inter-strain 
variability in levels of TCE conjugation metabolites in various tissues was characterized 
using 20 inbred strains of Collaborative Cross mice. 
 
3.3 Materials and Methods 
3.3.1 Chemicals 
S-(1,2-dichlorovinyl)-glutathione (DCVG, purity: 98.9%), 2-amino-5-[(2-
([(13C)carboxy(13C)methyl](15N)amino)-1-([1,2-dichloroethenyl]sulfanyl)-2-
oxoethyl)amino]-5-oxopentanoic acid (DCVG*, purity: 94.4%, isotopic enrichment: 
99.0%), S-(1,2-dichlorovinyl)-L-cysteine (DCVC, purity: 98.4%), and 2-(15N)amino-3-
([1,2-dichloroethenyl]sulfanyl)(13C3)propanoic acid (DCVC*, purity: 96.9%, isotopic 
enrichment: 99.0%) were obtained from TLC pharmaceutical standards (Vaughan, 
Canada). N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine (NAcDCVC, purity: 99.8%) and 3-
([1,2-dichloroethenyl]sulfanyl)-2-[(1-13C, d3)ethanoylamino]propanoic acid 
(NAcDCVC*, purity: 97.6%, isotopic enrichment: 99.0%) were purchased from Toronto 
Research Chemicals (Toronto, Canada). Acetic acid (>99.7%), TCE (>99.5%), and 
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chloroform (>99.9%) were obtained from Sigma-Aldrich (St. Louis, MO). Methanol 
(>99.9%) was purchased from Fischer Chemicals (Fair Lawn, NJ). De-ionized water was 
generated by Arium®Pro Ultrapure Water System (Goettingen, Germany). 
 
3.3.2 Animals and treatments 
Two animal studies were conducted, both used male mice because TCE is more 
efficiently metabolized in male, as compared to female, mice (National Toxicology 
Program, 1990). First was to demonstrate the application of the validated LC-MS/MS 
method in an in vivo study. Second was to characterize inter-individual variability of tissue 
levels of DCVG, DCVC, and NAcDCVC using a panel of mouse strains. All animal 
treatments and procedures were approved by the Institutional Animal Care and Use 
Committee at Texas A&M University and the University of North Carolina at Chapel Hill.  
First study was conducted in male B6C3F1/J mice (6-8 wks old) obtained from the 
Jackson Laboratory (Bar Harbor, ME). Mice were housed in standard polycarbonate 
shoebox mouse cages with air filtration system on a 12:12 hr light/dark cycle with free 
access to food (standard laboratory mouse chow) and filtered tap water. After a week-long 
acclimation, mice (n=3/group) were dosed with 0, 24, 240, 800 mg/kg of TCE (5 mL/kg 
in 5% alkamus-EL620 in saline) via oral gavage. The aqueous emulsion vehicle was used 
to aid oral absorption of TCE (Lee et al., 1996;  Lee et al., 2000). Dose range was selected 
based on previous acute and sub-chronic mouse studies showing that these amounts are 
well-tolerated; doses also corresponded to the range used in both 90-day and 2-year mouse 
studies (Buben and O'Flaherty, 1985;  National Toxicology Program, 1990;  Yoo, et al., 
2015b). It is also noted that mice form ~100 fold less GSH conjugation pathway 
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metabolites of TCE as compared to humans (Chiu, et al., 2009) which necessitated the use 
of doses that are higher than those expected in human exposures. 
Second study was conducted in male mice (8-12 weeks old) from 20 Collaborative 
Cross strains. The Collaborative Cross (CC) is a panel of inbred mouse strains that were 
recently developed through a community effort (Threadgill and Churchill, 2012). The CC 
addresses many shortcoming of other available mouse populations such as limited genetic 
diversity and a non-ideal population structure. The CC strains were derived from an eight 
way cross using a set of founders that include three wild-derived strains (A/J, C57BL/6J, 
129S1/SvImJ, NOD/LtJ, NZO/HlLtJ, CAST/EiJ, PWK/PhJ, and WSB/EiJ) to capture 
nearly 90% of the known variation present in laboratory mice. The goal of this study was 
to test inter-strain variability; therefore, the number of CC strains used is comparable to 
previous studies of inbred mouse panels (Bradford et al., 2011). Mice were acquired from 
the University of North Carolina Systems Genetics Core (Chapel Hill, NC). Housing and 
treatment conditions were identical to those detailed above. Mice were orally administered 
a single dose of TCE (800 mg/kg) prepared in 5% Alkamuls EL-620. In both studies, mice 
were euthanized with pentobarbital (50 mg/kg, i.p.) 2 hrs after dosing and tissues 
immediately dissected for collection of liver, kidney, and blood. Tissues were snap-frozen 
in liquid nitrogen and stored at -80oC until analyses. The time point for tissue collection 
was based on a toxicokinetic study of TCE metabolism that showed peak levels of 
glutathione conjugates several hours after dosing (Kim, et al., 2009b).       
The potential for ex vivo formation of conjugation metabolites of TCE was tested 
using serum (50 µl) and liver (50 mg) samples from untreated mice (male, B6C3F1/J). 
TCE (5 µM) was reacted with glutathione (5 mM) in saline, serum, or liver homogenates 
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for 1 hr at 37ºC. Some reactions were carried out with or without protein inactivation (by 
heating for 10 min at 90ºC), or glutathione depletion through addition of 2,4-
dinitrochlorobenzene (0.2 mM). Upon completion of these incubations, samples were 
extracted and analyzed as detailed below.  
 
3.3.3 Sample preparation 
Serum (50 μL) samples were spiked with 10 μL of internal standard mixture (5 μM 
for each analyte), mixed with 100 μL of methanol to precipitate protein, and then vortexed 
and centrifuged (10,000 g, 10 min, room temperature). Thereafter, the supernatant was 
diluted with 850 μL of distilled deionized water for solid phase extraction (SPE). Liver or 
kidney (50 mg) samples were spiked with 10 μL of internal standard mixture (5 μM for 
each analyte), and then homogenized in 200 μL of methanol and 200 μL of chloroform 
using stainless steel beads in a Bead Ruptor 24 (Omni Inc, Kennesaw, GA) for 30 s at 4 
m/s. Homogenates were centrifuged (10,000g, 5 min, room temperature), the supernatant 
was diluted with 1 mL of distilled deionized water, and the diluent was used for SPE. 
Strata-X-AW 96-well SPE plate (cat no. 8E-SO38-TGB, sorbent lot no. S308-0066; 
Phenomenex, Torrance, CA) was used. The SPE procedure was slightly modified from 
our previously published method (Luo et al., 2017). In the final step, the dried residue was 
reconstituted in 30 μL of water:methanol (9:1, v/v) containing 0.1% acetic acid. Samples 
were then transferred to an autosampler vial with a 200 μL insert, and stored at -20oC prior 
to analysis. 
 
 
  
48 
 
3.3.4 LC-MS/MS Method 
Samples (10 μL) were automatically injected and chromatographed on a ZORBAX 
SSHD Eclipse Plus C18 column (3.0ⅹ50 mm, 1.8 μm, cat no. 959757-302; Agilent, Santa 
Clara, CA) with a guard column (2.1x5 mm, 1.8 μm, cat no.821725-901; Agilent) via a 
Waters Acquity H-class LC system (Waters, Milford, MA). Column temperature was 
maintained at 25oC. Initial chromatographic condition was maintained at 90% solvent A 
(water with 0.1% acetic acid, v/v) and 10% solvent B (methanol with 0.1% acetic acid, 
v/v) for 1 mins, then increased to 90% solvent B by 3 mins, then to 98% solvent B by 4 
mins, and then returned to initial condition until 7 mins for sufficient equilibration prior 
to next run. Flow rate was set at 0.4 mL/min. All analyses were performed using Agilent 
6740 triple-quadrupole mass spectrometer. The optimal MS/MS parameters were obtained 
via direct infusion of standards and isotopically-labeled internal standards in mobile phase 
at the flow rate of 0.5 mL/min (1:1 methanol:water, v/v, containing 0.1% formic acid). An 
Agilent Optimizer Tool (MassHunter, ver B.08.00) was used to finalize the optimal 
parameters of the fragmentor, collision energy, cell accelerator voltage and mass transition 
for each analyte (Table 3.1). Along with the real chromatographic condition, capillary 
voltage was optimal at 3500V, sheath gas pressure and sheath gas temperature were 
optimal at 35 psi and 350oC, and the gas temperature was optimal at 300oC.  
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Table 3.1 Quantifiers and qualifiers for analysis of DCVG, DCVC, and NAcDCVC 
in multiple tissue. 
Analytes Ion transition (m/z) Collision energy (V) Fragmentor 
DCVG 402.0→272.9 13 110 
 402.0→169.9† 25 110 
 402.0→133.9 37 110 
DCVG* 409.0→173.9† 25 110 
 405.0→169.9 25 110 
DCVC 216.0→198.9† 8 70 
 216.0→126.9 25 70 
 216.0→82.9 45 70 
DCVC* 222.0→128.9† 25 80 
 220.0→201.9 10 80 
NAcDCVC 258.0→215.9 9 90 
 258.0→198.8† 17 90 
 258.0→179.9 5 90 
NAcDCVC* 262.0→216.9 9 90 
 262.0→198.8† 17 90 
† Selected quantifier for analysis. ₸ Alternative quantifier of DCVC* in serum. Dwell 
time and cell accelerator voltage were set at 25 ms and 2 V
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3.3.5 Method validation  
Selectivity of the method was determined by using pooled tissues and/or serum of 
untreated male animals of the same strain. Sensitivity was defined by both the limit of 
detection (LOD, the concentration with signal to noise ratio of 3) and the limit of 
quantification (LOQ, the concentration with signal to noise ratio of 10). Inter-channel 
cross talk and sample-to-sample carry over effects were evaluated by using the highest 
concentration in the calibration curve. Calibration curves of DCVG, DCVC, and 
NAcDCVC were prepared in liver, kidney, or serum samples obtained from untreated 
mice. Blank liver, kidney, or serum (50 mg or μL) was spiked with standard mixture at 0, 
0.25, 0.5, 1.25, 2.5, 6.25, 18.75, and 31.25 pmoles for each analyte. All standard solutions 
were also spiked with 50 pmole of each internal standard. Peak area ratio of standard and 
internal standard was used for quantitation of DCVG, DCVC, and NAcDCVC.  
Intra-day precision and accuracy (six replicates per matrix) were assessed in liver, 
kidney, and serum of untreated mice and in artificial urine (SurineTM negative urine control, 
Cerilliant, Round Rock, TX) after spiking in 2.5 pmole for each analyte. Inter-day 
precision and accuracy were evaluated over six consecutive days. Extraction performance 
was evaluated by recovery, matrix effect, and process efficiency as described elsewhere 
(Matuszewski, et al., 2003). Freeze and thaw stability (three freeze-thaw cycles on dry 
ice), short-term stability (storing samples at room temperature for 4 hrs), long-term 
stability (storing samples at -20oC for 30 days), and on-tray stability (storing samples at 
4oC for 8 hrs) of DCVG, DCVC, and NAcDCVC were evaluated by comparing extracted 
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samples before and after each test condition. Stability of the stock solutions was evaluated 
after they were stored at room temperature for 6 hrs.  
 
3.3.6 Statistical analyses 
One-way ANOVA and post-hoc tests were conducted by using GraphPad Prism 
(ver. 5, GraphPad Software, La Jolla, CA). A p-value of less than 0.05 was considered 
significant in all analyses.  
 
3.3.7 Calculation of uncertainty factors for toxicokinetic variability  
To avoid underestimation of toxicokinetic variability, concentrations for peaks 
between LOD and LOQ were estimated via extrapolation from the calibration curves. 
Values below LOD were replaced by ½ of the LOD, as recommended by US EPA 
(USEPA, 2000). For kidney DCVC, values below the background concentration were 
replaced by the background concentration derived from matrix-matched calibration curve. 
The uncertainty factor for human toxicokinetic variability (UFH,TK) can be 
expressed as the ratio between the internal dose in a “sensitive” individual (e.g., 95th or 
99th percentile) to that in a “typical” individual (e.g., median) (WHO/IPCS, 2005). For a 
number of chemicals, including TCE, population PBPK modeling has been used to 
estimate this ratio (U.S. EPA, 2011a;  U.S. EPA, 2011c). For TCE, Chiu et al. (2014) 
showed that mouse inter-strain variability is in agreement with human inter-individual 
variability. Whereas previously, UFH,TK was estimated only for the overall flux of GSH 
conjugation, here we can extend this to tissue- and metabolite-specific dose metrics. 
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Therefore, for each tissue and metabolite, given an inter-strain variance σ2, the UFH,TK was 
estimated for the 95th and 99th percentile as UFH,TK,95 = exp(z95 σ) and UFH,TK,99 = exp(z99 
σ), respectively, where z95 and z99 are the z-scores for the corresponding percentiles. 
The inter-strain variability of glutathione conjugation metabolites of TCE was 
estimated by decomposing the total observed variance across CC strains into two 
components: intrinsic inter-strain heterogeneity and intra-strain variability (e.g., due to 
environmental factors and measurement error). Only one sample from each CC strain was 
available, so the intra-strain variability was estimated by the observed variation across 
B6C3F1 mice, as follows: σ2inter-strain = σ2total – σ2intra-strain; σ2total= variance of log-
transformed data across 20 CC mice; σ2intra-strain= variance of log-transformed data across 
B6C3F1 mice. 
The uncertainty factor of the inter-strain variability in toxicokinetics (UFTKvar) is 
calculated from UFTKvar= e z*σ, where z= Z statistics and σ represents the square root of 
variance. The UFTKvar of glutathione conjugation metabolites are derived at 95% and 99%, 
respectively. 
 
3.3.8 Population PBPK modeling 
For comparison, mouse population PBPK modeling was used to estimate of serum 
concentrations of DCVG and DCVC was generated from 100 different populations (500 
individuals/population) as detailed in (Chiu, et al., 2014).  
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3.4 Results  
 3.4.1 LC-MS/MS method for detection of DCVG, DCVC, and NAcDCVC 
Figure 3.1 shows the LC-MS/MS chromatogram of DCVG, DCVC, and 
NAcDCVC in blank kidney tissue spiked with 0.25 pmoles of standards and 50 pmoles of 
isotopically labeled internal standards. Representative retention time was 2.5 min for 
DCVC and DCVC*, 3.35 min for DCVG and DCVG*, and 3.79 min for NAcDCVC and 
NAcDCVC*. 
 
 
 
Figure 3.1 Representative LC-MS/MS chromatograms and mass transitions for 
parent compounds (A) and isotopically labeled standards (B) of DCVG, DCVC, and 
NAcDCVC in kidney. The spiked amount on-column was 0.25 pmoles for standards 
and 50 pmoles for internal standards. 
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Selectivity test showed that a peak at 2.75 min in the mass transition of m/z 
220.0→201.9 and a peak at 2.55 min in the mass transition of m/z 216.0→82.9 commonly 
appeared in liver, kidney, and serum. A peak at 4.05 min in the mass transition of m/z 
258.0→179.9 and m/z 262.0→216.9 specifically appeared in serum. Even though the 
peaks of the target analytes were chromatographically separated from the aforementioned 
peaks, these mass transitions as quantifiers were not used to minimize the potential 
influences on our quantitative results. Calibration curves across different tissue matrices 
showed excellent linearity (r2>0.998), and the relative standard deviations of the slopes 
were less than 3% (1.1% for DCVG, 2.5% for DCVC, and 0.8% for NAcDCVC; Figure 
3.2). No inter-channel cross talk between standards and isotopically labeled standards 
occurred during the analysis. The sample-to-sample carry over effect at the highest 
concentration of calibration curve was less than 0.08% for DCVG, 0.03% for DCVC, and 
1.4% for NAcDCVC. Interestingly, a positive intercept was observed in the calibration 
curve of DCVC in kidney and serum, this background signal disappeared in the absence 
of isotopically labeled internal standards (Figure A-3). However, no background was 
observed in DCVC signal in liver, even in presence of isotopically labeled internal 
standards. It is likely that a small amount of the unlabeled portion of the internal standards 
(-dichloroethyl group) is released from the parent compound, and then reacts with the 
endogenous unbound S-cysteine, which is abundant in kidney and plasma, to generate a 
minute amount of DCVC as background signal. Therefore, a matrix-matched calibration 
curve is highly recommended to subtract the background signals specifically in kidney or 
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serum, even though the calibration curve in water showed excellent consistency with 
matrix-matched calibration curves. To test whether these metabolites can form ex vivo, 
TCE (5 µM) was reacted with glutathione (5 mM) in saline, as well as serum and liver 
homogenates. These reactions were carried out with or without protein inactivation or 
glutathione depletion. No ex vivo formation of DCVG, DCVC or NAcDCVC was 
observed at levels exceeding the limits of detection (data not shown). 
 
 
Figure 3.2 Matrix-matched calibration curves of DCVG, DCVC, and NAcDCVC in 
mouse tissues. The influence of matrix effects on quantitative analysis has been 
minimized by using isotopically labeled internal standards, with a relative standard 
deviation of slopes less than 3%. 
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Table 3.2 shows the method performance of DCVG, DCVC, and NAcDCVC in 
multiple mouse tissues. In serum, recovery of DCVG (43-73%) and DCVC (10-53%) was 
about 3-fold higher than previously reported (Kim, et al., 2009a). The low recovery of 
DCVC in liver and kidney likely results from sample loss during liquid-liquid extraction; 
however, to the best of our knowledge, the liquid-liquid extraction is required to minimize 
the matrix interference especially in liver and kidney. The ion suppression of DCVG, 
DCVC, and NAcDCVC was most pronounced (40-50%) in liver, it was more variable in 
serum [22% DCVG, 10% DCVC, and 40% NAcDCVC], and minimal in kidney (10-15%). 
The matrix effects on DCVG and DCVC reported herein were less pronounced as 
compared to those reported in (Kim, et al., 2009a) (up to 45% for DCVG and up to 78% 
for DCVC). Even though ion suppression effect occurs during the analysis, this method is 
accurate (bias <15%) and reliable (precision<15%) in liver, kidney, and serum by using 
isotopically-labeled internal standards (Table 3.2). The stability of DCVG, DCVC, and 
NAcDCVC was assessed with stock solutions and extracted samples under various storage 
conditions. Stock solutions were stable at room temperature for up to 8 hours (DCVG: 
98.3%, DCVC: 102.5%, NAcDCVC: 94.8%). Analytes in extracted samples were stable 
in liver, kidney, and serum when subjected to on-tray, short-term, long-term, and freeze-
thaw storage conditions (Table 3.2). 
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Table 3.2 Comparative analysis of method performance of DCVG, DCVC, and NAcDCVC in multiple tissues 
† Method validation for analysis of DCVG, DCVC, and NAcDCVC was compared at level of 50 pmole/g tissue or mL serum 
across different tissues. Recovery (RE), matrix effect (ME), and process efficiency (PE) were determined from n=5.  
₸ Inter-day (n=6) and intra-day (n=6) accuracy (%) are expressed as bias deviated from the nominal concentration. Precision (%) is 
expressed as relative standard deviation.  
* Results of stabilities are expressed in average±standard deviation (n=3). 
 
  Liver Kidney Serum 
    DCVG DCVC NAcDCVC DCVG DCVC NAcDCVC DCVG DCVC NAcDCVC 
 RE(%)† 73 15 58 43 10 57 69 53 83 
 ME(%) 60 62 50 85 85 90 78 90 60 
  PE(%) 44 9 29 37 8 52 54 48 50 
Intra-day₸ 
Accuracy(%) -3.4 +5.8 -0.3 -4.2 +13.6 -5.4 -3.3 -3.5 -5.4 
Precision(%) 1.4 7.9 3.0 1.5 7.5 3.0 2.0 6.3 1.6 
Inter-day 
Accuracy(%) -1.9 -2.4 -4.7 -4.2 +8.0 -4.5 -2.8 -9.9 -5.7 
Precision(%) 2.5 7.5 3.5 0.5 10.0 3.8 2.0 5.2 2.1 
On-tray stability (%)* 99.6±16.5 116.8±5.4 94.3±4.9 107.5±2.7 101.2±5.4 102.0±1.9 97.1±0.6 99.8±1.4 101.3±2.2 
Short-term stability (%) 98.5±1.3 100.6±13.8 101.9±1.5 97.4±1.9 106.3±4.2 107.1±3.4 99.9±2.1 93.6±6.5 104.1±2.7 
Long-term stability (%) 102.3±1.7 109.1±13.3 101.8±1.6 99.7±1.0 89.0±2.8 100.2±5.1 99.3±0.7 94.1±6.8 99.7±1.4 
Freeze-thaw stability (%) 100.4±0.9 101.0±0.3 100.9±5.0 98.7±0.9 96.8±3.1 97.7±1.8 97.3±2.8 113.0±3.0 100.3±5.6 
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3.4.2 Toxicokinetic profiling of TCE glutathione conjugates across tissues and 
strains 
The levels of DCVG, DCVC, and NAcDCVC were quantified in multiple tissues 
of B6C3F1 mice treated with single dose of TCE (24, 240, or 800 mg/kg) 2 hrs after oral 
gavage (Figure 3.3, Table B-10). DCVG and NAcDCVC were most abundant in liver, 
while DCVC was most abundant in kidney. Significant dose-response in formation of the 
conjugates was observed for all tissues and metabolites where levels were detectable in at 
least two dose groups, except for DCVC in kidney where non-linear kinetics was observed.  
 
 
Figure 3.3 Dose-dependent increases of (A) DCVG, (B) DCVC, and (C) NAcDCVC 
in liver, kidney, and serum of B6C3F1 mice treated with TCE (n=3 /group). The red 
dashed line indicates the instrumental LODs; the blue and red triangles locate the matrix-
matched LODs (S/N=3) and LOQs (S/N=10), respectively. One-way ANOVA and post 
hoc test for a linear trend was used to test the dose–response relationships in each tissue 
(*p<0.05). +The bar is shown as ½ LOD if an analyte was below the LOD. 
#Measurements between LOD and LOQ are expressed as estimated values. 
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The levels of DCVG, DCVC, and NAcDCVC were also successfully quantified in 
multiple tissues of CC mice treated with TCE (single dose, 800 mg/kg, Table B-11). 
Figure 3.4 shows that in liver, DCVG showed the highest detection rate (>LODs, 100%) 
as compared to DCVC (65%) and NAcDCVC (85%). Similarly, the detection rate of 
DCVG (89%) in serum was higher than that of DCVC (42%) and NAcDCVC (63%). 
NAcDCVC was most detectable in kidney (74%), followed by DCVG (68%) and DCVC 
(63%). Levels of glutathione conjugation metabolites in B6C3F1 mice were among the 
highest as compared to those in 20 CC strains.  
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Figure 3.4 Inter-individual variability of conjugative metabolites of TCE in (A) 
liver, (B) kidney, and (C) serum of mice at 2 hour after dosing with TCE (800 
mg/kg, oral gavage). Each data point represents the value reported in a CC mouse 
strain. The data point is shown as ½ LOD if an analyte was below the LOD. Data points 
with red color refer to the metabolite levels reported in male B6C3F1 mice. Middle line 
indicates the mean concentration among 20 CC strains. The box and whiskers plots (Min 
to Max) show the PBPK modeling estimates for serum levels of DCVG and DCVC 
based on Chiu et al 2014. The estimates were generated from the median distribution out 
of 100 different populations, with 500 individuals in each population. Different letters 
indicate different statistical groups, as determined by ANOVA with Turkey’s post hoc 
test (p<0.05). 
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Pairwise correlation analysis was conducted for all metabolites and tissues using 
data from 20 CC strains (Figure 3.5 and Figure A-4). Strong positive correlations were 
observed between liver DCVG and NAcDCVC (r=0.89), serum DCVG and liver DCVG 
(r=0.68), and liver NAcDCVC and kidney NAcDCVC (r=0.64). Medium positive 
correlations were observed between kidney DCVG and serum DCVC (r=0.57), liver 
DCVG and kidney DCVG (r=0.49), liver DCVG and serum DCVG (r=0.54), kidney 
DCVG and DCVC (r=0.50), kidney DCVG and NAcDCVC (r=0.53). Interestingly, the 
correlation between liver DCVG and kidney DCVC was statistically insignificant. 
 
 
 
Figure 3.5 Pairwise correlation analysis of DCVG, DCVC, and NAcDCVC across 
tissues. The correlation results are expressed in Spearman coefficient (ρ) and Pearson 
coefficient (r). A p-value less than 0.05 was considered significant across all analyses. 
ns, not significant.   
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As was hypothesized by Chiu et al (2014), inter-strain variability was used as a 
surrogate for human inter-individual variability to estimate uncertainty factors human 
toxicokinetic variability (UFH-TK) for DCVG, DCVC, and NAcDCVC in liver, kidney and 
serum (Table 3.3). As described in Methods, the variance obtained from B6C3F1 mice 
was used to estimate the intra-strain variability in a single CC strain, which was then 
subtracted from the overall observed variance across CC strains. The values of UFH-TK for 
the 95th percentile were 3.3-5.8 for DCVG, 2.1-6.7 for DCVC, and 2.7-4.6 for NAcDCVC. 
Values for the 99th percentile were correspondingly higher. DCVG and NAcDCVC 
showed the highest UFH-TK in liver, while DCVC showed the highest UFH-TK in kidney.   
The extent of variability in the levels of DCVG in serum was less than the 
population variability estimates from a PBPK model (Chiu, et al., 2014) (Figure 3.4). 
Specifically, using the Chiu et al (2014) PBPK model, UFH-TK,95 for DCVG and DCVC in 
serum had 95% confidence intervals of (16-110) and (5-26), respectively, whereas the 
values estimated here were 5.8 and 4.5 (Table 3.3). Additionally, model-derived estimates 
for DCVC in serum were lower than the measured values (Figure 3.4). These 
discrepancies may result from the relatively low detection rate of DCVC in serum (42%). 
About half of the model estimates are below the detection limit, which is also consistent 
with the percentage of undetectable samples. 
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Table 3.3 Derivation of uncertainty factors for inter-strain variability in toxicokinetics of DCVG, DCVC, and NAcDCVC 
in multiple mouse tissues. 
* GM= geometric mean, pmole/g tissue or mL serum; GSD= geometric standard deviation; Vartotal= Variance of log-transformed 
data of 20 CC study; Varintra-strain= Variance of log-transformed data of B6C3F1 study; Varinter-strain = Vartotal -Varintra-strain; UFTKvar, 
Uncertainty factors for inter-strain variability in toxicokinetics of DCVG, DCVC, and NAcDCVC.
  DCVG DCVC NAcDCVC 
  Liver Kidney Serum Liver Kidney Serum Liver Kidney Serum 
 GM 20.3 1.5 1.1 2.0 10.5 0.5 4.4 3.3 2.1 
 GSD 2.9 2.1 2.9 1.6 3.3 2.5 2.5 2.2 1.8 
 σ2total * 1.22 0.57 1.15 0.23 1.06 0.86 0.86 0.61 0.37 
 σ2intra-strain 0.09 0.05 0.02 0.02 0.02 0.04 0.001 0.0007 0.012 
 σ2inter-strain 1.12 0.52 1.13 0.20 1.04 0.82 0.86 0.61 0.36 
 UFH-TK,95 5.72 3.27 5.75 2.10 5.4 4.45 4.61 3.60 2.66 
 UFH-TK,99 11.84 5.35 11.93 2.87 10.9 8.28 8.71 6.15 4.01 
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3.5 Discussion 
Characterization of tissue levels of nephrotoxic glutathione metabolites of TCE is 
an important challenge in regulatory toxicology, compounded by lack of sensitive 
analytical methods. Several analytical methods are available for analysis of DCVG, 
DCVC, and NAcDCVC (Table 3.4). In general, LC-MS/MS-based methods (Kim, et al., 
2009a;  Yoo, et al., 2015a;  Yoo, et al., 2015b) have superior sensitivity for DCVG and 
DCVC. The LC-MS/MS based method for simultaneous detection of DCVG and DCVC 
was developed for mouse serum (Kim, et al., 2009a); however, the applicability of this 
method to parenchymal tissues (e.g. liver and kidney), especially at lower doses of TCE, 
was questionable. Yoo et al. tailored extraction methods to quantify DCVG and DCVC in 
liver (Yoo, et al., 2015a) and kidney (Yoo, et al., 2015b); still, difference in extraction 
methods may result in a systematic bias (Luo, et al., 2017). In this study, tissue extraction 
protocols were optimized, the sensitivity of detection for DCVG and DCVC across tissues 
further enhanced, and the method extended to quantification of NAcDCVC.  
The method was used to characterize tissue-specific variation in formation of 
glutathione conjugation metabolites of TCE. Consistent with our knowledge of the 
metabolic pathways for glutathione metabolism of halogenated solvents, the most 
abundant metabolites of TCE were the glutathione conjugate in liver and the cysteine 
conjugate in kidney (Krzysik and Adibi, 1977;  Moron, et al., 1979;  Whitfield, 2001). 
Importantly, our study allows addressing several additional important gaps in our 
knowledge with respect to glutathione conjugation metabolism of TCE.
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Table 3.4 Comparative analysis of sensitivities for DCVG, DCVC, and NAcDCVC between tissues and studies. 
Reference Matrix Extraction method* Detect Method DCVG
† 
(fmole) 
DCVC 
(fmole) 
NAcDCVC 
(fmole) 
This study 
Liver 
LL-SPE 
LC-MS/MS 
8.7 26.3 20.6 
Kidney 11.7 10.8 24 
Serum PP-SPE 2.9 5.3 24.1 
Instrumental  
LOD₸  0.8 1.2 11 
Kim et al., 2009 Serum LL-SPE LC-MS/MS 37.5 37.5 N/R 
Lash et al., 1999  Blood/urine 
PP-derivatization with 
iodoaceatate and 1-
fluoro-2,4-dinitrobenzene 
LC-UV 50,000 5,000 N/R 
Yoo et al., 2015 Kidney  LL-SPE LC-MS/MS 25⊥ 250 N/R 
Yoo et al., 2015 Liver  SPE LC-MS/MS 100‡ 1,000 N/R 
Lash et al., 2006 Blood/urine Derivatization with 
iodoaceatate and 1-
fluoro-2,4-dinitrobenzene 
LC-UV 
110┬ 110 N/R 
 Liver 1,100 1,100 N/R 
 Kidney 2,200 2,200 N/R 
Bloemen et al., 2001 Urine Derivatization with HCl and diethyl ether GC-MS N/R N/R 80
╒ 
† Limit of detection (LOD) is defined as the tested concentration with the signal-to-noise ratio equals to 3, and expressed with the 
on-column amount of analyte. N/R: Not reported. ₸ Instrumental LOD was tested in de-ionized water. *LL-SPE: liquid-liquid 
extraction coupled with SPE; PP-SPE: protein precipitation coupled with SPE. ⊥Estimated on-column amount from LLOQ of 1 
pmole/g kidney with starting tissue materials of 50 mg tissue. ‡Estimated on-column amount from LLOQ of 2 pmole/g liver with 
starting tissue materials of 100 mg tissue. ┬Estimated on-column amount from LODs of urine/blood (1.1 pmol/ml), liver (11 
pmol/g tissue), and kidney (22 pmol/g tissue) with starting tissue materials of 0.5 ml/500 mg tissue.╒Estimated on-line amount 
from LOD of 0.04 μmol/L.  
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First, it is interesting that NAcDCVC was most abundant in liver. Formation of 
mercapturic acids from glutathione conjugates involves both liver and kidney (Hinchman 
and Ballatori, 1994;  Inoue et al., 1984;  Inoue et al., 1987;  Lash, et al., 1998). DCVG 
synthesized within hepatocytes can be secreted across the canalicular membrane into bile, 
broken down to form DCVC, reabsorbed and n-acetylated to form NAcDCVC in liver. No 
ex vivo formation of glutathione conjugates from TCE was observed. When quantified 
across tissues and individual strains, high correlations were found for liver DCVG and 
serum DCVG, and for liver DCVG and NAcDCVC which suggests that DCVG can be 
directly transported from liver into blood. Fast conversion from DCVG to NAcDCVC is 
also plausible in liver. Interestingly, liver DCVG and NAcDCVC were not correlated with 
kidney DCVC, but they were correlated with kidney NAcDCVC. These findings suggest 
that i) formation and elimination of DCVC in kidney may be a critical source of inter-
individual variability among strains, and ii) liver may be the primary site for generation of 
NAcDCVC. 
Second, this study enabled quantitative comparisons of conjugative metabolism 
pathways between TCE and tetrachloroethylene (PCE). Levels of glutathione conjugation 
metabolites in all tissues examined were lower upon exposure to TCE at the equivalent 
molar dose (6 mmole/kg) and time point as compared to PCE (Luo, et al., 2017). 
Specifically, concentrations of DCVG were lower by 3.9-fold in liver, 2.4-fold in kidney, 
and 3.3-fold in serum as compared to S-(1,2,2-trichlorovinyl) glutathione (TCVG). 
Concentrations of DCVC were 2.6-fold lower in kidney and 5.3-fold in serum, while were 
1.2-fold higher in liver, as compared to S-(1,2,2-trichlorovinyl)-L-cysteine (TCVC). 
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These findings are consistent with reports that in the absence of hepatic metabolism of 
glutathione conjugates, PCE is more cytotoxic than TCE to isolated kidney cells (Lash, et 
al., 2007), and that DCVC is less nephrotoxic than TCVC in vivo (Birner, et al., 1997). 
However, kidney cancer hazard evidence in humans is stronger for TCE than PCE (Guha, 
et al., 2012), indicating that bioactivation to downstream reactive sulfoxides, DCVCSO 
and NAcDCVCSO, may be most critical part of cancer etiology in the kidney (Irving et 
al., 2013;  Lash et al., 1994). It is also plausible that lower levels of DCVC and NAcDCVC, 
as compared to those of TCVC and NAcTCVC, are the product of a higher conversion 
rate to their corresponding sulfoxides, a process that is mediated by hepatic cytochrome 
P450 3A enzymes (Werner et al., 1996).  
Third, this study characterized inter-strain variability in toxicokinetics of TCE 
glutathione conjugates (Table B-12). Inter-strain variability in toxicokinetics of DCVG 
was greatest in liver (GSD=2.9, 44-fold differences). Corresponding values for serum and 
kidney were 2.5 (6-fold) and 2.1 (5-fold). These differences may result from the inter-
strain variability in enzyme activities, or in other PK modifiers such as absorption and 
elimination efficiency of TCE, cellular transporters, and plasma protein levels. The inter-
individual variability in human enzyme activities related to formation of DCVG, DCVC, 
and NAcDCVC has been reported for GSTs (4-92 fold differences), gamma-glutamyl 
transferase (3-fold), n-acetyltransferase (70-fold), and acylase (7.4-fold), as well as flavin 
monooxygenase 3 (10-fold), beta-lyase (4-fold), and CYP3A (40-fold) (Gul Altuntas and 
Kharasch, 2002;  Helander et al., 1998;  Lamba et al., 2002;  Mccarthy et al., 1994;  Slone 
et al., 1995;  Stormer et al., 2000). The importance of both toxicokinetic and 
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toxicodynamic variability is further supported by observations that allelic variations in 
human enzymes involved in both toxicokinetics and toxicodynamics, such as GSTθ and 
renal β lyase, have been associated with TCE renal cancer risk (Moore et al., 2010;  
Spearow et al., 2017).  
Quantitative estimates of variability among strains and tissues have important 
implications for risk assessment because in the absence of chemical-specific data a default 
“uncertainty factor” of 100.5 (3.16) is used for inter-individual variability in toxicokinetics. 
Although intended to be “conservative,” it is common for variability to exceed this value. 
In the most recent analysis by WHO/IPCS (Chiu and Slob, 2015), the GSD for 
toxicokinetic variability has a 90% confidence interval of 1.2 to 2.6, which corresponds to 
UFH-TK,99 protecting 99% of the population of 1.4 to 8.9, with a median of 3.6. Thus, the 
“default” value is actually closer to a central estimate of toxicokinetic variability, 
suggesting that chemical-specific data are needed. Indeed, consistent with previous 
analyses by Chiu et al. (2009, 2014), the data for GSH conjugation metabolites of TCE 
suggest that for most tissues and metabolites, a factor of 3.16 is not sufficient to cover 
99% of the population variability in toxicokinetics (Table 3.3).   
There are several key limitations to this study. First, the analyte recovery of DCVC 
is inadequate (10~15%) as compared to those of DCVG and NAcDCVC. Improvements 
in sample preparation techniques are needed to further enhance the sensitivity of DCVC 
detection. Second, because only a single sample from each CC strain was available, inter-
strain variability was estimated by subtracting total observed variability from intra-strain 
variability in B6C3F1 mice. Future studies may benefit from the characterization of intra-
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strain variability in CC strains. Third, the data in CC mice was only at a single dose and 
time point. Future studies need to include time-course data at multiple dose levels to 
improve the estimates of tissue-specific GSH conjugation dosimetry, particularly if 
incorporated into a population PBPK model. To date, the PBPK modeling of inter-strain 
variability in oxidative metabolism of TCE has been well characterized, but the PBPK 
compartments in conjugative metabolism of TCE, especially at target organs, are yet to be 
fully established (Chiu, et al., 2014).      
 
3.6 Conclusions 
Herein, a LC-MS/MS method that simultaneously detects DCVG, DCVC, and 
NAcDCVC in multiple mouse tissues has been successfully developed, and applied in 
animal studies. With this method, for the first time, the inter-individual variability in 
conjugative metabolism of TCE has been characterized in multiple tissues of a panel of 
genetically diverse CC mice. Despite some study limitations, our data suggest that for 
TCE, the default uncertainty factor of 3.16 for toxicokinetic variability would be 
inadequate to protect 99% of the population for organ-specific toxicity mediated by 
DCVG, DCVC, and NAcDCVC.  
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CHAPTER IV   
 
MODULATION OF TETRACHLOROETHYLENE-ASSOCIATED KIDNEY 
EFFECTS BY NONALCOHOLIC FATTY LIVER OR STEATOHEPATITIS IN 
MALE C57BL/6J MICE 
 
 
4.1 Overview 
Accounting for genetic and other (e.g., underlying disease states) factors that may 
lead to inter-individual variability in susceptibility to xenobiotic-induced injury is a 
challenge in human health assessments. A previous study demonstrated that nonalcoholic 
fatty liver disease (NAFLD), one of the common underlying disease states, enhances 
tetrachloroethylene (PCE)-associated hepatotoxicity in mice. Interestingly, NAFLD 
resulted in a decrease in metabolism of PCE to nephrotoxic glutathione conjugates; we 
therefore hypothesized that NAFLD would protect against PCE-associated nephrotoxicity. 
Male C57BL/6J mice were fed a low-fat (LFD), high-fat (31% fat, HFD), or high-fat 
methionine/choline/folate-deficient (31% fat, MCD) diets. After 8 weeks mice were 
administered either a single dose of PCE (300 mg/kg i.g.) and euthanized at 1-36 hours 
post dose, or five daily doses of PCE (300 mg/kg/d; 4 hrs post-dose). Relative to LFD-fed 
mice, HFD- or MCD-fed mice exhibited decreased PCE concentrations and increased 
trichloroacetate (TCA) in kidneys. S-(1,2,2-trichlorovinyl)glutathione (TCVG), S-(1,2,2-
trichlorovinyl)-L-cysteine (TCVC), and N-acetyl-S-(1,2,2,-trichlorovinyl)-L-cysteine 
(NAcTCVC) were also significantly lower in kidney and urine of HFD- or MCD-fed mice 
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compared to LFD-fed mice. Despite differences in levels of nephrotoxic PCE metabolites 
in kidney, LFD- and MCD-fed mice demonstrated similar degree of nephrotoxicity. 
However, HFD-fed mice were less sensitive to PCE-induced nephrotoxicity. Thus, while 
both MCD- and HFD-induced fatty liver reduced the delivered dose of nephrotoxic PCE 
metabolites to the kidney, only HFD was protective against PCE-induced nephrotoxicity, 
possibly due to greater toxicodynamic sensitivity induced by methyl and choline 
deficiency.  These results therefore demonstrate that preexisting disease conditions can 
lead to a complex interplay of toxicokinetic and toxicodynamic changes that modulate 
susceptibility to the toxicity of xenobiotics.  
 
4.2 Introduction 
Human health risk assessors face a considerable challenge when it comes to 
addressing inter-individual variability of adverse health effects associated with 
environmental exposures (Zeise, et al., 2013). In addition to genetics, sex and diet, pre-
existing disease states may also affect inter-individual variability. Nonalcoholic fatty liver 
disease (NAFLD) is a good example of a prevalent chronic disease in the developed 
countries such as the United States, Germany, and Israel (Browning et al., 2004;  Kuhn et 
al., 2017;  Zelber-Sagi et al., 2006). The global prevalence of NAFLD is estimated to be 
~25% (Younossi et al., 2016b), and associated economic burden on health care is 
substantial (Younossi et al., 2016a). NAFLD is a spectrum of health conditions that 
initially presents as nonalcoholic fatty liver (NAFL) and that can progress to nonalcoholic 
steatohepatitis (NASH), a liver disease state characterized by accumulation of fat, 
  
72 
 
inflammation, and cell injury (ballooning) (Chalasani, et al., 2012). Even though NAFL 
is considered a benign form of the disease, subjects with NAFL may be more susceptible 
to further liver damage by other exposures. Exacerbated liver injury has been 
demonstrated in rodents with experimental NAFLD that were exposed to vinyl chloride 
(Lang et al., 2018), methotrexate (Hardwick, et al., 2014), or a ubiquitous environmental 
contaminant tetrachloroethylene (PCE) (Cichocki, et al., 2017b). 
PCE is a chemical that was extensively used in metal degreasing, as a feedstock in 
chemical syntheses, or in dry-cleaning (IARC, 2014;  U.S. EPA, 2011b). PCE is one of 
the most commonly found contaminants at hazardous waste sites (National Research 
Council, 2010). In the United States, 90% of the population had detectable levels of PCE 
in their blood (Jia, et al., 2012). PCE exposure has been associated with cancer and non-
cancer toxicity, including nephrotoxicity in humans and rodents (Cichocki, et al., 2016;  
U.S. EPA, 2011b). Toxicity of PCE in the kidney has been attributed to its tissue-specific 
metabolism (Cichocki, et al., 2016). 
Metabolism of PCE is mediated by both cytochrome P450s (CYPs) and 
glutathione-S transferases (GSTs) in the liver (Lash and Parker, 2001). The oxidative 
pathway yields trichloroacetate (TCA), a rodent hepatocarcinogen (Bull et al., 1990;  
Herren-Freund et al., 1987). The glutathione conjugation pathway in the liver forms 1,2,2-
trichlorovinyl-L-glutathione (TCVG) which can be transported via circulation to the 
kidney where it is further metabolized to 1,2,2-trichlorovinyl-L-cysteine (TCVC) (Lash 
and Parker, 2001). The fate of TCVC is either metabolic activation to reactive species, 
including cytotoxic TCVC-sulfoxide (Elfarra and Krause, 2007), or detoxification via N-
  
73 
 
acetyltransferase-mediated formation of N-acetyl-1,2,2,-trichlorovinyl-L-cysteine 
(NAcTCVC), a mercapturate that is excreted in the urine in humans and rodents (Lash and 
Parker, 2001). NAcTCVC can also be converted to NAcTCVC-sulfoxide, which is another 
nephrotoxic metabolite both in vivo and in vitro (Cristofori et al., 2015). 
A previous study characterized the toxicokinetics of PCE, as well as its oxidative 
(TCA) and glutathione conjugation metabolites (TCVG, TCVC, and NAcTCVC) in the 
liver, serum, and urine of mice with various degrees of NAFLD that were exposed to a 
single dose of PCE (Cichocki, et al., 2017a). Interestingly, mice with NAFLD generated 
higher levels of liver TCA, which in turn resulted in more pronounced liver injury 
(Cichocki, et al., 2017b). While much is known about the oxidative metabolites of PCE, 
little information is available on the toxicokinetics of glutathione conjugates of PCE in 
vivo. NAFLD resulted in a significant reduction in levels of TCVG, TCVC, and 
NAcTCVC in liver, serum, and urine (Cichocki, et al., 2017a); however, the kinetics of 
PCE glutathione conjugates has not been explored in kidney, a target organ for PCE 
toxicity. Therefore, we tested the hypothesis that, compared to healthy mice, mice with 
diet-induced NAFLD would have lower kidney concentrations of TCVG, TCVC, and 
NAcTCVC following exposure to PCE, and this reduction in metabolite concentration 
would be associated with decreased sensitivity to PCE-associated nephrotoxicity.  
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4.3 Material and Methods 
4.3.1 Chemicals  
PCE (CAS 127-18-4) was obtained from Sigma Aldrich (Cat No. 270393, Batch 
No. SHLFD9374V, purity 99.93%; St. Louis, MO). S-(1,2,2-trichlorovinyl) glutathione 
(TCVG), 13C2,15N-TCVG, S-(1,2,2-trichlorovinyl)-L-cysteine (TCVC), 13C5,15N-TCVC, 
N-acetyl-S-(1,2,2-trichlorovinyl)-L-cysteine (NAcTCVC), and 13C3,15N-NAcTCVC were 
graciously provided by Dr. Avram Gold at the University of North Carolina, Chapel Hill. 
The purity of all standards was determined to be >95% by NMR and HPLC-UV. All other 
chemicals were of the highest purity available and were acquired from Sigma Aldrich. 
4.3.2 Animals  
The in-life portion of this study has been previously described in (Cichocki, et al., 
2017a). Briefly, five-week-old male C57BL/6J mice (n=150) were obtained from the 
Jackson Laboratory (Bar Harbor, ME) and acclimatized for one week on a standard rodent 
chow containing 4% calories from fat (low-fat diet; LFD; Teklad Rodent Diet #8604; 
Harlan, Madison, WI). Mice were randomly assigned (five mice per cage) into groups fed 
a control LFD, a diet containing 31% calories from fat (high fat diet, HFD; Diet #519567; 
Dyets Inc., Bethlehem, PA), or a diet depleted in methionine and devoid of choline and 
folate (methyl and choline-deficient diet, MCD; Diet #519541; Dyets, Bethlehem, PA). 
The overall study design is shown in Figure 4.1 and the study aimed to model conditions 
of (i) healthy liver and (ii) mild, or (iii) severe NAFLD phenotypes.  
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4.3.3 Toxicokinetic Study Design 
Following eight weeks of feeding with the aforementioned diets, mice were 
exposed to a single dose of PCE (300 mg/kg in 5% Alkamuls-EL620 in saline; 5 mL/kg). 
All exposures took place between 07:00 and 10:00 hours. Mice (n=5/diet/time-point) were 
euthanized at 1, 2, 4, 12, or 24 hours after gavage (total n=75). An additional four mice 
per diet group were individually housed in stainless steel metabolic cages with wire mesh 
bottoms (Techniplast, Chester, PA) for 36 hours for urine collection (total n=12). Five 
mice per diet were treated with vehicle and euthanized at 24 hours post gavage to perform 
additional biochemical analyses (total n=15). Serum was prepared from blood drawn at 
exsanguination via centrifugation (Z gel tubes; Sarstedt, Nümbrecht, Germany). Kidneys 
were excised, rinsed in saline, blotted dry, weighed, snap-frozen in liquid nitrogen, and 
stored at -80oC until analyzed.  
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Figure 4.1 Schematic representation of study designs. Adult male C57BL/6J mice 
were used in these studies. Mice were fed with low fat diet (LFD), high fat diet (HFD), 
or methionine and choline-deficient diet (MCD) for 8 weeks, and then intragastrically 
dosed with tetrachloroethylene (PCE). The first study investigated the toxicokinetics of 
PCE metabolites up to 36 hrs after a single dose of PCE (300 mg/kg). The second study 
examined the toxicodynamic phenotypes of mice administered with repeated doses for 5 
consecutive days (300 mg/kg/d); samples were collected 4 hrs after the last dose. 
Vertical lines indicate the time points of sample collections. Down arrows represent 
chemical treatments. Collected endpoints in each study are shown as a bulleted list. 
 
4.3.4 Toxicodynamic Study Design  
After eight weeks of feeding with the diets above, mice were intragastrically 
administered a single dose of PCE (300 mg/kg/d in 5% Alkamuls-EL620 in saline, 5 
mL/kg) or vehicle for five consecutive days (n=8/diet/treatment). This dose was selected 
as the toxicokinetics of PCE and TCA in male mice after exposure to 150-1000 mg/kg 
PCE has been characterized in liver and blood and was shown to be well-tolerated in acute 
(Philip, et al., 2007) and sub-chronic studies (National Toxicology Program, 1977). All 
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exposures took place between 07:00 and 10:00 hours. Three days prior to necropsy, 
animals were administered 5-bromo-2'-deoxyuridine in drinking water (0.02%, w/v). At 
four hours following the last dose of PCE, animals were deeply anesthetized with 
pentobarbital (50 mg/kg, i.p.) and sacrificed via exsanguination through the vena cava. 
This time point was selected based on our previously published toxicokinetic data where 
we showed that PCE and its oxidative and conjugative metabolites were detectable in 
mouse liver and serum four hours following a single dose of PCE (Cichocki, et al., 2017a;  
Luo, 2018). Mice were euthanized, and serum and kidneys were harvested as described 
above. A small section of one kidney was fixed in formalin for histological examination. 
 
4.3.5 Analysis of PCE and TCA via Gas Chromatography/Mass Spectrometry  
PCE and TCA were measured in kidney tissue as previously described . Briefly, 
methanolic kidney homogenates were analyzed for PCE via purge-and-trap (dynamic) 
headspace gas chromatography/mass spectrometry (GC/MS). TCA was analyzed via a 
modified US EPA Method (EPA 815-B-03-002). Briefly, aqueous kidney homogenates 
were incubated with 10 % (v:v) sulfuric acid in methanol (50 oC, 2 hr) to generate TCA 
methyl ester. After liquid-liquid extraction, the derivatives were analyzed via GC/MS. 
 
4.3.6 Liquid Chromatography/Mass-Spectroscopy (LC/MS) Analysis of TCVG, 
TCVC, and NAcTCVC 
The method of Luo et al. (Luo, et al., 2017) was used for detection of TCVG, 
TCVC, and NAcTCVC in kidney tissue. Briefly, kidney homogenates were subjected to 
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liquid-liquid extraction, and solid-phase extraction prior to chromatographic separation 
and detection via LC/MS-MS.  
 
4.3.7 Serum clinical chemistry 
Blood urea nitrogen (BUN) and serum creatinine levels were measured in serum 
samples using a VetScan 2 (Abaxis, Union City, CA) and a Comprehensive Diagnostic 
Profile rotor according to the manufacturer’s instructions.  
 
4.3.8 Histopathology 
Kidney samples were embedded in paraffin, sectioned at 5 µm, and stained with 
hematoxylin and eosin (H&E). A veterinary pathologist who was blinded to the 
experimental design and sample identification numbers evaluated the slides. 
 
4.3.9 Immunohistochemical staining of Kidney injury molecule-1 (KIM-1) 
Tissues were sectioned at 5 µm onto poly-l-lysine-coated slides. Deparaffinized 
and rehydrated slides were hydrolyzed with warm (37oC) 2N HCl for 20 minutes in an 
oven. Slides were rinsed with water (1 minute) and then placed in pre-warmed water in a 
37oC oven for 20 minutes. Samples were then incubated in pre-warmed pepsin solution 
(2g/500 mL of 0.2N HCl; Dako, Santa Clara, CA) for 15 min at 37oC. Slides were rinsed 
with water twice (1 minute each), and then with phosphate-buffered saline with 0.1% 
Tween-20 (PBS-T) twice (3 minutes each). Endogenous peroxidase activity was blocked 
using a Peroxidase Blocking Reagent (Dako) for 5 minutes. After washing with PBS-T, 
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slides were incubated for 10 minutes at room temperature with a goat anti KIM-1 antibody 
(1 µg/mL; AF1817, Lot KCA0415031; R&D systems, Minneapolis, MN) prepared in an 
Antibody Diluent (Dako). After washing with PBS-T, slides were incubated with rabbit 
anti-goat HRP-conjugated secondary antibody (1:200 dilution; 10 minutes at room 
temperature), washed with PBS-T again, and then incubated with 3,3’-diaminobenzidine 
reagent (Dako) for 8 minutes at room temperature. After ample washing in deionized 
water, slides were placed in Mayer’s Hematoxylin (1 minute), and then thoroughly washed 
under running tap water. Slides were dehydrated, mounted using Permount (Thermo 
Fisher Scientific), and examined using light microscopy. Approximately 250 tubules from 
5 random fields (100X) were evaluated for each animal. The ratio of positively-stained 
tubules to the total number of tubules was recorded. Results were verified by an individual 
who was blinded to study design and animal identification numbers. 
 
4.3.10 Enzyme-linked immunosorbent assay (ELISA) detection of KIM-1 protein 
Kidney levels of KIM-1 protein were determined by using a Mouse TIM-1/KIM-
1/HAVCR Quantikine ELISA Kit (R & D systems, Minneapolis, MN). Briefly, kidney 
tissue (10 mg) was homogenized in 1 mL of calibrator diluent RD5-26 buffer using Bead 
Ruptor 24 Elite (Omni International, Kennesaw, GA). The homogenate was centrifuged 
at 10,000 rpm for 5 mins, and the supernatant was subject to ELISA detection of KIM-1 
according to the manufacturer’s instructions. 
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4.3.11 Immunohistochemical Detection of BrdU 
BrdU-positive cells were counted on paraffin-embedded sections using a 
commercially available kit (Invitrogen, Carlsbad, CA). Each slide contained a section of 
duodenum for positive control of BrdU incorporation. Five random fields (200X), or at 
least 500 tubular nuclei, were counted for each animal. The ratio of positively stained 
nuclei to total nuclei was determined for each animal. Results were verified by an 
individual who was blinded to study design and animal identification numbers. 
 
4.3.12 Quantitative Reverse Transcriptase real-time polymerase chain reaction 
(qRT-PCR)  
 qRT-PCR was carried out using 40 ng of kidney cDNA as previously described 
for liver tissue (Cichocki et al., 2017c). TaqMan probes (Havcr1: Mm00506686_m1; 
Fabp1: Mm00444340_m1; Lcn2: Mm01324470_m1; Tbp: Mm01277042_m1; Thermo 
Fisher Scientific) were used as per the manufacturer’s instructions. Expression of Tbp was 
used as a reference. 
 
4.3.13 mRNA sequencing  
The protocol for mRNA sequencing has been previously described . Briefly, 
cDNA libraries were generated from high-quality (RNA integrity number >8.0) RNA 
samples from RNA extracted from pulverized kidney tissue using an Illumina TruSeq 
mRNA stranded HT kit (Illumina, San Diego, CA). An Illumina HT-2500 was used for 
sequencing; all samples were run on the same flow cell. After filtering and mapping to the 
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GRcm38/mm10 assembly, a list of 20,032 genes was obtained. Differential gene 
expression was determined via the R (v 3.3.1) package DESeq2 (v 1.12.3) (Love et al., 
2014), following recommended guidelines by the authors. To be deemed differentially-
expressed, log2 fold-changes and false discovery rate (FDR)-adjusted p-values were cut 
off at 0.58 and 0.1, respectively. A cut-off for log2 of 0.58 represents an approximate 1.5-
fold change in expression level compared to the reference (LFD) group. Default settings 
in DESeq2 were used for FDR adjustment. 
 
4.3.14 Statistical Analyses  
GraphPad Prism (v 5.0), was used for statistical analysis for biochemical analyses. 
One-way ANOVA followed by Newman-Keuls post-hoc test was used for comparisons 
between different disease states, where a p-value <0.05 was deemed statistically 
significant. For analysis of correlations between metabolizing enzyme transcript 
abundance and toxicokinetic phenotype, Pearson correlation coefficients were determined 
and associated p-values were corrected for multiple comparisons . 
 
4.3.15 Data Availability  
RNA sequencing data are publically-available through Gene Expression Omnibus 
(GEO; accession ID: GSE115641; 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115641) and individual animal 
phenotype data are supplied as Supplementary Files. In addition to GEO, complete lists of 
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differentially-expressed genes and enriched pathways are provided as Supplementary 
Files. 
 
4.4 Results 
4.4.1 NAFLD affects the toxicokinetics of PCE and its oxidative and conjugative 
metabolites.  
 We first determined whether experimental NAFLD affects the kidney 
toxicokinetics of parent compound (PCE), oxidative (TCA), and GSH conjugative 
metabolites (TCVG, TCVC, and NAcTCVC) up to 36 hours after a single oral dose of 
PCE (300 mg/kg). The kidney kinetics of PCE were qualitatively similar among LFD-, 
HFD-, and MCD-fed mice (Figure 4.2, left panel). However, HFD- or MCD-fed mice had 
lower concentrations of PCE in the kidney, where the area under the concentration-time 
curve (AUC) of PCE was 1.3-fold or 2.1-fold lower in HFD- or MCD-fed mice, 
respectively, compared to LFD-fed mice (Figure 4.2, right panel). HFD- or MCD-fed mice 
showed a delayed or inhibited clearance of TCA from kidney tissue compared to LFD-fed 
mice, which led to an apparent accumulation of TCA in the kidneys. Correspondingly, the 
AUC of TCA in the kidney was approximately 1.6- to 1.7-fold higher in HFD- and MCD-
fed mice compared to LFD-fed mice. While the results for PCE and TCA were interesting, 
perhaps the more toxicologically-relevant finding was that mice with NAFLD had 
considerably lower AUCs of TCVG, TCVC, and NAcTCVC in kidney tissue. Of 
particular note was the finding that the AUC of TCVC, which may be metabolically-
activated to electrophilic, cytotoxic, genotoxic, and/or mutagenic intermediates, was 
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approximately 30-40% lower in the kidneys of mice with NAFLD compared to LFD-fed 
mice.  
 
Figure 4.2 Kidney toxicokinetics of parent compound (PCE), oxidative metabolite 
(TCA), and glutathione conjugation metabolites of PCE (single dose, 300 mg/kg, 
i.g.) in male C57BL/6J mice fed with low fat diet (LFD), high fat diet (HFD), or 
methyl and choline deficient diet (MCD). Left panel shows the kinetic profiles, where 
the diet groups are identified by symbols (triangle, LFD; circle, HFD; square, MCD) and 
the line graph are shown as mean ± SD (n=4-5/time point/group). Right panel indicates 
the area under the concentration-time curves (AUCs) that are derived from the group 
mean kinetic profiles of PCE metabolites up to 36 hrs after dosing. The dotted-line 
represents values for LFD-fed mice. 
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4.4.2 Biochemical and histopathological evaluation of kidney injury. 
Absolute kidney weight, but not kidney-to-bodyweight ratio, has been shown to 
correlate strongly with sub-chronic and chronic renal injury in rats (Craig et al., 2015). 
Absolute kidney weight was unaffected by diet or PCE exposure (Table 4.1); however, 
kidney-to-body weight ratio was decreased in HFD-fed mice compared to LFD-fed 
control, and was significantly increased by PCE exposure in all three diet groups. This 
effect was likely due to PCE causing about a 10% decrease in body weight (Cichocki, et 
al., 2017b). There was no effect of diet or PCE exposure on BUN or serum creatinine 
levels. Histopathological assessment of PCE effects on the kidneys showed no 
pathological changes in either group (data not shown). 
Table 4.1 Absolute kidney weight and kidney to bodyweight ratio in this study 
LFD HFD MCD 
Vehicle PCE Vehicle PCE Vehicle PCE 
Absolute kidney 
weight  0.28±0.03 0.30±0.02 0.31±0.02 0.31±0.02 0.29±0.01 0.30±0.02 
Kidney: BW ratio 1.07±0.09a 1.19±0.08b 0.90±0.06c 1.00±0.03a 1.01±0.05 a 1.09±0.07 a 
*Different superscripts indicate different statistical groups (ANOVA with Tukey’s post-
hoc test; p<0.05)
4.4.3 HFD-induced NAFLD manifests protective effects on kidney proximal tubule 
injury caused by PCE.  
KIM-1 is a sensitive marker of acute renal injury and is especially useful for 
diagnosing xenobiotic-induced proximal tubular injury (Vaidya et al., 2008). We observed 
very few KIM-1-stained proximal tubules in vehicle-treated mice (Figure 4.3A). In PCE-
exposed LFD- and MCD-fed mice, approximately 40-50% of the proximal tubules were 
85 
Figure 4.3 PCE-induced proximal tubular injury in mice after 8 weeks of low fat diet 
(LFD), high fat diet (HFD), or methyl and choline deficient diet (MCD). The PCE-
induced proximal tubular injury is visualized by staining kidney injury molecule-1 (A). The 
percentage of positively-stained proximal tubules (B), gene expressions (C) and protein levels 
(D) of KIM-1 are shown in scatter plots. Groups with different letters are significantly 
different (One-way ANOVA with Newman-Keuls post hoc test, p<0.05). 
positively-stained for KIM-1, indicating kidney injury, whereas only about 10% of the 
proximal tubules expressed detectable levels of KIM-1 in HFD-fed mice (Figure 4.3B). 
Data from immunohistochemical detection of KIM-1 were in concordance with gene 
expression of Havcr1 (Figure 4.3C) and KIM-1 protein levels in kidney homogenates 
(Figure 4.3D).   
4.4.4 Effect of NAFLD on kidney transcriptome. 
To characterize the molecular effects of PCE exposure on the kidneys in mice with 
or without NAFLD we used RNA sequencing. First, we sought to understand the effect of 
HFD and MCD diets on kidney gene expression in absence of PCE. Principal component 
analysis revealed that LFD-fed mice were completely separated from HFD- and MCD-fed 
mice, but the two NAFLD groups clustered together (Figure 4.4A). In HFD- or MCD-fed 
mice, a total of 223 and 165 genes, respectively, were differentially expressed compared 
to LFD-fed mice, with the majority of genes overlapping between these two groups 
(Figure 4.4B). There was a strong positive correlation between the gene expression data 
in HFD- and MCD-fed mice (Pearson’s r=0.80), indicating that the directionality of 
change in expression (i.e. up-regulated or down-regulated) was similar between these two 
groups (Figure 4.4C). Molecular pathway analysis of the 125 genes that were differentially 
expressed in both HFD- and MCD-fed mice revealed altered retinol and drug metabolism 
and glycolysis/gluconeogenesis in the kidneys of mice with NAFLD (Table 4.2). With 
respect to genes involved in xenobiotic metabolism that were differentially-expressed in 
HFD- of MCD-fed vehicle-treated mice (Figure 4.4D), we found that Ces1g, Cyp2d12, 
Cyp2c68, Cyp2c69, and Slc22a29 were down-regulated in HFD- or MCD-fed mice. At 
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the same time, Slco1a1, Nat8f5, Ugt2b5, and Ugt2b37 were up-regulated compared to 
vehicle-treated LFD-fed mice. Generally, the effect of NAFLD on the expression of genes 
involved in xenobiotic metabolism was more pronounced in HFD- compared to MCD-fed 
mice. 
Figure 4.4 Effect of diets on kidney transcriptome. All analyses were conducted on 
vehicle-treated mice (24 hr time point) after 8 weeks of low fat diet (LFD), high fat diet 
(HFD), or methyl and choline deficient diet (MCD). (A) Principle component analysis of 
diet-mediated effects on kidney transcriptome. (B) Venn diagram showing the 
differentially-expressed genes of HFD or MCD group as compared to LFD group. 
Transcript with an absolute value of log2 fold change > 0.58 and an adjusted q-value < 
0.1 is deemed to be differentially-expressed. (C) Plot of fold changes (log2, compared 
with LFD) of individual transcripts in HFD- and MCD-fed mice. Transcripts changed by 
diets are colored in green (HFD), orange (MCD), or purple (both). (D) Heatmap of diet 
effects on xenobiotic metabolism-associated genes. Transcripts changed by diet are 
colored by red (up-regulation) or blue (down-regulation). 
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Table 4.2 Molecular pathways perturbed by HFD or MCD in mouse kidney 
KEGG_PATHWAY No. of  genes 
Fold 
Enrichment 
Benjamini 
corrected q-
value 
HFD:  223 
mmu01100:Metabolic pathways 33 2.2 8.56E-04 
mmu00140:Steroid hormone biosynthesis 9 8.7 1.10E-03 
mmu00830:Retinol metabolism 8 7.5 3.88E-03 
mmu00983:Drug metabolism - other enzymes 6 9.9 9.20E-03 
mmu00053:Ascorbate and aldarate metabolism 5 15.5 9.49E-03 
mmu00980:Metabolism of xenobiotics by 
cytochrome P450 6 7.9 1.47E-02 
mmu00982:Drug metabolism - cytochrome P450 6 7.6 1.52E-02 
mmu00010:Glycolysis / Gluconeogenesis 6 7.6 1.52E-02 
mmu01130:Biosynthesis of antibiotics 10 3.9 1.64E-02 
mmu00040:Pentose and glucuronate 
interconversions 5 11.7 1.67E-02 
mmu05204:Chemical carcinogenesis 7 6.4 1.76E-02 
mmu04610:Complement and coagulation cascades 6 6.6 2.59E-02 
mmu00340:Histidine metabolism 4 14.0 3.26E-02 
mmu04512:ECM-receptor interaction 6 5.7 4.13E-02 
MCD: 165 
mmu04610:Complement and coagulation cascades 9 12.9 4.63E-05 
mmu00830:Retinol metabolism 7 8.6 9.44E-03 
mmu00140:Steroid hormone biosynthesis 6 7.5 4.74E-02 
mmu01100:Metabolic pathways 23 2.0 4.84E-02 
Common genes 125 
mmu00830:Retinol metabolism 7 10.5 5.46E-03 
mmu00140:Steroid hormone biosynthesis 6 9.2 2.58E-02 
mmu01100:Metabolic pathways 21 2.2 2.06E-02 
mmu00010:Glycolysis / Gluconeogenesis 5 10.1 4.09E-02 
4.4.5 NAFLD-dependent perturbation of kidney lipid metabolism in mice following 
PCE exposure.  
PCE exposure was associated with differential expression of 378, 315, and 222 
genes in kidneys of LFD-, HFD-, and MCD-fed mice, respectively. Of these genes, 109 
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overlapped among all three groups (Figure 4.5A). Gene set enrichment analysis revealed 
a number of molecular pathways in the kidneys were perturbed by PCE exposure, 
including fatty acid synthesis and metabolism, PPARα signaling, and xenobiotic 
metabolism (Figure 4.5B), among which biosynthesis of unsaturated fatty acids and fatty 
acid metabolism were the most enriched pathways in MCD-fed mice. While many 
pathways were enriched in all diet groups, a few PCE-dependent pathways were 
modulated in a diet-specific fashion. Xenobiotic metabolism and transport were enriched 
only in PCE-exposed LFD-fed mice, while butanoate metabolism and amino acid 
degradation were enriched only in PCE-exposed MCD-fed mice. 
Next, we extracted unique genes from the top five enriched pathways 
(“biosynthesis of unsaturated fatty acids”, “fatty acid metabolism”, PPAR signaling 
pathways”, “drug metabolism”, and “metabolism of xenobiotics by cytochrome P450”) 
and performed unsupervised hierarchical clustering of the individual genes (Figure 4.5C). 
Two anion transporter genes (Slc7a13 and Slc22a7) were down-regulated in all PCE-
treated animals. Metabolism–associated genes (Ugt1a10, Ugt1a2, Aldh1b1, and Pck2), 
amino acid transporter gene (Slc43a1), and Kim-1 gene (Havcr1) are up-regulated in PCE-
treated animals; the effects were more pronounced in LFD-fed mice. The rest of xenobiotic 
metabolism-associated genes were also induced by PCE, but were more pronounced in 
HFD-fed mice. As a PPARα responsive gene, Cyp4a10 expression was induced by PCE 
in all three diet groups, with the greatest induction being observed in MCD- and HFD-fed 
mice compared to LFD-fed mice. The extent of Cyp4a10 induction is concordant with the 
kidney levels of TCA, which is a known PPARα activator. To confirm these diet-
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dependent effects of PCE on kidney gene expression that were discovered by RNA-
sequencing, we measured the expression of Lcn2, Havcr1, and Fabp1 via qRT-PCR. The 
results were largely similar between qRT-PCR (Figure A-5A-C) and RNA-sequencing 
(Figure A-5D-F).   
Figure 4.5 Diet-specific effects of PCE exposure on kidney transcriptomes. (A) Venn 
diagram showing the differentially-expressed genes in PCE-exposed group as compared 
to diet-matched, vehicle-treated group. Transcript with an absolute value of log2 fold 
change > 0.58 and an adjusted q-value < 0.1 is deemed to be differentially-expressed. 
(B) Perturbed biological pathways due to PCE exposure in mice fed with LFD, HFD, or
MCD for 8 weeks. The fold enrichment scores are colored, and scaled from 0 (white) to
20 (orange). (C) Heatmap of diet-and PCE-induced effects on xenobiotic metabolism-
associated genes. Transcripts are colored by row Z-score, and scaled from -2 (blue) to 2
(red). (D) Quantitative RT-PCR results for Cyp4a10 expression in mouse kidney.
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4.5 Discussion 
NAFLD is known to alter the expression of transporter and metabolism genes in 
the liver (Cichocki, et al., 2017b;  Clarke et al., 2014;  Hardwick, et al., 2014;  Uno, et al., 
2018), which in turn can affect the delivered dose of xenobiotics to this organ (Cichocki, 
et al., 2017a). The differences in a delivered dose depending on the liver disease state 
contributes to altered chemical-induced effects in the liver, as shown for benzo[a]pyrene 
(Uno, et al., 2018), vinyl chloride (Lang, et al., 2018), carbon tetrachloride (Donthamsetty 
et al., 2007) and PCE (Cichocki, et al., 2017b). However, even though NAFLD has also 
been shown to change the expression of renal xenobiotic transporters (Canet et al., 2015), 
few studies examined the effects of NAFLD on xenobiotic-induced renal injury. In this 
study, by using PCE as a model compound, we reveal several important findings for the 
effects of NAFLD on kidney metabolism and toxicity in mice. 
First, NAFLD can modulate the metabolism and disposition of xenobiotics in the 
kidney. In this study, mice fed either a HFD or MCD had 0.5- to 0.8-fold lower levels of 
PCE in kidney tissue compared to LFD-fed mice. It was previously demonstrated in liver 
tissue from these same mice that HFD- or MCD-fed mice had higher 1.5- to 2-fold higher 
PCE levels compared to LFD-fed mice, an effect which was attributed to an increased 
affinity of PCE for the lipid-laden liver tissue of mice with NAFLD (Cichocki, et al., 
2017a). Indeed, the liver:air partition coefficients were reported to be 2.4- to 4.9-fold 
higher in HFD- or MCD-fed mice compared to LFD-fed mice (Cichocki, et al., 2017a). 
As PCE also induces liver fat accumulation (Cichocki, et al., 2017b;  Cichocki, et al., 
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2017c), it is not surprising that the majority of PCE, a lipophilic compound, is retained in 
fatty liver tissue, thereby decreasing its transport  to the kidney for subsequent metabolism. 
Interestingly, HFD- or MCD-fed mice had greater TCA levels in kidney tissue 
compared to those in liver tissue (Cichocki, et al., 2017a). The elimination of TCA from 
kidney also appeared to be considerably delayed in HFD- or MCD-fed mice, as supported 
by observations of increased retention of TCA in the liver and decreased urinary 
elimination of TCA (Cichocki et al 2017b). Even though the expression of hepatic genes 
associated with PCE oxidation (Cyp2c29, Cyp3a11, and Cyp2b10) are downregulated in 
HFD- or MCD-fed mice (Cichocki, et al., 2017b), we observed higher levels of TCA in 
liver and kidney tissue from HFD- or MCD-fed mice compared to LFD-fed mice, an effect 
which may have been due to xenobiotic transporter activity or physiochemical properties. 
We also found that levels of the PCE glutathione conjugation metabolites TCVG, 
TCVC, and NAcTCVC were lower in the kidney of HFD- or MCD-fed mice compared to 
LFD-fed mice, which is concordant with the levels of these metabolites previously 
measured in liver and urine (Cichocki, et al., 2017a). The lower levels of glutathione 
conjugation metabolites are consistent with the repressed expression of GSTs in the liver 
of HFD- or MCD-fed mice compared to LFD-fed mice (Cichocki, et al., 2017a). Notably, 
the tissue disposition of glutathione conjugation metabolites is qualitatively similar among 
LFD-, HFD-, and MCD-fed mice, where the most abundant metabolite is TCVG in liver 
but TCVC in kidney. The tissue-specific disposition of TCVG and TCVC is consistent 
with the results from previous studies (Luo, et al., 2017). Collectively, these data suggest 
that the effect of liver disease state on the toxicokinetic properties of a xenobiotic is 
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complex and involves hepatic and extrahepatic tissue (e.g. kidney), chemical-
physiological factors (e.g. liver:blood partition coefficient), metabolism (e.g. Cyp 
expression), and elimination (e.g. urinary clearance).  
Second, we show that NAFLD can also modulate chemical-induced kidney 
toxicity. Sub-chronic or chronic exposure to PCE via inhalation was associated with 
karyomegaly of the renal tubular epithelial cells, renal casts, and nephrosis in mice, and 
tubular cell karyomegaly and hyperplasia in rats (Japanese Industrial Safety Association, 
1993;  National Toxicology Program, 1986). Traditional measures of kidney dysfunction, 
such as blood urea nitrogen levels and histopathological assessment fail to detect kidney 
injury by PCE as shown in this study and by others (Philip, et al., 2007).  However, renal 
proximal tubular injury by PCE has been reported with more sensitive markers of kidney 
injury, such as KIM-1 (Luo et al., 2018b). Indeed, in our study we also observed kidney 
damage in LFD-fed mice. What is most intriguing, this effect was almost fully abrogated 
in HFD-fed mice, but not in MCD-fed mice. Severe methyl and choline deficiency during 
weaning is known to result in acute kidney failure(Roberti et al., 1988), but more tempered 
dietary deficiency that is used to model NAFLD in rodents, even when administered for 
up to 10 months, has no pathologic effects(Porta et al., 1985).  Thus, it is possible that 
MCD diet in conjunction with PCE exhibited a potentiation effect on kidney injury 
through increased toxicodynamic sensitivity, counter-balancing the decreased 
toxicokinetic sensitivity exhibited by reduced glutathione conjugation metabolite levels. 
In support of this hypothesis, it was previously shown that rats with MCD-induced 
NAFLD were more sensitive to the nephrotoxic effects of methotrexate, including tubular 
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generation, necrosis, and the inability to regenerate damaged tubules, compared to control 
diet-fed rats (Hardwick, et al., 2014). 
Gene expression profiling served as another sensitive measure of diet- and PCE-
induced effects on the kidney. Methyl-donor deficient diet induces profound changes in 
gene expression in mouse liver (Cichocki, et al., 2017a;  Tryndyak et al., 2012a); however, 
the effects of this diet on gene expression in the mouse kidney is negligible (Glen et al., 
2015). We also found that the effect of either HFD or MCD on the kidney transcriptome 
was mild and similar between the two diets. MCD diet results in major epigenetic effects 
in the liver, but produces no changes in DNA methylation level or activity of DNA 
methyltransferase in the rat kidney, even when treated for up to 36 weeks (Pogribny et al., 
2004). These studies show that overall, MCD diet has little effect on the molecular changes 
in the kidney, as opposed to the liver. However, the modifications of the PCE-induced 
effects on the kidney transcriptome by HFD- or MCD-feeding were noteworthy. For 
example, mice fed the HFD and, especially, MCD exhibited more pronounced PCE-
induced changes in lipid metabolism, but less pronounced PCE-induced changes in 
xenobiotic metabolism and ABC transporters. Interestingly, transcripts related to amino 
acid transporters (e.g. Slc38a3, Slc34a2, Slc22a3, and Slc22a14) are more profoundly 
upregulated in kidney of HFD- or MCD-fed mice. Increased transcription of these amino 
acid transporters may contribute to the lower levels of TCVG, TCVC, and NAcTCVC in 
kidney; however, whether these compounds are substrates for renal xenobiotic 
transporters remain to be determined.  
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Overall, relative insensitivity of HFD-fed mice to PCE-induced kidney injury, as 
compared to MCD-fed mice, is a noteworthy finding. One possible explanation is the 
degree of NAFLD in these mouse models (Machado et al., 2015) and its role in kidney 
disease (Musso et al., 2015). Indeed, in the animals examined herein, MCD diet resulted 
in NASH, whereas HFD diet produced only NAFL (Cichocki, et al., 2017b).  Our finding 
of greater PCE-induced kidney injury in MCD-fed mice are in a good agreement with 
previous reports that NASH is associated with a higher prevalence of chronic kidney 
disease in humans (Musso et al., 2014). Mechanistically, the development of kidney injury 
in MCD-fed mice may be attributed, at least in part, to (i) inflammation induced by pro-
inflammatory cytokines released from NASH-inflamed liver; (ii) dysregulated lipid 
metabolism and toxic lipid accumulation in kidney; and (iii) deregulation of lipoprotein 
metabolism (Musso, et al., 2015;  Rivkin et al., 2016). 
Third, the internal dosimetry of PCE and its metabolites agree with what is known 
and/or hypothesized about the target organ toxicity of PCE. For instance, the greater tissue 
levels of TCA in HFD- or MCD-fed mice concur with the more pronounced PPARα 
activation in the liver and kidney of these mice compared to LFD-fed controls. Likewise, 
the lower glutathione metabolite levels in kidney is concordant with the milder proximal 
tubule injury found in mice with NAFLD, particularly in HFD-fed mice, and with the 
lower number of differentially-expressed genes observed in kidney tissue. These 
observations are in accord with the results from a study using cytochrome P450 2E1 
(CYP2E1) knockout and humanized transgenic mice to investigate the metabolism and 
toxicity of PCE (Luo, et al., 2018b), in which CYP2E1 knockout mice exhibited lower 
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TCVG, TCVC, and NAcTCVC levels in kidney, which was associated with a milder PCE-
induced proximal tubular injury as compared to wild-type mice. Collectively, these data 
support the long-lasting hypothesis that glutathione-derived metabolites are the major 
determinants of PCE-induced nephrotoxicity in vivo.  
There are a number of limitations to this study. For example, animals were 
administered a relatively high dose of PCE (300 mg/kg, i.g.), which is unlikely to occur 
in humans. PCE oxidation is saturable at doses over 200 mg/kg (Buben and O'Flaherty, 
1985), which may limit our interpretation for the kinetics observed in this study to those 
that occur at environmentally-relevant exposures. However, the glutathione conjugation 
pathway is approximately 100-fold less efficient in mice compared to humans for the 
related compound trichloroethylene (Chiu, et al., 2009), therefore suggesting that the 
internal dose of glutathione metabolites in mouse kidney could still be relevant to PCE 
exposures to humans, albeit human data are not available and a PBPK model showed 
1000-fold uncertainty in PCE glutathione conjugation (Chiu and Ginsberg, 2011). The 
other limitation of this study is the applicability of animal NAFLD/NASH models to 
human NAFLD, a contentious issue in the field (Maher, 2011;  Teufel et al., 2016). Even 
though HFD-fed animals can mimic the histopathological phenotype of human NAFLD, 
the degree of injury depends on a number of factors including rodent strains (Lau et al., 
2017). In addition, the metabolic profile of methionine/choline/folate-deficient (e.g. 
MCD-fed) mice is different from human NASH (Rinella and Green, 2004) and is also
dependent on rodent strain (Tryndyak et al., 2012b). Despite these limitations, in this study 
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we were able to characterize the effects of pre-existing liver disease on kidney metabolism 
and toxicity of PCE.      
In summary, we confirmed that NAFLD can alter the internal dosimetry of PCE 
and its metabolites in kidney, which in turn affects PCE-induced nephrotoxicity in vivo. 
While experimental NAFLD sensitized mice to PCE-induced liver toxicity (Cichocki, et 
al., 2017b), we show here that NAFLD may be a protective factor for PCE-associated 
kidney effects due to reduced production and delivery of nephrotoxic glutathione 
conjugation-derived metabolites, as shown in male C57BL/6J fed HFD. However, this 
protective effect was abrogated in MCD-fed mice, which showed similarly decreased 
toxicokinetic sensitivity in the form of reduced nephrotoxic metabolite concentrations, but 
increased toxicodynamic sensitivity.  These data, along with our previous study of how 
NAFLD affects liver toxicity (Cichocki, et al., 2017b), demonstrate not only that 
underlying disease state could be an important factor to consider in future human health 
assessments of environmental toxicants, but also that the relationship between common 
diseases such as NAFLD and xenobiotic-induced toxicity may involve a complex, organ-
specific interplay of toxicokinetic and toxicodynamic effects. 
98 
Table 4.3 Molecular pathways perturbed by PCE in mouse kidney 
KEGG_PATHWAY No. of  genes Enrichment Benjamini q-value 
LFD:  378 
mmu00980:Metabolism of xenobiotics by 
cytochrome P450 14 10.3 1.05E-07 
mmu00982:Drug metabolism - cytochrome P450 14 10.0 7.88E-08 
mmu01100:Metabolic pathways 58 2.1 4.04E-07 
mmu03320:PPAR signaling pathway 14 8.2 4.70E-07 
mmu00830:Retinol metabolism 14 7.4 1.42E-06 
mmu00071:Fatty acid degradation 11 10.6 1.78E-06 
mmu05204:Chemical carcinogenesis 14 7.2 1.53E-06 
mmu01040:Biosynthesis of unsaturated fatty acids 6 10.5 5.40E-03 
mmu00053:Ascorbate and aldarate metabolism 6 10.5 5.40E-03 
mmu04146:Peroxisome 9 5.1 7.50E-03 
mmu00140:Steroid hormone biosynthesis 9 4.9 9.30E-03 
HFD: 315 
mmu00071:Fatty acid degradation 15 14.2 1.85E-10 
mmu00830:Retinol metabolism 14 7.3 4.52E-06 
mmu00980:Metabolism of xenobiotics by 
cytochrome P450 12 8.7 6.10E-06 
mmu03320:PPAR signaling pathway 13 7.5 5.63E-06 
mmu01100:Metabolic pathways 54 2.0 2.48E-05 
mmu00040:Pentose and glucuronate 
interconversions 9 11.6 2.36E-05 
mmu01212:Fatty acid metabolism 10 9.1 3.20E-05 
mmu00053:Ascorbate and aldarate metabolism 8 13.7 2.92E-05 
mmu00982:Drug metabolism - cytochrome P450 10 7.0 2.30E-04 
mmu00983:Drug metabolism - other enzymes 9 8.2 2.26E-04 
mmu01040:Biosynthesis of unsaturated fatty acids 7 12.0 3.37E-04 
mmu00860:Porphyrin and chlorophyll metabolism 8 9.0 3.83E-04 
mmu05204:Chemical carcinogenesis 11 5.5 3.95E-04 
mmu04610:Complement and coagulation cascades 10 6.1 4.73E-04 
mmu00140:Steroid hormone biosynthesis 10 5.3 1.30E-03 
mmu00062:Fatty acid elongation 6 10.7 2.49E-03 
MCD: 222 
mmu00071:Fatty acid degradation 14 20.2 1.10E-11 
mmu01100:Metabolic pathways 43 2.4 1.63E-06 
mmu03320:PPAR signaling pathway 11 9.7 7.77E-06 
mmu00062:Fatty acid elongation 7 19.1 5.08E-05 
mmu01040:Biosynthesis of unsaturated fatty acids 7 18.4 5.17E-05 
mmu00830:Retinol metabolism 10 8.0 1.04E-04 
mmu01212:Fatty acid metabolism 8 11.1 1.46E-04 
mmu01130:Biosynthesis of antibiotics 13 4.3 8.60E-04 
mmu04146:Peroxisome 8 6.8 2.82E-03 
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CHAPTER V 
METABOLISM AND TOXICITY OF TRICHLOROETHYLENE AND 
TETRACHLOROETHYLENE IN CYTOCHROME P450 2E1 KNOCKOUT AND 
HUMANIZED TRANSGENIC MICE3 
5.1 Overview 
Trichloroethylene (TCE) and tetrachloroethylene (PCE) are structurally similar 
olefins that can cause liver and kidney toxicity. Adverse effects of these chemicals are 
associated with metabolism to oxidative and glutathione conjugation moieties. It is 
thought that CYP2E1 is crucial to the oxidative metabolism of TCE and PCE, and may 
also play a role in formation of nephrotoxic metabolites; however, inter-species and inter-
individual differences in contribution of CYP2E1 to metabolism and toxicity are not well 
understood. Therefore, the role of CYP2E1 in metabolism and toxic effects of TCE and 
PCE was investigated using male and female wild-type [129S1/SvlmJ], Cyp2e1(-/-), and 
humanized Cyp2e1 [hCYP2E1] mice. To fill in existing gaps in our knowledge, we 
conducted a toxicokinetic study of TCE (600 mg/kg, single dose, i.g.) and a sub-acute 
study of PCE (500 mg/kg/d, 5 days, i.g.) in three strains. Liver and kidney tissues were 
3 This is a pre-copyedited, author-produced version of an article accepted for publication in Toxicological 
Sciences following peer review. The version of record is available online at 
https://doi.org/10.1093/toxsci/kfy099 
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subject to profiling of oxidative and glutathione conjugation metabolites of TCE and PCE, 
as well as toxicity endpoints. The amounts of TCA formed in the liver was hCYP2E1≈ 
129S1/SvlmJ>Cyp2e1(-/-) for both TCE and PCE; levels in males were about 2-fold 
higher than in females. Interestingly, 2-3-fold higher levels of conjugation metabolites 
were observed in TCE-treated Cyp2e1(-/-) mice. PCE induced lipid accumulation only in 
liver of 129S1/SvlmJ mice. In the kidney, PCE exposure resulted in acute proximal tubule 
injury in both sexes in all strains (hCYP2E1≈129S1/SvlmJ>Cyp2e1(-/-)). In conclusion, 
our results demonstrate that CYP2E1 is an important, but not exclusive actor in the 
oxidative metabolism and toxicity of TCE and PCE.  
5.2 Introduction 
Trichloroethylene (TCE) and tetrachloroethylene (PCE) are structurally-similar 
olefins and high-production volume chemicals that have been used in chemical synthesis, 
metal degreasing, dry cleaning, and other industrial applications (U.S. EPA, 2011b;  U.S. 
EPA, 2011c). TCE and PCE are extensively present in air, soil, and surface and ground 
water supplies (IARC, 2014). They are also frequently found at the hazardous waste sites 
on the National Priorities List (ATSDR, 2014). TCE and PCE are also detectable in human 
blood samples collected in the National Health and Nutrition Examination Survey (Jia, et 
al., 2012). TCE and PCE are classified as “carcinogenic to humans” and “probably 
carcinogenic to humans,” respectively, by the International Agency for Research on 
Cancer (Guha, et al., 2012). They also can cause non-cancer effects in liver and kidney 
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(Cichocki, et al., 2016). TCE and PCE are among the top 10 chemicals of concerns for the 
risks to human health and environment under the revised Toxic Substances Control Act 
(U.S. EPA, 2017). 
Tissue-specific toxicity of TCE and PCE results from metabolism through the 
oxidative and glutathione conjugation pathways. Oxidation of TCE and PCE occurs on 
the double bond via cytochrome P450s (CYP) to form an epoxide intermediate, which is 
subsequently metabolized to oxidative species, including trichloroacetic acid (TCA) 
and/or TCE-specific metabolite trichloroethanol (TCOH) (Cichocki, et al., 2016). TCA is 
a ligand to mouse and human peroxisome proliferation activated receptor alpha (PPARα) 
(Zhou and Waxman, 1998), which may be associated with cell proliferation in liver 
(Laughter et al., 2004). Both TCE and PCE are also metabolized by glutathione 
conjugation via glutathione-S-transferases (GSTs) to generate dichloro- or trichloro-
glutathione conjugates (DCVG/TCVG) (Lash, et al., 2000). These conjugates can be 
further metabolized by hepatic or renal gamma glutamyl transferase and dipeptidase to 
form cysteine conjugates (DCVC/TCVC), and then are subject to n-acetylation to form 
NAcDCVC or NAcTCVC. These can be further bio-activated by a number of enzymes, 
including cysteine s-conjugate beta lyase, flavin monooxygenase, and CYPs, to form 
nephrotoxic metabolites such as reactive thiols (Volkel and Dekant, 1998) and sulfoxides 
(Elfarra and Krause, 2007;  Lash, et al., 2001a;  Lash, et al., 2003;  Ripp, et al., 1997;  
Werner, et al., 1996). For both TCE and PCE, various CYPs play a critical role in 
generating metabolites that cause toxicity in both liver and kidney. 
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Among the CYPs isoenzymes, cytochrome P450 2E1 (CYP2E1) is the major 
contributor to oxidation of chlorinated solvents (Kim and Ghanayem, 2006;  Nakajima et 
al., 1993;  Ramdhan, et al., 2008). CYP2E1 is highly variable in expression (12-fold) in 
human liver (Lin and Lu, 2001) and inter-individual differences in CYP activity are 
thought to be a major contributor to population variability in adverse effects of TCE and 
PCE (Cichocki, et al., 2016). In studies with TCE, both hepatotoxicity and production of 
oxidative metabolites were ameliorated in CYP2E1 knockout mice (Kim and Ghanayem, 
2006;  Ramdhan, et al., 2008), albeit little is known about the exact role of CYP2E1 in 
TCE toxicokinetics. In experiments with PCE, one study posited that CYP2E1 can 
contribute to PCE toxicity (Hanioka et al., 1995), but another study concluded that 
CYP2E1 is not the critical enzyme in sub-chronic effects of PCE (Philip, et al., 2007). No 
study examined metabolism or toxicity of PCE in CYP2E1 knockout or humanized mice. 
Therefore, in this work, we aimed to address existing knowledge gaps on the role 
of mouse and human CYP2E1 in the metabolism and toxicity of TCE and PCE. Because 
several studies already established that CYP2E1 is playing a role in liver effects of TCE, 
but its precise role in the formation of TCE metabolites is largely unknown, we conducted 
a toxicokinetic study of TCE in male and female 129S1/SvlmJ, Cyp2e1(-/-), and 
humanized (hCYP2E1) mice. For PCE, we aimed to test whether CYP2E1 plays a role in 
the toxicity of PCE by using the same genetic models and a sub-acute study design.  
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5.3 Materials and Methods 
5.3.1 Chemicals  
TCE (≥99.5%), PCE (≥99.9%), TCA (≥99.0%), TCOH (≥99.0%), 2-bromobutyric 
acid (≥ 97%), chloroform (≥99.9%), and formic acid (≥95%) were obtained from Sigma-
Aldrich (St. Louis, MO). Methanol (≥99.9%) was from Fischer Scientific (Hampton, NH). 
S-(1,2-dichlorovinyl)-cysteine (DCVC, ≥98.0%), S-(1,2-dichlorovinyl)-cysteine-13C3-15N 
(DCVC*, purity ≥95.0%, isotopic purity ≥98.0%), S-(1,2-dichlorovinyl)-glutathione 
(DCVG, ≥98.9%), and S-(1,2-dichlorovinyl)-glutathione-13C2-15N (DCVG*, purity 
≥90.0%, isotopic purity ≥98.0%) were obtained from TLC Pharmaceutical Standards 
(Aurora, Canada). N-acetyl-S-(1,2-dichlorovinyl)-cysteine (NAcDCVC, 99.8%) and N-
acetyl-S-(1, 2-dichlorovinyl)-cysteine-13C, d3 (NAcDCVC*, purity: 97.6%, isotopic 
purity: 99.0%), and NAcTCVC (purity: 99.7%) were purchased from Toronto Research 
Chemicals (Toronto, Canada). S-(1,2,2-trichlorovinyl)-glutathione-13C2-15N (TCVG*, 
purity: 90.4%), S-(1,2,2-trichlorovinyl)-cysteine-13C3-15N (TCVC*, purity: 97.5%), and 
N-acetyl-S-(1,2-dichlorovinyl)-cysteine-13C3-15N (NAcTCVC*, purity: 99.0%) were used
as internal standards for TCVG, TCVC, and NAcTCVC, respectively. TCVG (purity: 
98.9%), TCVC (purity: 98.4%), and all stable isotopically-labeled internal standards were 
synthesized by Dr. Avram Gold at the University of North Carolina at Chapel Hill. 
5.3.2 Animals and treatments 
Male and female wild type, Cyp2e1(-/-), and hCYP2E1 mice on 129S1/SvlmJ 
(Sv129, The Jackson Laboratory, Bar Harbor, ME) were used in this study. Transgenic 
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mice were bred and genotyped by PCR before being used in this study. The primer 
sequences are detailed in Table B-13. Mice were housed in polycarbonate cages on Sani-
Chips irradiated hardwood bedding (P.J. Murphy Forest Products, Montville, NJ), and 
supplied with NTP-2000 (Zeigler Brothers, Gardners, PA) wafer diet and water ad libitum 
on a 12 h light-dark cycle. After a week-long acclimatization, mice were intragastrically 
administered with TCE or PCE as detailed below (Figure 5.1). All treatments and 
procedures were approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill. 
Figure 5.1 Schematic representation of study designs. Male and female mice from 
three strains (129S1/SvlmJ wild type, Cyp2e1(-/-) and hCYP2E1) were used in these 
studies. One study examined toxicokinetics of trichloroethylene in a single dose (600 
mg/kg, gavage) study where samples were collected for up to 24 hrs. Second study 
examined metabolism and toxicity of tetrachloroethylene that was administered for 5 
consecutive days (500 mg/kg, gavage); samples were collected 2 hrs after the last dose. 
Alkamuls EL-620 (5%, 10 ml/kg) was used as an aqueous emulsion vehicle for 
administration of both chemicals. Vertical lines indicate time points of sample 
collection. Down-arrows indicate chemical treatments. Endpoints collected in each study 
are shown as a bulleted list. 
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In a study of TCE toxicokinetics, mice were administered a single dose of 600 
mg/kg TCE or vehicle (5% Alkamuls EL-620 in saline). The dose was selected based upon 
previous mouse studies showing that this amount was well tolerated in acute, 90-day, and 
2-year studies (Buben and O'Flaherty, 1985;  Luo et al., 2018a;  National Toxicology
Program, 1990;  Yoo, et al., 2015a). In addition, mice form approximately 100-fold less 
glutathione conjugation metabolites (Chiu, et al., 2009), which justifies the use of a dose 
that is higher than the environmental exposure to TCE. After dosing, mice were 
anesthetized (pentobarbital, 50 mg/kg i.p.) and sacrificed by exsanguination through the 
vena cava at 2, 5, 12, and 24 h (n=2-4 per group per time point, as detailed in Table B-
14). Mice dosed with vehicle were sacrificed at 5 h after gavage. Livers and kidneys were 
collected, blotted dry, and snap-frozen in liquid nitrogen. Serum was prepared by using Z-
gel tubes (Sarstedt, Darmstadt, Germany). All tissues and serum were stored at -80oC until 
analyzed.  
In a study of PCE metabolism and toxicity, mice were treated for 5 days with single 
daily dose (9 am) of 500 mg/kg/d PCE or vehicle (5% Alkamuls EL-620 in saline). The 
dose was selected based upon previous studies showing no saturation of PCE oxidation at 
similar doses (Buben and O'Flaherty, 1985;  Philip, et al., 2007), and that this amount was 
well tolerated in acute, 90-day, and 2-year studies (Buben and O'Flaherty, 1985;  Cichocki, 
et al., 2017a;  Luo, et al., 2017;  National Toxicology Program, 1977). Mice were given 
drinking water containing 5-bromo-2′-deoxyuridine (BrdU) 72 hr prior to sacrifice. Mice 
were anesthetized and sacrificed by exsanguination through vena cava 2 h after the last 
dose of PCE or vehicle (n=4-7 per group, as detailed in Table B-15). Serum was prepared 
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by using Z-gel tubes, and then stored at -80oC until analyzed. Tissue sections from left 
liver lobe and kidney were fixed in 10% formalin and embedded in paraffin. The 
remaining tissues were snap-frozen in liquid nitrogen and stored at -80oC until analyzed.  
5.3.3 Protein measurement of CYP 2E1 
Total proteins were extracted from 20 mg of liver and kidney samples using T-
PER Tissue Protein Extraction Reagent (Thermo Scientific, Rockford, IL) with Halt 
Protease Inhibitor Cocktail (Thermo Scientific). Protein concentration was determined 
using Pierce BCA Protein Assay Kit (Thermo Scientific) and a DTX 880 Multimode 
detector (Beckman Coulter, Brea, CA). Protein extract (20 μg) was loaded onto a Mini-
Protein TGX Precast Gel (Bio-Rad, Hercules, CA) and transferred to a polyvinylidene 
difluoride membrane. Membrane was blocked with Odyssey Blocking Buffer (LI-COR, 
Lincoln, NE), probed with CYP2E1 primary antibody (1:5000, catalogue #: 28146, abcam, 
Cambridge, MA) or beta-actin primary antibody (1:2500, catalogue #: ab8227, abcam, 
Cambridge, MA) overnight at 4oC, washed with 0.1% Tween 20 in 0.01M PBS buffer, 
probed with goat anti rabbit  IgG antibody (1:2500, catalogue #: AP132P, Millipore Corp., 
Billerica, MA) for 90 min at room temperature, and detected using an Odyssey Infared 
Imaging system (LI-COR).   
5.3.4 Quantification of TCA 
Tissue levels of TCA were measured using the US EPA method 815-B-03-002 
(Domino et al., 2003) with slight modifications. Tissues (50 mg) were spiked with 11 
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nmole of internal standard (2-bromobutyric acid), and homogenized in 1 mL of 
methanol:chloroform (1:1). After centrifugation at 14,000 g for 10 mins, supernatant was 
mixed with 1.5 mL of methanolic sulfuric acid (10%, v:v). The mixture was incubated in 
water batch at 55oC for 2 h to derive respective methyl esters. The derivative was then 
mixed well with 2 mL of methyl tert-butyl ether and 3 mL of sodium sulfate buffer (150 
g/L). The upper layer was collected and mixed well with 3 mL of saturated sodium 
bicarbonate. Again, the upper layer was collected, concentrated under nitrogen stream to 
a volume of ~20 µL, and analyzed via gas chromatography mass spectrometry. 
Quantitative analyses were achieved by using the peak area ratios of TCA to internal 
standards in an eight-point calibration curve (0, 4.1, 12.3, 37.0, 111.1, 333.3, 1000, and 
3000 nmole spiked TCA). 
5.3.5 Quantification of TCOH 
Liver or kidney tissues (30 mg) were homogenized in 0.5 mL of sodium acetate 
(0.1 M, pH 4.6), spiked in 1000 units of beta-glucuronidase, and incubated in a 
thermomixer overnight at 37oC. The incubated homogenate was spiked with 20 μl of ethyl 
benzene (1000 nmol/mL), and then incubated in 1.5 mL of 10% sulfuric acid in methanol 
at 50 oC for 1 h. Afterwards, the incubated solution was evenly mixed with 2 mL of MTBE 
and 3 mL of sodium sulfate (150 g/L), and centrifuged at 2,500 g for 3 min. The MTBE 
layer was neutralized by 3 mL of saturated sodium bicarbonate, collected, and 
concentrated with nitrogen gas to ~20 μL for GC-MS analysis (Song and Ho, 2003). 
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Quantitative analyses were achieved by using the peak area ratios of TCOH to ethyl 
benzene in an eight-point calibration curve (0-1200 nmole TCOH/g tissue). 
5.3.6 Quantification of D/TCVG, D/TCVC, and NAcD/TCVC 
Tissue levels of dichloro and trichloro conjugates of TCE and PCE (D/TCVG, 
D/TCVC, and NAcD/TCVC) were evaluated as reported in (Luo, et al., 2017;  Luo, et al., 
2018a). In brief, tissue homogenate underwent a liquid-liquid extraction with 400 µL of 
methanol:chloroform (1:1) and a solid-phase extraction using a weak anion C-18 cartridge 
(Strata-X-AW, Phenomenex, Torrance, CA). The eluent was dried under vacuum, and 
reconstituted with 50 µL of methanol:water (20:80) with 0.1 % acetic acid. Tissue levels 
of metabolites were quantified by using the peak area ratios of standards to isotopically-
labeled internal standards in an eight-point calibration curve (0, 0.25, 0.5, 1.25, 2.5, 6.25, 
18.75, and 31.25 pmole) via UPLC-MS/MS. 
5.3.7 Serum Alanine Aminotransferase and Aspartate Aminotransferase 
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
were determined by commercially available kits (Sigma Aldrich) according to the 
manufacturer’s instructions. 
5.3.8 Triglyceride Measurements 
Serum and liver triglycerides were measured with a commercially available kit 
(Wako, Richmond, Virginia) according to the manufacturer’s instructions. 
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5.3.9 Histopathological Evaluation 
Formalin-fixed/paraffin embedded liver and kidney sections were stained with 
hematoxylin/eosin (H&E). Stained H&E slides were evaluated in a blind manner by a 
certificated veterinary pathologist.   
5.3.10 KIM-1 Immunohistochemistry Staining 
Kidney sections were dewaxed in xylene and rehydrated in graded ethanols, and 
then subjected to hydrochloric acid and pepsin antigen retrieval. Endogenous peroxidase 
activity was blocked with peroxidase and alkaline phosphatase blocking reagent (Dako, 
Carpinteria, CA) at 25 oC for 10 mins. Thereafter, kidney sections were subsequently 
incubated with goat anti-mouse TIM-1/KIM-1/HAVCR (R&D systems, Minneapolis, 
MN; 2 μm/ml, 10 min, room temperature) and secondary goat IgG HRP-conjugated 
antibody (R&D systems, Minneapolis, MN; 1:100, 10 min, room temperature) using Dako 
Antibody Dilution solution (Dako), and visualized by Dako Liquid DAB+Substrate 
chromogen System (Dako). Processed slides were counterstained with hematoxylin for 5 
mins. Quantitative analysis was performed by using Image-Pro Premier 9.1 (Media 
Cybernetics, Silver Spring, MD) at 200× magnification. Five fields of kidney section were 
randomly selected to calculate the percentage of positive proximal tubules versus total 
proximal tubules.  
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5.3.11 BrdU Immunohistochemistry Staining 
Kidney sections were subject to de-paraffinization, rehydration, antigen retrieval, 
and peroxidase blocking procedures as described above. Thereafter, Dako EnVision 
System HRP kit with a monoclonal anti-BrdU antibody (1:200 dilution, M074401-8, 
Dako) was used for detection of BrdU-incorporated nuclei. Quantitative analysis was 
performed by using Image-Pro Premier 9.1 (Media Cybernetics) at 200× magnification. 
Five fields of each kidney section were randomly selected for evaluation. Data are 
presented as a fraction of positively stained nuclei versus total proximal tubule nuclei (%). 
5.4 Results 
5.4.1 Protein Expression of CYP2E1 
CYP2E1 status in various strains was verified by genotyping before the study. In 
addition, to quantify the effects of treatments on CYP2E1 protein levels, we conducted 
Western blotting experiments. In agreement with previous studies of Cyp2e1(-/-) and 
hCYP2E1 transgenic mice (Lu et al., 2010), CYP2E1 expression in liver was higher in 
hCYP2E1 strain than in Sv129 strain, it was undetectable in Cyp2e1(-/-) mice (Figure 5.2). 
Protein levels of CYP2E1 were much greater in liver than in kidney, also concordant with 
previous reports of gene expression in the mouse (Yue et al., 2014). Lack of expression 
of CYP2E1 in mouse kidneys is also consistent with low levels of CYP2E1 in human 
kidneys (Fagerberg, et al., 2014). In addition, protein levels of CYP2E1 were slightly 
higher in liver of male mice as compared to female mice. This sex-dependent difference 
was even more pronounced in kidneys where no detectable CYP2E1 protein was found in 
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females. The sex difference was not found in the liver of Sv129 mice (Nakajima et al., 
2000) or CD-1 mice (Hoivik et al., 1995); however, it was observed in kidney of CD-1 
mice (Hoivik, et al., 1995) where protein level of CYP2E1 was higher in male mice as 
compared to female mice. We found that TCE induced expression in CYP2E1 only in liver 
of female mice of both hCYP2E1 and Sv129 strains, suggesting that TCE treatment and 
sex hormones may regulate liver expression of CYP2E1.  
Figure 5.2 Protein expression of CYP2E1 in liver and kidney of (A) male and (B) 
female 129S1/SvlmJ, Cyp2e1(-/-), and hCYP2E1 mice at 4 hours after dosing with a 
single dose of vehicle (V, Alkamuls EL-620) or TCE (T, 600 mg/kg). Representative 
Western blots and quantitative analysis of CYP2E1 protein expression are shown 
(n=4/group). Expression of beta actin (Actb) was used to normalize for protein loading. 
Data are shown as mean±SD. Asterisks denote statistical significant difference between 
groups (one-way ANOVA with Newman-Keuls post hoc test, p<0.05). 
5.4.2 The Role of CYP2E1 in Toxicokinetics of TCE 
Next, we sought to examine TCE toxicokinetics as a factor of CYP2E1 status in 
each strain and sex. We examined concentration-time profiles of TCA, TCOH, DCVG and 
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NAcDCVC in liver (Figure 5.3). In male Sv129 mice, we found that liver toxicokinetics 
of TCA, TCOH, and  DCVG were similar to those reported in previous studies using 
129S1/SvImJ mice (Yoo, et al., 2015a;  Yoo, et al., 2015c), B6C3F1/J mice (Luo, et al., 
2018a), and Collaborative Cross mice (Venkatratnam et al., 2017). The area under curve 
(AUC) analysis of the metabolite levels revealed sex-dependent differences in liver 
toxicokinetics of TCE. In Sv129 mice, AUC was higher in male mice as compared to 
female mice for TCA and TCOH (2.2-fold for TCA and 33.9fold for TCOH), but lower 
for DCVG and NAcDCVC(1.9 fold for DCVG and 1.6 fold for NacDCVC). The sex-
dependent differences in liver toxicokinetics for TCA and TCOH were also observed in 
the previous study (Yoo, et al., 2015c), while the sex differences for liver toxicokinetics 
of DCVG and NAcDCVC has not been previously investigated.  
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Figure 5.3 Comparative analysis of liver (Li) toxicokinetics of major oxidative 
(TCA and TCOH), and glutathione conjugation (DCVG) metabolites of 
trichloroethylene (600 mg/kg) in (A) male and (B) female 129S1/SvlmJ (SV129), 
Cyp2e1(-/-), and hCYP2E1 mice. Average kinetic profiles (left panels, strains are 
identified by symbols as shown in an inset in the top left graph) and area under the curve 
(AUC, right panels) are shown (n=2-4 per group per time point, as detailed in Table B-
14) 
In agreement with the lack of CYP2E1 expression, the AUCs were 2.9-fold lower 
for TCA, and 1.4-fold lower for TCOH in male Cyp2e1(-/-) mice as compared to those in 
male Sv129 mice. A decrease in formation of oxidative metabolites of TCE was less 
pronounced in female Cyp2e1(-/-) mice. Interestingly, elimination of TCA in the liver was 
slower in Sv129 mice as compared to Cyp2e1(-/-)and hCYP2E1 mice. Slower formation 
of TCOH was most pronounced in male Cyp2e1(-/-) mice with a peak concentration 
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(Cmax) at 5 h and the differences in the timing of Cmax for TCOH between Cyp2e1(-/-)and 
hCYP2E1 mice may have affected the AUC values. Interestingly, the AUC of DCVG was 
1.5-2.4 fold higher in Cyp2e1(-/-) mice of both sexes, but 2.9-3.2 fold lower in hCYP2E1 
mice as compared to Sv129 mice. For the AUCs of NAcTCVC, similar trend was observed 
in male mice but not in female mice.    
Metabolites from GSH conjugative pathway have been postulated to cause kidney 
toxicities; therefore, we also examined concentration-time profiles of TCA, DCVG, 
DCVC, and NAcDCVC in the kidney (Figure 5.4). In male Sv129 mice, we found that 
kidney toxicokinetics of TCA, DCVG, and DCVC was similar to that previously reported 
in 129S1/SvImJ mice (Yoo, et al., 2015c), B6C3F1/J mice (Luo, et al., 2018a), and 
C57BL/6J and NOD/ShiLtJ mice (Yoo, et al., 2015b). Similar to the observations in the 
liver, there were pronounced sex-dependent differences in kidney levels of TCA, TCOH, 
and NAcDCVC. In male Sv129 mice, the kidney AUC values were 2.2 fold higher for 
TCA, but 2.5 fold lower for NAcDCVC compared to  female mice. With respect to the 
CYP2E1-mediated effects, the kidney AUCs were 1.6-5.1 fold lower for TCA, and 1.9-
3.3 fold lower for TCOH in Cyp2e1(-/-) mice as compared to Sv129 mice, whereas these 
differences were less pronounced in female mice. Interestingly, in both male and female 
mice, the elimination of TCA was the slowest in the kidney of Sv129 of the strains 
examined herein. The AUC of DCVG was 1.4-1.9 fold higher in Cyp2e1(-/-) mice, but 
1.2-1.4 fold lower in hCYP2E1 mice, as compared to Sv129 mice.    
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Figure 5.4 Comparative analysis of kidney (Kd) toxicokinetics of oxidative (TCA), 
and glutathione conjugation metabolites (DCVG, DCVC and NAcDCVC ) of TCE 
(single dose, 600 mg/kg) in (A) male and (B) female 129S1/SvlmJ (SV129), Cyp2e1(-
/-), and hCYP2E1 mice. Average kinetic profiles (left panels, strains are identified by 
symbols as shown in an inset in the top left graph) and area under the curve (AUC, right 
panels) are shown (n=2-4 per group per time point, as detailed in Table B-14). 
5.4.3 Comparison of the Effect of CYP2E1 on Metabolisms of TCE and PCE 
Much less is known about metabolism and toxicity of PCE, as compared to TCE 
(Cichocki, et al., 2016). No study has tested the role of CYP2E1 in metabolism of PCE. 
Therefore, we compared the levels of key oxidative and glutathione conjugation 
metabolites of TCE and PCE in the liver and kidney of three strains of mice 2 hours after 
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the last dose (Figure 5.5). The comparison for TCA levels between TCE-treated and PCE-
treated mice has limitations because TCE was administered as a single dose while PCE 
treatment was repeated over 5 days; still, the patterns of differences between sexes and 
strains are informative.  In Sv129 strain, liver levels of TCA were about 2-fold higher in 
PCE-treated male and female mice as compared to TCE-treated mice. In our recent study 
in B6C3F1 mice we found that at equimolar doses, more TCA was found in both liver and 
kidney tissue from PCE-exposed mice compared with TCE-exposed groups (Zhou et al., 
2017). In male and female Cyp2e1(-/-) mice, TCA level in liver was about half of that in 
Sv129 mice. At the same time, TCA levels in liver of hCYP2E1 mice were the same as in 
Sv129 mice, in both males and females.  
Importantly, there are major differences in the flux of metabolism through 
glutathione pathway for PCE as compared to TCE, even though we consider different 
dosing designs between TCE and PCE. Metabolites from GSH conjugative pathway are 
rapidly excreted within 24 h after dosing. In addition, the relationship between T/PCE 
dose and GSH metabolites is linear within the dose range used in this study. Therefore, 
the comparison for GSH conjugates between TCE and PCE is more relevant than that for 
TCA levels.  In the liver, the glutathione conjugate of PCE – TCVG – was found to be 
present at over 5-fold greater levels than DCVG. Kidney glutathione metabolites of PCE 
– TCVC and NAcTCVC – were found in the amounts greater than one order of magnitude
than DCVC and NAcDCVC. Interestingly, levels of TCVG in the liver and TCVC in the 
kidney were lower in male Cyp2e1(-/-) mice, but unchanged in female Cyp2e1(-/-) mice.. 
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NAcTCVC in the kidney was lower in male and female Cyp2e1(-/-) mice as compared to 
either Sv129 or hCYP2E1 mice. 
Figure 5.5 Comparative analysis of liver (Li) and kidney (Kd) levels of major 
oxidative (TCA), and glutathione conjugation (DCVG, DCVC and NAcDCVC for 
trichloroethylene; TCVG, TCVC and NAcTCVC for tetrachloroethylene) 
metabolites. Data for (A) trichloroethylene (600 mg/kg) and (B) tetrachloroethylene (5 
daily doses, 500 mg/kg) in male and female 129S1/SvlmJ (Sv129), Cyp2e1(-/-), and 
hCYP2E1 mice are shown. Metabolite levels shown are for a 2 hrs time point after 
dosing. Data are shown as mean±SD. Bars with different letters are significantly 
different (one-way ANOVA with Newman-Keuls post hoc test, p<0.05). 
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5.4.4 Effect of CYP2E1 on PCE-induced Liver and Kidney Toxicity 
We also examined whether strain-specific differences in PCE metabolism are 
associated with differences in toxicity in liver and kidney. Liver toxicity was investigated 
by histopathological evaluation, triglycerides measurements and assessment of cell 
proliferation. Treatment with PCE for 5 days induced lipid accumulation in the liver of 
male Sv129 mice, but had no such effect in male Cyp2e1(-/-) or hCYP2E1 mice (Figure 
5.6A). This histopathological finding was confirmed by measurements of liver and serum 
triglycerides. Liver triglycerides were about 6-fold higher and serum about 2-fold lower 
in PCE-treated male Sv129 mice as compared to vehicle-treated mice (Figures 5.6B-C). 
Similar observations were made in female mice of three strains, with PCE effect being 
observed only in Sv129 mice. There was no PCE-induced acute liver injury as assessed 
by serum ASTs and ALT, and there was no significant effect on liver cell proliferation.  
Kidney effects of PCE were evaluated by measuring proximal tubule injury and 
cell proliferation in male (Figure 5.7) and female mice. We found that PCE treatment 
induced proximal tubule injury (16.4~39.3% increase in KIM-1 positive proximal 
tubules), an effect that was significant in male and female Sv129 mice and male hCYP2E1 
mice. No increase in cell proliferation was found in the kidney of PCE-treated male mice; 
in fact, cell proliferation was significantly lower in PCE-treated male Sv129 mice 
compared to strain-matched control group. Interestingly, we found higher basal levels of 
proximal tubule injury and cell proliferation in kidneys of female mice as compared to 
male mice. 
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Figure 5.6 Effects of tetrachloroethylene on liver fat accumulation in male 
129S1/SvlmJ (Sv129), Cyp2e1(-/-), and hCYP2E1 mice treated with five consecutive 
daily doses of vehicle (V, Alkamuls EL-620) or tetrachloroethylene (P, 500 mg/kg). 
(A) Representative images of H&E staining with 200× magnification. Yellow arrows
point to fat accumulation. Red arrows point to accumulation of glycogen. Triglyceride
levels in (B) liver (Li) and (C) serum (Se) are shown as mean±SD. Bars with letters are
significantly different from other groups (one-way ANOVA with Newman-Keuls post
hoc test, p<0.05).
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Figure 5.7 Effects of tetrachloroethylene on (A) proximal tubule injury and (B) cell 
proliferation in kidney of male 129S1/SvlmJ (SV129), Cyp2e1 (-/-), and hCYP2E1 
mice treated with five consecutive daily doses of vehicle (V, Alkamuls EL-620) or 
PCE (500 mg/kg) The top figures show the representative images of KIM-1 or BrdU 
staining with 400× magnification. Quantitative results of proximal tubule injury and cell 
proliferation are expressed as % positive/total proximal tubules or nuclei, and are 
summarized in the lower bar charts.  Asterisks denote significant difference by paired t-
test (p<0.05). 
5.5 Discussion 
The role of CYP2E1 in TCE metabolism has been studied by comparing wild-type 
mice and CYP2E1 transgenic mice (Forkert et al., 2006;  Kim and Ghanayem, 2006; 
Ramdhan, et al., 2008). Even though these studies focused on CYP2E1-mediated toxic 
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effects of TCE, CYP2E1-mediated effects on metabolism were also investigated by 
measuring the urinary excretion of TCA and TCOH. Decreased TCA and TCOH levels 
were found in urine of Cyp2e1(-/-) mice; however, the internal dosimetry of these 
oxidative metabolites in liver and kidney, as well as that of glutathione conjugation 
metabolites, was not explored in these studies. To address this significant data gap, we 
conducted a study of concentration-time profiles of both oxidative and glutathione 
conjugation metabolites of TCE in liver and kidney. Furthermore, we included both 
Cyp2e1(-/-) and hCYP2E1 mice and both males and females to provide insights into the 
role that CYP2E1 plays in TCE metabolism. We also extended this study to investigate 
the CYP2E1-mediated metabolism and toxic effects of a related chemical of human health 
concern, PCE. 
First, we found that CYP2E1 has a role in generation of oxidative metabolites of 
TCE in liver and kidney. Formation of TCA from TCE in liver was reduced by about 65 
% without the expression of CYP2E1, which concurs with previous observations in urine 
of Cyp2e1(-/-) mice (Ramdhan, et al., 2008). However, Cyp2e1(-/-) mice still can generate 
TCA from TCE, suggesting that other CYPs, such as CYP2F and CYP2B1, may also 
participate in TCE oxidation (Forkert et al., 2005). Interestingly, Cyp2e1(-/-) mice exhibit 
a retarded Tmax for TCOH, but generate a comparable amount of TCOH in liver. In 
addition, hCYP2E1 mice, which had the highest level of CYP2E1 expression in liver, 
formed the lowest amount of TCOH. Collectively, these results suggest that CYP2E1 
plays a major, but not exclusive, role in converting TCOH to TCA. Importantly, in absence 
of CYP2E1 expression, an increase in generation of glutathione conjugates was observed. 
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This result supports the notion that even though glutathione conjugation is a minor 
pathway of TCE metabolism in the mouse, CYP-mediated oxidation does compete with 
glutathione conjugation.  
Second, we found quantitative differences in the extent of metabolism between 
TCE and PCE and that CYP2E1 also has a role in formation of TCA in PCE-treated mice. 
It has been assumed that PCE metabolism and toxicity are similar to TCE due to their 
structural similarity (Cichocki, et al., 2016). Even though qualitative and quantitative 
differences in oxidative metabolisms between TCE and PCE are known (IARC, 2014;  
U.S. EPA, 2011b;  U.S. EPA, 2011c), data on glutathione conjugation metabolism are still 
limited.  Overall, the flux to both oxidative and glutathione conjugation metabolites is 
higher in PCE-treated mice compared to TCE-treated mice. Taking into account the dose 
differences, we found that PCE-produced metabolite levels were approximately 3-fold 
greater for TCA, 4-fold greater for the glutathione conjugate, and 25-fold greater for 
cysteine and n-acetyl cysteine conjugates. These quantitative differences are in agreement 
with those reported recently (Luo, et al., 2017;  Luo, et al., 2018a;  Zhou, et al., 2017).  
In addition, our results show that CYP2E1 status could modify glutathione 
conjugative metabolism differently between TCE and PCE. Knocking out the expression 
of CYP2E1 led to increases in DCVG, DCVC, and NAcDCVC, but decreases levels of 
TCVG, TCVC, and NAcTCVC in livers and kidneys. In PCE-treated mice, CYP2E1-
mediated oxidation was not competing with the glutathione conjugation. This suggests 
that other CYPs could be important in PCE oxidation. An in vitro study also showed that 
PCE oxidation is primarily catalyzed by the CYP2B family, rather than CYP2E1 (White 
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and De Matteis, 2001). The role for CYP2E1 in the conversion from TCOH to TCA may 
also account for, at least in part, the competition between oxidation and glutathione 
conjugation pathways in TCE-treated mice. TCOH is a TCE-specific metabolite (Chiu, et 
al., 2007;  Zhou, et al., 2017) and the conversion from TCOH to TCA is thought to be 
catalyzed by CYPs (Lash, et al., 2014). Lack of CYP2E1 was likely the cause of TCOH 
accumulation, which in turn impedes the initial oxidation of TCE. Correspondingly, the 
total flux through glutathione conjugation would increase in CYP-deficient individuals.   
Third, we found that presence of mouse CYP2E1 results in PCE-induced liver 
steatosis, while kidney effects of PCE are largely unaffected by CYP2E1 status. Liver fat 
accumulation has been reported in PCE-treated mice but not in TCE-treated mice (Buben 
and O'Flaherty, 1985;  Cichocki, et al., 2017c). However, liver steatosis was observed in 
TCE-treated, Pparα(-/-) and hPPARα transgenic mice (Ramdhan et al., 2010).  PPARα 
activation results in an increase in fatty acid catabolism in liver (Rakhshandehroo et al., 
2010;  Ramdhan, et al., 2010), and the suppression of PPARα activation causes 
hepatosteatosis. Interestingly, hepatic level of TCA, a PPARα activator, was the highest 
in liver of wild type mice compared to Pparα(-/-) and hPPARα transgenic mice (Yoo, et 
al., 2015c), supporting the aforementioned hypothesis. In our study, the amount of TCA 
generated in PCE-treated mice was even greater than that in TCE-treated mice; however, 
we found fat accumulation in the liver of Sv129 mice. Surprisingly, there was no liver 
steatosis in PCE-treated Cyp2e1(-/-) and hCYP2E1 mice. These observations suggest that, 
aside from PPARα activation, CYP2E1 status also may affect lipid metabolism in liver. 
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Additional studies are required to uncover the underlying molecular mechanisms behind 
the CYP2E1-mediated effects of PCE in mouse liver.  
Similar to no effect of CYP2E1 status on glutathione conjugation metabolite 
formation from PCE, we found no effect of CYP2E1 status on kidney injury. We did 
observe an increase in KIM-1 staining in PCE-treated mice, showing that kidney is a target 
tissue in the mouse. It has been postulated that the bio-activation of TCVC and 
NAcTCVC, catalyzed by renal β lyase or other enzymes such as flavin monooxygenase 
and CYP3A, is a critical step for nephrotoxicity of PCE (Irving, et al., 2013;  Lash, et al., 
1994). It is likely that CYP2E1 may also play a role in sulfoxidation of cysteine and n-
acetyl cysteine conjugates of PCE, as it was shown that CYP2E1 is involved in 
sulfoxidation of S-methyl N,N-diethylthiolcarbamate (Madan et al., 1995) and 
diethyldithiocarbamate methyl ester (Madan et al., 1998).   
Fourth, our data provide important clues into sex differences in metabolism and 
toxicity of chlorinated solvents. Protein levels of CYP2E1, as well as the oxidative 
metabolites of TCE and PCE, were higher in liver and kidney of male mice as compared 
to female mice. The sex-dependent difference in metabolism of TCE was previously 
reported (Yoo, et al., 2015c). Indeed, studies showed that steroid sex hormones can 
regulate constitutive expression of CYP2E1 in mice (Konstandi et al., 2013;  Penaloza et 
al., 2014), which can further modulate chemical-induced toxicity (Hu et al., 1993).       
We also note that this study is not without limitations. First, the experimental 
designs were not identical between TCE and PCE arms of the study. Still, we are able to 
indirectly compare TCE and PCE metabolites, and we report that there are potential 
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differences in glutathione conjugative metabolism between TCE and PCE. However, 
direct comparison between toxicokinetics of TCE and PCE will further advance our 
knowledge in the relationship between metabolism and toxicity. Second, due to difficulties 
in breeding transgenic mice, the number of Cyp2e1(-/-) mice were limited. Future studies 
may benefit from increasing the sample size and breeding scale, if technically and 
economically possible.  
In summary, this study provides a comprehensive analysis of the role of CYP2E1 
in the metabolism and toxicity of TCE and PCE. CYP2E1 status affects levels of both 
oxidative and glutathione conjugation metabolites in mouse liver and kidney. We conclude 
that CYP2E1 is an important, but not exclusive actor in the oxidative metabolism and 
toxicity of TCE and PCE. CYP2E1 status also affects liver fat accumulation in PCE-
treated mice.  
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CHAPTER VI 
COMPARATIVE ANALYSIS OF METABOLISM OF TRICHLOROETHYLENE 
AND TETRACHLOROETHYLENE AMONG TISSUES AND MOUSE STRAINS 
6.1 Overview 
Trichloroethylene (TCE) and tetrachloroethylene (PCE) are structurally similar 
chemicals that are metabolized through oxidation and glutathione conjugation pathways. 
Both chemicals have been shown to elicit liver and kidney toxicity in rodents and humans; 
however, TCE has been studied much more extensively in terms of both metabolism and 
toxicity. Despite their qualitative similarities, quantitative comparison of tissue- and 
strain-specific metabolism of TCE and PCE has not been performed. To fill this gap, we 
conducted a comparative toxicokinetic study where equimolar single oral doses of TCE 
(800 mg/kg) or PCE (1000 mg/kg) were administered to male mice of C57BL/6J, 
B6C3F1/J, and NZW/LacJ strains. Samples of liver, kidney, serum, brain, and lung were 
obtained for up to 36 hours after dosing. For each tissue, concentrations of parent 
compounds, as well as their oxidative and glutathione conjugation metabolites were 
measured and concentration-time profiles constructed. A multi-compartment 
toxicokinetic model was developed to quantitatively compare TCE and PCE metabolism. 
As expected, the flux through oxidation metabolism pathway predominated over that 
through conjugation across all mouse strains examined, it is 1,200-3,800 fold higher for 
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TCE and 26-34 fold higher for PCE. However, the flux through glutathione conjugation, 
albeit a minor metabolic pathway, was 21-fold higher for PCE as compared to TCE. The 
degree of inter-strain variability was greatest for oxidative metabolites in TCE-treated and 
for glutathione conjugation metabolites in PCE-treated mice. This study provides critical 
data for quantitative comparisons of TCE and PCE metabolism, and may explain the 
differences in organ-specific toxicity between these structurally similar chemicals. 
6.2 Introduction 
Trichloroethylene (TCE) and tetrachloroethylene (PCE) are structurally similar 
chlorinated olefins that are used in chemical manufacture, metal degreasing, and other 
industrial applications (U.S. EPA, 2011b;  U.S. EPA, 2011c). TCE and PCE are high 
production volume chemicals and are ubiquitous in air, soil, and surface and ground water 
(IARC, 2014). Humans can be exposed to these chemicals via inhalation and ingestion 
(ATSDR, 1997;  Wu and Schaum, 2000). For TCE, assuming an ambient TCE 
concentration range of 100-500 ppt and an adult breathing rate of 20 m3/day, the average 
daily intake of TCE through inhalation for the general population is estimated as 11-33 
µg/day. The average daily intake of TCE through ingestion is 2-20 µg/day, assuming a 
concentration range of 2-7 ppb and total water consumption of 2 liters/day. For PCE, the 
total daily intake was estimated in the range of 1.22 to 2.67 µg/body weight (bw) for the 
general population in Canada, where drinking water ingestion only accounts for a small 
amount of the total exposure, estimated to be 0.002 to 0.06 μg/kg bw per day (CEPA, 
1993). In a National Health and Nutrition Examination Survey (2013-2014), the rate of 
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detection for TCE and PCE in blood was 0.6% for TCE and 7.4% for PCE (CDC, 2017), 
which had dramatically declined compared to those reported in 2000 (Jia, et al., 2012). 
These data demonstrate that the exposure of TCE and PCE to the general population has 
declined; however, TCE and PCE are still prioritized for evaluation of the risks to human 
health and environment (U.S. EPA, 2017).  
There are differences in toxic effects of TCE and PCE in liver, kidney and other 
tissues (Cichocki, et al., 2016). TCE is classified as “carcinogenic to humans” by US EPA 
(U.S. EPA, 2011c) and IARC (Guha, et al., 2012); while PCE is classified as “likely to be 
a human carcinogen” by US EPA (U.S. EPA, 2011b) and as “probably carcinogenic to 
humans” by IARC (Guha, et al., 2012). A comparative study of toxicodynamics of TCE 
and PCE in mice showed differences in the effects on liver and kidney, PCE perturbed 
more molecular pathways in mouse liver and kidney as compared to TCE (Zhou, et al., 
2017). However, no study performed comparative analysis of toxicokinetics of TCE and 
PCE. 
Upon absorption, TCE and PCE are metabolized through oxidative and glutathione 
conjugation pathways. Initial oxidation occurs on the double bond by cytochrome P450s 
(CYPs) to generate an epoxide, which can be further metabolized. Trichloroacetic acid 
(TCA) is the major oxidative metabolite of both TCE and PCE, and is a common urinary 
biomarker of exposure (Forkert et al., 2003;  Volkel, et al., 1998). The other oxidative 
metabolite, trichloroethanol (TCOH), is a TCE-specific oxidative metabolite that is 
formed through oxidation of TCE to chloral hydrate (CH), while PCE oxidation occurs 
through trichloroacetyl chloride (Chiu, et al., 2007). Both TCE and PCE can enzymatically 
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conjugate with glutathione to form dichloro- or trichloro-glutathione conjugates (DCVG 
or TCVG) (Lash, et al., 2000). These conjugates can be further metabolized via hepatic or 
renal gamma-glutamyl transferase and di-peptidase to form corresponding cysteine 
conjugates, DCVC or TCVC, which are then n-acetylated via N-acetyltransferase to 
generate NAcDCVC or NAcTCVC, respectively. In addition, both NAcDCVC or 
NAcTCVC can be deacetylated via acylase to yield DCVC or TCVC. Apart from N-
acetylation, DCVC and TCVC can be further bio-activated via cysteine conjugate β lyase 
to generate reactive thioketenes, or flavin-containing monooxygenase to form sulfoxides 
DCVCSO or TCVCSO (Lash, et al., 2014). These and other reactive species derived from 
glutathione conjugation are thought to be significant contributors to the nephrotoxicity of 
TCE and PCE (Lash, et al., 2001a;  Lash, et al., 2003).      
Quantitative estimation of inter-individual variability in metabolism is also a 
critical challenge in human health assessments of TCE and PCE (Cichocki, et al., 2017c;  
Cichocki, et al., 2016;  Venkatratnam, et al., 2017). The inter-strain variability in TCE 
metabolism has been characterized by using a multi-strain panel of inbred mice (Bradford, 
et al., 2011) and the Collaborative Cross mouse population (Luo, et al., 2018a;  
Venkatratnam, et al., 2017;  Venkatratnam et al., 2018). Likewise, the inter-individual 
variability in PCE metabolism has also been studied in the Collaborative Cross mouse 
population (Cichocki, et al., 2017c), and a nonalcoholic steatohepatitis mouse model 
(Cichocki, et al., 2017a). However, these studies of inter-strain variability in metabolism 
and toxicity were conducted separately for TCE or PCE and using doses that were not 
equivalent. Because of the close structural similarity of these chemicals and paucity of the 
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available toxicokinetic data, a comparative study of equimolar doses was conducted 
concurrently using three inbred strains, selected based on variability observed across 
strains with respect to oxidative and glutathione conjugation metabolism for TCE 
(Bradford, et al., 2011). The data from this study fill critical gaps in our understanding of 
the quantitative differences in TCE and PCE toxicokinetics. 
6.3 Methods 
6.3.1 Chemicals 
TCE (PN: 24254, ≥ 99.0%), PCE (PN: 270393, ≥ 99.9%), TCA (PN: T6399, ≥ 
99.0%), TCOH (PN: T54801, ≥ 99%), 2-bromobutyric acid (PN: 147877, 97%), 
ethylbenzene (PN: E12508, 99%), methyl tert-butyl ether (PN: 443808, ≥ 99.0%), 
chloroform (PN: 650498, ≥ 99.9%), sulfuric acid (PN: 339741, ≥ 99.999%), sodium 
sulfate (PN: 239313, ≥ 99.0%), β-glucuronidase (PN: G0751, ≥300,000 units/ g solid), 
and sodium bicarbonate (PN: S6014, ≥ 99.7%) were obtained from Sigma Aldrich (St 
Louis, MO). Methanol (HPLC grade) was from Fischer Chemicals (Fair Lawn, NJ). S-
(1,2-dichlorovinyl)-cysteine (DCVC, ≥98.0%), 2-(15N)amino-3-([1,2-
dichloroethenyl]sulfanyl)(13C3)propanoic acid (DCVC*, purity ≥95.0%, isotopic purity 
≥98.0%), S-(1,2-dichlorovinyl)-glutathione (DCVG, ≥98.9%), and 2-amino-5-[(2-
([(13C)carboxy(13C)methyl] (15N)amino)-1-([1,2 dichloroethenyl]sulfanyl)-2-
oxoethyl)amino]-5-oxopentanoic acid (DCVG*, purity ≥90.0%, isotopic purity ≥98.0%) 
were purchased from TLC Pharmaceutical Standards (Aurora, Canada). N-acetyl-S-(1,2-
dichlorovinyl)-cysteine (NAcDCVC, 99.8%) and 3-([1,2-dichloroethenyl]sulfanyl)-2-[(1-
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13C, d3)ethanoylamino]propanoic acid (NAcDCVC*, purity: 97.6%, isotopic purity: 
99.0%), and NAcTCVC (purity: 99.7%) were obtained from Toronto Research Chemicals 
(Toronto, Canada). TCVG (purity: 98.9%), TCVC (purity: 98.4%), 2-Amino-5-[(1-
{[(13C)carboxy(13C)methyl](15N) amino}-1-oxo-3-[(trichloroethenyl)sulfanyl]propan-2-
yl)amino]-5-oxopentanoic acid (TCVG*, purity: 90.4%), 2-(15N)amino-3-
[(trichloroethenyl)sulfanyl](13C3)propanoic acid (TCVC*, purity: 97.5%), and 2-
[acetyl(15N)amino]-3-[(trichloroethenyl)sulfanyl] (13C3)propanoic acid (NAcTCVC*, 
purity: 99.0%) were synthesized by Dr. Avram Gold at the University of North Carolina 
at Chapel Hill. De-ionized water was generated via Arium®Pro Ultrapure Water System 
(Gottingen, Germany). 
6.3.2 Animals and treatments 
Adult male C57BL/6J, B6C3F1/J, and NZW/LacJ mice (6-7 weeks of age) were 
obtained from the Jackson laboratory (Bar Harbor, ME). Animals were housed in 
polycarbonate cages on Sani-Chips irradiated hardwood bedding (P.J. Murphy Forest 
Products, Montville, NJ), and fed with NTP-2000 (Zeigler Brothers, Gardners, PA) wafer 
diet and water ad libitum on a 12 h light-dark cycle. Animals were acclimated for one 
week, and then gavaged (Figure 6.1) with a molar-equivalent single dose (6 mmole/kg) of 
TCE or PCE in vehicle (5% Alkamuls El-620 in saline, 5 mL/kg). Mice were sacrificed 
with overdose anesthesia (pentobarbital, 50 mg/kg i.p.)  at 1, 2, 6, 12, 24, 36 h after dosing. 
The dose was selected based on our previous study comparing transcriptomic effects of 
TCE and PCE (Zhou, et al., 2017), and other studies showing that this dose is well-
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tolerated in acute, sub-chronic, 90-day, and 2-year studies in mice (Buben and O'Flaherty, 
1985;  Cichocki, et al., 2017a;  Cichocki, et al., 2017c;  National Toxicology Program, 
1977;  National Toxicology Program, 1990;  Philip, et al., 2007;  Yoo, et al., 2015c). Time 
points (1, 2, 6, 12, 24, 36 h) were selected to maximize the metabolic information from 
both oxidative and glutathione conjugation pathways (Kim, et al., 2009b). Organs (liver, 
kidney, brain, and lung) were rinsed in phosphate-buffered saline, blotted dry, weighed, 
and snap-frozen in liquid nitrogen. Serum was prepared using Z-gel tubes (Sarstedt, 
Germany) by centrifugation of blood collected from vena cava. All studies were 
conducted and approved by the Institutional Animal Care & Use Committee at the 
University of North Carolina-Chapel Hill. Raw data at the individual mouse level are 
available at the Mouse Phenome Database (https://phenome.jax.org/projects/Rusyn10 and 
https://phenome.jax.org/projects/Rusyn11). 
Figure 6.1 Schematic representation of study design. Male mice from one hybrid 
strain and two inbred strain (B6C3F1/J, C57BL/6J, and NZW/LacJ) were used in this 
study. Mice were intragastrically administered with a single dose of trichloroethylene or 
tetrachloroethylene (6 mmole/kg in 5% Alkamuls EL-620 (5 ml/kg)). Unchanged 
(T/PCE), oxidative (TCA and TCOH), and GSH conjugation metabolites (D/TCVG, 
D/TCVC, and NAcD/TCVC) were quantified in liver, kidney, brain, lung, and serum at 
various time points up to 36 hours (n=3/ time point/strain).   
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6.3.3 Quantification of TCE and PCE 
Tissue levels of TCE and PCE were quantified via a dynamic headspace gas 
chromatography-mass spectrometry as reported in (Cichocki, et al., 2017c). Briefly, 
tissues (20 mg) were homogenized with 0.5 mL of ethylbenzene solution (0.5 µM in 
methanol). Homogenate was transferred to a 40 mL amber glass headspace vial containing 
4 mL of deionized water, and analyzed via a dynamic headspace purge & trap GC-MS 
with single ion monitoring mode.  The peak area ratio of TCE or PCE to ethylbenzene was 
used to construct an eight-point calibration curve (0, 0.015, 0.045, 0.137, 0.41, 1.23, 3.70, 
and 11.11 nmole spiked TCE or PCE) for quantitation of TCE or PCE. 
6.3.4 Quantification of TCA 
Tissue levels of TCA were measured according to the US EPA method 815-B-03-
002 (Domino, et al., 2003) with slight modifications. Tissue samples (liver: 50 mg; kidney, 
brain, and lung: 30 mg; serum: 30 µL) were spiked with 11 nmole of 2-bromobutyric acid, 
homogenized in 1 mL of methanol:chloroform (1:1), and centrifuged at 14,000 g for 10 
mins. The supernatant was mixed well with 1.5 mL of methanolic sulfuric acid (10%, v:v), 
and incubated in water batch at 55oC for 2 h to derive respective methyl esters. Thereafter, 
the derivative was mixed with 2 mL of methyl tert-butyl ether and 3 mL of sodium sulfate 
buffer (150 g/L). The collected upper layer was mixed well with 3 mL of saturated sodium 
bicarbonate. Again, the upper layer was collected, concentrated under nitrogen stream to 
a volume of ~20 µL, and analyzed via GC-MS. The peak area ratio of TCA to internal 
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standards was used to construct an eight-point calibration curve (0, 4.1, 12.3, 37.0, 111.1, 
333.3, 1000, and 3000 nmole spiked TCA) for quantitation of TCA.  
6.3.5 Quantification of TCOH 
Tissue levels of TCOH were determined as described elsewhere(Luo, et al., 
2018b). Briefly, liver (50 mg), kidney (30 mg), brain (30mg), serum (30 µL), and lung (20 
mg) tissues were homogenized with sodium acetate (0.1 M, pH 4.6), and mixed well with 
beta-glucuronidase (2000 units/ ml) in a thermomixer. After overnight incubation at 37 
oC, the incubated homogenate was spiked with ethyl benzene (20 nmole), and then further 
incubated in 10% sulfuric acid in methanol (1.5 ml) at 50 oC for 1 h. Afterwards, the 
reaction mixture was evenly mixed with MTBE (2 mL) and sodium sulfate (3 mL, 150 
g/L), and then centrifuged at 2,500 g for 3 min. The extracted MTBE layer was neutralized 
by saturated sodium bicarbonate (3 mL), transferred to a new vial, and concentrated with 
nitrogen gas to ~20 μL for GC-MS analysis (Song and Ho 2003). Peak area ratio of TCOH 
to ethyl benzene was used to establish an eight-point calibration curve (0, 0.37, 1.11, 3.33, 
10, 20, 30, and 60 nmole spiked TCOH) for quantification of total TCOH (free TCOH 
+TCOH-glucuronide (TCOG)).
6.3.6 Quantification of DCVG/TCVG, DCVC/TCVC, and NAcDCVC/NAcTCVC 
Tissue levels of DCVG/TCVG, DCVC/TCVC, and NAcDCVC/NAcTCVC were 
measured as detailed in (Luo, et al., 2017;  Luo, et al., 2018a). In brief, tissue homogenates 
were subject to a liquid-liquid extraction with 400 µL of methanol:chloroform (1:1) and a 
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solid-phase extraction (SPE) using a weak anion C-18 cartridge (Strata-X-AW, PN: 8E-
S038-TGB, Phenomenex, Torrance, CA). Serum samples were mixed with methanol, 
centrifuged and the supernatant was collected. The supernatant was diluted with water and 
further processed by solid-phase extraction. The SPE eluent was dried under vacuum, and 
reconstituted with 50 µL of methanol: water (20:80) with 0.1 % acetic acid. Tissue levels 
of metabolites were determined by an eight-point calibration curve (0, 0.25, 0.5, 1.25, 2.5, 
6.25, 18.75, and 31.25 pmole) using the peak area ratios of standards to isotopically-
labeled internal standards via UPLC-MS/MS. 
 6.3.7 Toxicokinetic model 
A multi-compartment model to describe the toxicokinetics of TCE and PCE was 
developed based on the model reported in Kim et al. (2009). A compendium of differential 
equations with first-order kinetics was used to describe the metabolism, and elimination 
of TCE or PCE and their metabolites from oxidative and glutathione conjugation pathways 
(Figure 6.2). The model also includes formation of reactive species from cysteine 
conjugates. Additionally, we assumed that the ingested dose of TCE or PCE was rapidly 
absorbed into the blood and distributed to other tissues. Unlike physiologically-based 
pharmacokinetic (PBPK) models that use the partition coefficient to describe the ratio of 
concentration in blood and tissues, this model utilized a “lumped” compartment to 
represent the total quantity of each compound in the body. To describe the quantity of 
TCE or PCE and its metabolites in tissues, we created fraction parameters that individually 
distribute the cumulative dose in the lumped compartment, which can be represented as, 
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𝑄𝑄𝑇𝑇 = 𝑄𝑄𝑇𝑇�𝑓𝑓𝑆𝑆𝑆𝑆𝑆𝑆 + 𝑓𝑓𝐿𝐿𝐿𝐿𝐿𝐿 + 𝑓𝑓𝐾𝐾𝐿𝐿𝐾𝐾 + 𝑓𝑓𝐵𝐵𝑆𝑆𝐵𝐵 + 𝑓𝑓𝐿𝐿𝐵𝐵𝐿𝐿 + 𝑓𝑓𝑂𝑂𝑂𝑂ℎ�, where 𝑄𝑄𝑇𝑇  is the quantity of parent 
compounds (or its metabolites). The fraction parameters include serum (𝑓𝑓𝑆𝑆𝑆𝑆𝑆𝑆), liver (𝑓𝑓𝐿𝐿𝐿𝐿𝐿𝐿), 
kidney (𝑓𝑓𝐾𝐾𝐿𝐿𝐾𝐾), brain (𝑓𝑓𝐾𝐾𝐿𝐿𝐾𝐾), lung (𝑓𝑓𝐿𝐿𝐵𝐵𝐿𝐿), and all other tissues (𝑓𝑓𝑂𝑂𝑂𝑂ℎ), respectively. The 
quantity of a chemical can be calculated by multiplying the total quantity and distributed 
fraction such as, 𝑄𝑄𝐿𝐿𝐿𝐿𝐿𝐿 = 𝑄𝑄𝑇𝑇 ∙ 𝑓𝑓𝐿𝐿𝐿𝐿𝐿𝐿. Then, we can estimate the concentration by using tissue 
weights measured in this study and the reference blood volume. To investigate the 
disposition of TCE and PCE metabolites, we estimated the final cumulative dose in the 
compartments of all elimination (TCE/PCE, TCA, TCOH, and GSH conjugation) and bio-
activation routes (the dotted boxes shown in Figure 6.2). The estimations followed the 
mass-balance rule, where the final cumulative dose from elimination and bio-activation 
routes was equal to the initial oral dose of TCE/PCE. The percentage of excreted T/PCE, 
TCA, TCOH, and GSH conjugation was obtained by dividing the excreted amount of 
individual compound with the given oral dose. We estimated metabolism, excretion, and 
fraction parameters using a Bayesian approach, assuming non-informative priors for each 
parameter, and estimating posterior distributions using Markov chain Monte Carlo 
simulations.  
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Figure 6.2 Toxicokinetics analyses of TCE and PCE metabolites. The model is 
composed of one parent compartment (TCE or PCE), up to two oxidative compartments 
(TCA and TCOH), three GSH conjugation compartments (D/TCVG, D/TCVC, and 
NAcD/TCVC), and one bio-activation compartment (“Reactive species”). The first order 
kinetics of formation of TCA, TCOH, D/TCVG, D/TCVC, NAcD/TCVC, and reactive 
species was described by rate constants KTCA, KTCOH, KGSH, KCys, KNAc, and Kbio 
accordingly. The first order elimination kinetics of T/PCE, TCA, TCOH, and 
NAcD/TCVC was described by KeT/PCE, KeTCA, KeTCOH, and KeNAc. Median estimates of 
selected rate constants are shown. All rate constants are listed in Table 1. 
6.3.8 Statistical analysis 
The fitness of toxicokinetic models developed in this study was examined by using 
Spearman (ρ) and Pearson (r) correlation. The correlation was deemed to be statistically 
significant if p<0.05. The area under curve within the study period (AUC0-36) was 
calculated based on a trapezoidal rule by using the R software (v 3.3.3). 
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6.4 Results 
 Levels of parent compounds (TCE and PCE), as well as their oxidative (TCA and 
TCOH) and glutathione conjugation metabolites (DCVG, DCVC, NAcDCVC, TCVG, 
TCVC, and NAcTCVC) [see comparative schematics of metabolism for TCE and PCE in 
(Cichocki, et al., 2016;  Luo, et al., 2018b)] were quantified in liver, kidney, brain, lung 
and serum of male mice of three strains across a range of time points. These data were 
used to develop toxicokinetic models for TCE and PCE metabolism. 
6.4.1 Model evaluation 
The model (Figure 6.2) fits well to oxidative (r=0.69-0.81; ρ=0.69-0.73) and 
glutathione conjugation (r=0.52-0.64; ρ=0.55-0.79) metabolites of TCE or PCE in 
multiple tissues of male C57BL/6J, B6C3F1/J, and NZW/LacJ mice (Figure 6.3). With 
respect to each parent chemical and their oxidative metabolites, the model demonstrated 
higher performance in TCE-treated mice (r= 0.81; ρ=0.73) as compared to PCE-treated 
mice (r=0.69; ρ=0.69). For glutathione conjugation metabolites, the model fits better in 
PCE-treated mice (r=0.64; ρ=0.79) than in TCE-treated mice (r=0.52; ρ=0.55).   
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Figure 6.3 Global evaluation of toxicokinetic model fit for TCE (A), PCE (B), and 
their respective metabolites. Pearson (r) and spearman (ρ) correlation were used to 
evaluate the model fit. The correlation was considered statistically significant if p-value 
was lower than 0.05. 
6.4.2 Toxicokinetics of TCE and PCE metabolites in multiple mouse tissues 
Based on the model outputs, we compared the toxicokinetics of TCE and PCE 
metabolites in multiple tissues of male B6C3F1/J, C57BL/6J, and NZW/LacJ mice. Tissue 
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levels of TCE were lower than those of PCE; this was most pronounced in kidney. The 
AUC0-36 of TCE was 2.3-3.4 fold lower in serum, liver, brain, and lung, and 49-fold lower 
in kidney as compared to the AUC0-36 of PCE in B6C3F1/J mice (Figure 6.4, Table B-16). 
TCE elimination rate constant was 2.8-fold higher than that for PCE (Table 6.1, Figure A-
6). These data are concordant with the results from previous studies (Cichocki, et al., 
2017a;  Yoo, et al., 2015c), suggesting that TCE may be metabolized and eliminated more 
rapidly than PCE in male mice. In addition, saturation of the metabolism of PCE at dose 
of 1000 mg/kg (Buben and O'Flaherty 1985) may also contribute to the higher AUC0-36 of 
PCE and lower Ke, pce compared to those of TCE. 
Upon absorption, TCE and PCE are metabolized primarily via oxidation to TCA 
and/or TCOH (TCOH is a TCE-specific metabolite). Tissue levels of TCA were largely 
comparable between TCE- and PCE-treated mice. Except the C57BL/6J mice, the AUC0-
36 of TCA in TCE-treated mice was 1.2-1.7 fold higher in serum, liver, brain, and lung, 
but similar in kidney as compared to PCE-treated mice. The formation rate constant of 
TCA (KTCA) in TCE-treated mice was 2.4 fold higher than that in PCE-treated mice. The 
elimination rate constant (Ke) of TCA in TCE-treated mice was 1.6-fold lower than that 
in PCE- treated mice (Table 1). The more rapid formation of TCA concurs with the faster 
elimination of TCE, as compared to PCE-treated mice. With regard to the TCE-specific 
metabolite TCOH, it was generally most abundant in kidney. Interestingly, the AUC0-36 of 
TCOH was 2-2.5 fold lower in serum, brain, and lung, but 2.7-3.2fold higher in kidney 
than those of TCA. These findings showed that generation of TCOH and TCOG is more 
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efficient in kidney, which is concordant with the higher expression of UDP-
glucuronosyltransferases and alcohol dehydrogenase in mouse kidney (Yue, et al., 2014). 
Figure 6.4 The AUCs of parent compound (TCE or PCE), oxidative metabolites 
(TCA and TCOH), and GSH conjugation metabolites (D/TCVG, D/TCVC, and 
NAcD/TCVC) in liver, kidney, and serum of male B6C3F1/J (∆), C57BL/6J (○), and 
NZW/LacJ (□) mice. Data points are shown as mean ± standard deviation. Open 
symbols represent TCE, and closed symbols PCE. The grey lines represent the 
population means of TCE-treated (dashed line) and PCE-treated (solid line) groups. 
142 
Table 6.1 Toxicokinetic parameter estimates (mean ± sd) for TCE and PCE 
metabolism. 
TCE PCE 
Oxidation 
T/PCE→TCA 0.034±0.010 0.014±0.003 
T/PCE→TCOH 0.13±0.04 — 
GSH 
conjugation 
T/PCE→D/TCVG (3.5±1.1)*10-6 (460±230)*10-6 
D/TCVG→D/TCVC 0.30±0.07 31.9±20.6 
D/TCVC→NAcD/TCVC 73.4±17.4 43.2±28.7 
D/TCVC→Reactive species 1.69±0.45 37.4±19.2 
Excretion 
T/PCE→ 0.49±0.12 0.17±0.04 
TCA→ 0.05±0.02 0.08±0.02 
TCOH→ 0.49±0.13 — 
NAcT/DCVC→ 23.8±10.5 16.4±10.1 
On the other hand, GSH conjugation pathway was approximately 30-3000 fold 
less efficient than oxidative pathway for TCE and PCE, where the flux through glutathione 
conjugation pathway was even smaller in TCE-treated mice compared to PCE-treated 
mice. In TCE-treated mice, the AUC0-36 values for GSH conjugates were 4.9-12.8 fold 
lower in liver, with a net difference of 0.43-1.12 nmole*hr/g liver, and the AUC0-36 values 
for cysteine conjugates were 2.4-13.3 fold lower in kidney, with a net difference of 0.33-
1.47 nmole*hr/g kidney compared with PCE. The formation rate constant was 131.4-fold 
lower for GSH conjugates, 106-fold lower for cysteine conjugates, and 1.7-fold higher for 
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n-acetylcysteine conjugates in TCE-treated mice as compared to PCE-treated mice. On
the other hand, the Ke was 1.5-fold higher for n-acetylcysteine conjugates in TCE-treated 
mice as compared to PCE-treated mice. Tissue-specific variation of these GSH 
conjugation metabolites was similar between TCE-treated and PCE-treated mice, with the 
highest level of the GSH conjugates found in liver and the highest level of the cysteine 
conjugates found in kidney, in accord with recent studies (Luo, et al., 2017;  Luo, et al., 
2018a;  Yoo, et al., 2015a;  Yoo, et al., 2015b).  
We also examined the inter-strain variability in formation of TCE and PCE 
metabolites based on the model-derived AUCs (Table B-17). The AUC values across 
strains were similar for parent compounds (geometric standard deviation, GSD=1.10-1.46 
for TCE, and =1.02-1.30 for PCE). For oxidative metabolites (TCA and TCOH), the inter-
strain variability was larger in TCE treated mice (GSD=1.24-2.04) as compared to PCE-
treated mice (GSD=1.06-1.52). However, for glutathione conjugation metabolites, the 
inter-strain variability was more prominent in PCE treated mice (GSD=1.12-2.77) as 
compared to TCE treated mice (GSD=1.04-1.92).   
6.4.3 Disposition of TCE and PCE in male B6C3F1/J, C57BL/6J, and NZW/Lac 
mice 
The fractions of administered TCE or PCE that were metabolized to oxidative or 
glutathione conjugation metabolites in each strain at steady state were also estimated 
(Figure 6.5). Most of the parent compounds remained unmetabolized until excretion, the 
fraction of the total administered dose ranged from 61.7% to 84.3% for TCE, and from 
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90.3% to 93.5% for PCE. The unmetabolized fractions of TCE and PCE are likely cleared 
via exhalation, as shown in mice orally dosed with 500 mg/kg 14C-labelled PCE  where 
exhalation fraction of PCE was 82.6 % (Schumann et al., 1980). Excreted TCA accounted 
for 3.5%-7.1% of the total dose for TCE, and 6.4-9.4% for PCE. With respect to the TCE-
specific oxidative metabolite TCOH, it accounted for 12.2-31.2% of the total dose for 
TCE.  
With respect to the glutathione conjugation metabolism, the overall flux to 
conjugation was less than 0.3% of the administered dose for both chemicals. However, it 
was 20-fold higher in PCE-treated mice (0.19%-0.30%) as compared to TCE-treated mice 
(0.010%-0.013%). Importantly, the estimated fraction of the reactive species formation 
from cysteine conjugates ranged from 2.1% to 2.4% for TCE, but from 46.7% to 52.6% 
for PCE. 
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Figure 6.5 Predicted disposition of TCE (A), PCE (B), and their respective 
metabolites in male B6C3F1/J, C57BL/6J, and NZW/LacJ mice. Pie charts are used 
to provide a relative comparison among various metabolites as predicted by the model in 
each strain. Parent compounds (black) or their oxidative metabolites (TCOH, dark gray; 
TCE, light gray) are shown on the left with the GSH conjugation fraction magnified to 
the right of the main pie chart. For GSH conjugate pie charts, the fraction of reactive 
species formed is represented by a yellow slice. 
6.5 Discussion 
The most notable finding of this comparative study of toxicokinetics of TCE and 
PCE in mice is the observation of considerable differences in metabolism between these 
structurally-similar compounds. A larger portion of the parent compound undergoes 
metabolism in TCE-treated mice (15.7%-38.3%) as compared to PCE-treated mice (6.6%-
9.7%), a finding that provides empirical data in strong support of the estimates from PBPK 
models (Chiu, et al., 2014;  Chiu and Ginsberg, 2011). The more efficient oxidative 
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metabolism of TCE as compared to PCE is also concordant with previous animal studies 
(Cichocki, et al., 2017a;  Green and Prout, 1985;  Larson and Bull, 1992) and PBPK 
modeling estimates (Chiu, et al., 2014;  Chiu and Ginsberg, 2011;  Chiu, et al., 2009).  
Previous PBPK models were developed using only limited data for glutathione 
conjugation pathway and suggested that the overall flux through the glutathione 
conjugation pathway was comparable between TCE and PCE (Tables 6.2 and 6.3). 
However, the model estimates presented herein for activation of cysteine conjugates to 
reactive metabolites showed that this process is more efficient in PCE-treated mice as 
compared to TCE-treated mice. In this study, we show that even though the glutathione 
conjugation pathway only accounts for less than 0.3% of the total dose of TCE and PCE, 
the metabolic flux through glutathione conjugation is approximately 21-fold higher for 
PCE compared to TCE. Higher levels of glutathione conjugation metabolites were 
previously reported for PCE as compared to TCE in previous studies in mice (Cichocki, 
et al., 2017a;  Luo, et al., 2017;  Luo, et al., 2018a;  Luo, et al., 2018b); however, the 
dissimilarities in dose and times of metabolite detection made direct comparisons difficult. 
Therefore, our findings are significant with respect to providing direct evidence for 
considerable differences in toxicokinetics between TCE and PCE and are consistent with 
the observations that PCE is more extensively metabolized via glutathione conjugation 
that TCE (U.S. EPA, 2011b).
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Table 6.2 Comparative analysis of toxicokinetics of TCE metabolites in mice, rat, and humans. 
Study Dose† Route Species Strains Sex TCA (%)‡ 
TCOH 
(%) 
GSH conjugation 
(%) 
Oxidation to 
GSH 
This study 800 oral mice 
B6C3F1/J 
M 
5.8 21 0.0131 2045.8 
C57BL/6J 3.5 12 0.0129 1201.6 
NZW/LacJ 7.1 31 0.0104 3663.5 
Chiu et al 2014‖ 2100 oral mice B6C3F1/J M 4.4 — 0.065 290 
Chiu et al 2009‖ 1000 oral mice — — 90 0.2 450 
Larson and Bull 1992 600 oral mice B6C3F1/J M 3.9 31 — — 
Fisher et al. 1991‖ 368 inhalation mice B6C3F1/J M 7 — — — 
Green and Prout 1985 500 oral mice B6C3F1/J M 7.2* 91.1* — — 
Dekant et al. 1984 200 stomach tube mice NMRI F 0.1* 94.3* — — 
Chiu et al 2009‖ 100 inhalation rat — — 40 0.06 666.7 
Bernauer et al 1996 160 inhalation rat Wistar M&F — — — 2562¶ 
Larson and Bull 1992 600 oral rat 
Sprague-
Dawley M 4.1 23.2 — — 
Fisher et al. 1991‖ 505 inhalation rat F344 M 6 — — — 
Commandeur 1990 400 i.p. rat Wistar M — — 0.0026¶ — 
Green and Prout 1985 500 oral rat 
Osborne-
Mendal M 6.3* 90.1* — — 
Dekant et al. 1984 200 stomach tube rat Wistar F 15.3* 73.6* — — 
Chiu et al 2009‖ 1 inhalation human — — 38 5 7.6 
Chiu et al 2006 1 inhalation human — M 1-2 16-28 — — 
Bernauer et al 1996 160 inhalation human — M — — — 7163¶ 
Monster 1979 70 inhalation human — M 21 43 — — 
Monster 1976 70 inhalation human — M 18 39 — — 
† Dose units: ppm for inhalation route; mg/kg for other routes. ‡ Percentage of administered TCE excreted in urine. ‖ Estimates derived from 
PBPK model. * Percentage of total urinary metabolite calculated based on radioactivity. ¶ Use excreted n-acetyl cysteine conjugates to 
represent GSH conjugation of TCE.   
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Table 6.3 Comparative analysis of toxicokinetics of PCE metabolites in mice, rat, and humans. 
† Dose units: ppm for inhalation route; mg/kg for other routes. ‡ Percentage of administered TCE excreted in urine. ‖Estimates derived from 
PBPK models
Study Dose† Route Species Strains Sex TCA (%)‡ GSH conjugation (%) Oxidation to GSH 
This study 800 oral mice 
B6C3F1/J M 6.4 0.187 34.2 
C57BL/6J M 6.6 0.253 26.1 
NZW/LacJ M 9.4 0.298 31.5 
Cichocki et al 2017 300 oral mice C57BL/6J M 5.9 0.79 7.5 
Chiu et al 2011‖ 
10 inhalation mice — — 12 0.02 600 
100 oral mice — — 35 0.07 500 
10 inhalation rat — — 3.9 0.2 19.5 
100 oral rat — — 8.9 0.6 14.8 
Volkel et al 1998 
40 
inhalation rat Wistar M&F 
— — 316.4 
20 — — 540.6 
10 — — 623.6 
Chiu et al 2011‖ 10 inhalation human — — 0.98 9.4 0.1 100 oral human — — 1.8 18 0.1 
Chiu et al 2006  1 inhalation human — M 0.2-0.8 — — 
Volkel et al 1998 
40 
inhalation human 
— 
M&F 
— — 96.3 
20 — — — 89.1 
10 — — — 107.7 
Monster 1979 72 inhalation human — M 2 — — 
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The toxicokinetic profiles for TCE and PCE metabolites are modified by doses, 
species, and administration routes (Tables 6.2 and 6.3) (Bernauer et al., 1996;  Chiu, et 
al., 2014;  Chiu and Ginsberg, 2011;  Chiu, et al., 2007;  Chiu, et al., 2009;  Cichocki, et 
al., 2017a;  Commandeur and Vermeulen, 1990;  Dekant et al., 1984;  Fisher et al., 1991; 
Green and Prout, 1985;  Larson and Bull, 1992;  Monster et al., 1976;  Monster and 
Houtkooper, 1979;  Volkel, et al., 1998). Inter-species differences in toxicokinetics of 
TCE and PCE metabolites has also been reported. In general, mice are thought to be more 
efficient in oxidative metabolism, but less efficient in glutathione conjugation as compared 
to rats and humans, whether in TCE-treated or PCE-treated mice (Chiu and Ginsberg, 
2011;  Chiu, et al., 2009). However, our results show that the quantitative differences in 
metabolism between rats and mice may not be as large as the previously modeled 
estimates. The ratio of oxidative metabolites to glutathione conjugation metabolites is 
closer to that predicted in rats (Chiu and Ginsberg, 2011). The measurement of glutathione 
conjugates in rats and humans would be of great interests to address the inter-species 
differences in GSH conjugative metabolism of TCE and PCE.  
It has been postulated that the reactive species generated from cysteine conjugates 
of chlorinated solvents are the critical nephrotoxic metabolites in animals and humans 
(Lash, et al., 2001a;  Lash, et al., 2007;  Lash, et al., 2001b;  Lash, et al., 2002). Thus, the 
difference in flux through glutathione metabolites of TCE and PCE reported herein needs 
to be reconciled with the evidence for kidney toxicity and carcinogenicity of TCE and 
PCE (Cichocki, et al., 2016). For the parent compounds, the strength of evidence for 
human kidney cancer is greater for TCE as compared to PCE (IARC, 2014). Similarly, 
non-cancer effects were found at lower doses of TCE as compared to PCE (U.S. EPA, 
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2011b;  U.S. EPA, 2011c). Studies that used more sensitive markers of kidney toxicity, 
such as Kim-1 (Luo, et al., 2018b;  Yoo, et al., 2015b) and gene expression (Zhou, et al., 
2017), also confirmed that TCE is more toxic to the kidney as compared to PCE when 
dose is taken into account.  
A different picture emerges from studies in rats and mice that examined kidney 
toxicity of directly administered cysteine conjugates of TCE and PCE in a variety of acute, 
sub-acute and sub-chronic exposure scenarios (Birner, et al., 1997;  Shirai et al., 2012;  
Vaidya et al., 2003). Nephrotoxicity of DCVC and TCVC is firmly established and most 
studies reported effects at doses above 10 mg/kg, with some adverse effects observable as 
doses as low as 1 mg/kg (Shirai, et al., 2012). It should be noted that all of these studies 
did not use sensitive markers of kidney injury and relied on histopathology and relatively 
insensitive serum markers of kidney injury. Furthermore, not many studies conducted a 
comparative analysis of the effects of DCVC and TCVC, one study showed that TCVC is 
more nephrotoxic than DCVC when equimolar doses were compared (Birner, et al., 1997). 
Thus, our toxicokinetic study is highly informative with respect to this apparent disconnect 
because we show that the total amount of reactive glutathione conjugates that can be 
formed from a high dose of either TCE or PCE is at least an order of magnitude lower than 
that which has been shown to elicit nephrotoxicity in rodents and suggests that other 
mechanisms of kidney injury may exist.  
One such additional mechanism is through TCOH, a metabolite that is specific to 
TCE (Chiu, et al., 2007). We found that upon administration of TCE, TCOH levels were 
the highest in kidney among the tissues examined, suggesting that this can be another 
mechanism for kidney toxicity of TCE. The enzymes associated with generation of TCOH 
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(i.e., ADHs) and its conversion to TCOG (i.e., UGTs) have high activity in kidney, which 
may account for the high total TCOH level observed in kidney. To date, there is no 
consensus on TCOH-induced kidney toxicity, but it is likely resulting through perturbation 
of formate metabolism. The oxidative metabolites of TCE, TCA and TCOH, are known 
to mediate formic aciduria in rats (Yaqoob, et al., 2013) and mice (Lock, et al., 2017). It 
was also reported that TCE, but not TCOH, can induce elevated renal injury markers in 
rats after 12 weeks of exposure (Yaqoob, et al., 2014), even though both chemicals can 
cause formic aciduria in rats and mice. However, with chronic exposure up to 52 weeks, 
TCOH has been shown to stimulate formic acid excretion, cell replication, protein 
accumulation, and increased incidence of basophilic tubules in the cortex of rat kidney 
(Green, et al., 2003). Although TCOH alone does not sufficiently explain the full range of 
renal effects after TCE exposure (U.S. EPA, 2011c), the high level of TCOH found in the 
kidney is consistent with the hypothesis that TCE-induced formic aciduria may contribute 
to chronic renal injury observed in rats and mice, a mechanism that is absent in PCE-
treated mice.    
The inter-strain variability in metabolism has been demonstrated in mice for TCE 
(Bradford, et al., 2011;  Luo, et al., 2018a;  Venkatratnam, et al., 2017;  Yoo, et al., 2015a; 
Yoo, et al., 2015b) and PCE (Cichocki, et al., 2017a;  Cichocki, et al., 2017c). Even 
though TCE and PCE differ only by one chlorine atom in structure, we found substantial 
differences in metabolism between TCE and PCE in vivo, especially in the products of 
glutathione conjugation pathway. We selected three strains, B6C3F1/J, C57BL/6J, and 
NZW/LacJ, based on their differences in formation of TCA and glutathione conjugates in 
a multi-strain study of TCE (Bradford, et al., 2011). We posited that these strains would 
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be informative of the range of inter-strain variability in metabolism of TCE and PCE. 
Results from our study lead to several important findings for the metabolism of TCE and 
PCE. The inter-strain variability was larger for TCA, but smaller for glutathione 
conjugates in TCE-treated mice as compared to PCE-treated mice (Table B-17). These 
findings show that chemical-specific data are needed for even structurally similar 
chemicals. The inter-strain variability of TCA levels in liver was recently examined by 
using the Collaborative Cross mouse population with a single oral dose of TCE or PCE, 
where the GSD was 2.24 for TCE-treated mice (Venkatratnam, et al., 2017) and 1.64 for 
PCE-treated mice (Cichocki, et al., 2017c). Our study confirms this difference, we also 
observed a larger variability of TCA level in TCE-treated mice (GSD=1.81) as compared 
to PCE-treated mice (GSD=1.19). The larger inter-strain variability seen in TCE treated 
mice may result from the generation of TCE-specific metabolite TCOH, which was highly 
variable across strains in this study (Figure 6.5). The production and subsequent 
metabolism of TCOH involves a number of metabolic enzymes such as alcohol 
dehydrogenase, CYPs, and UDP-glucuronosyltransferases, and could be the source of the 
observed inter-strain variability. In addition, the enterohepatic recirculation of TCE 
specific metabolites CH, TCOH, and TCOG would also be a significant source of TCA, 
and may introduce the observed inter-strain variability (Stenner, et al., 1997). With regard 
to the glutathione conjugation metabolites, the inter-strain variability is larger in PCE-
treated mice as compared to TCE-treated mice (Table B-17). This observation can be 
attributed to the higher metabolic flux through glutathione conjugation in PCE-treated 
mice as compared to TCE-treated mice. Interestingly, for both TCE and PCE, the highest 
metabolite levels were found in NZW/LacJ mice. This finding is concordant with 
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previously reports that NZW/LacJ mice produced the highest levels of TCA when treated 
with TCE (Bradford, et al., 2011;  Yoo, et al., 2015b).   
We note that this study is not without limitations. First, the doses used in this study 
(6 mmoles/kg) are orders of magnitude higher than those expected in the general human 
population; still, the doses used herein are in the range of doses used in other animal 
studies, including sub-chronic and chronic animal bioassays with both TCE and PCE 
(National Toxicology Program, 1990). Second, the oxidative metabolism of PCE is likely 
saturated at these high oral doses (Buben and O'Flaherty, 1985). Saturation of oxidation 
leads to greater relative formation of glutathione conjugates, which may have greater 
human relevance given evidence that at low doses rodents form approximately 100-fold 
less glutathione conjugation pathway metabolites of TCE as compared to humans (Chiu, 
et al., 2009). Still, some caution is warranted in interpreting our comparative analysis due 
to non-linearities at high doses, so understanding of toxicokinetics at lower doses is an 
area of future research focus that would benefit from more sensitive methods for 
measuring oxidative and glutathione conjugation metabolites, as well as use of PBPK 
modeling to address non-linearities due to metabolic saturation. Our recent analytical 
methods (Luo, et al., 2017;  Luo, et al., 2018a) can be applied in the dose range of 10-100 
mg/kg, but additional improvements to the sensitivity are needed. Third, the use of one 
hybrid and two inbred mouse strains may not be representative for the inter-strain 
variability of T/PCE metabolites. The selection of these three strains was based on the 
crude estimate of the inter-strain variability (Bradford, et al., 2011). A population-based 
mouse model, such as the Collaborative Cross mouse population, would advance our 
knowledge of inter-strain variability in metabolism and toxicity of T/PCE. Finally, the 
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presumed bio-activation of cysteine conjugates necessitates an additional compartment in 
the current model. However, further experimental data (e.g., measurement of 
dichloroacetic acid [DCA] or unidentified reactive metabolites) would be useful to 
confirm our predictions. DCA in particular is of interest because it is a multispecies 
hepatocarcinogen and can be formed via multiple pathways from TCE and PCE, but there 
have been long-standing concerns about its measurement due to the potential for ex vivo 
formation (Chiu et al., 2006b). Still, this study is the first to systematically compare 
oxidative and GSH conjugative metabolism between TCE and PCE. Our next step will be 
updating the PBPK models for TCE and PCE, which is of importance for the health risk 
assessments of TCE and PCE. 
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CHAPTER VII 
SUMMARY AND CONCLUSIONS 
7.1 Summary 
The goal of these studies was to advance our knowledge in organ-specific 
metabolism and toxicity of chlorinated olefins, and to a broader context, in inter-individual 
variability in metabolism and toxicity of environmental toxicants. In summary, we showed 
that the xenobiotic metabolism drove the organ-specific toxicity of chlorinated olefins and 
that the extrinsic (e.g., diet-triggered disease states) and intrinsic factor (e.g., genetics) 
could alter xenobiotic metabolism, and thus may affect the individual’s susceptibility to 
chemical exposures. 
Little is known regarding GSH conjugation pathway of TCE and PCE in vivo due 
to the lack of sensitive analytical assays. Herein, we validated two LC-MS/MS methods 
for simultaneous detection of GSH conjugates in multiple mouse tissues for PCE (Specific 
Aim 1) and TCE (Specific Aim 2).  
The advancement in the analytical methods for detection of GSH metabolites of 
TCE and PCE has opened up a new horizon for studies on metabolism and toxicity of TCE 
and PCE. By applying the newly developed LC-MS/MS method in a study of 20 strains 
of Collaborative Cross mice, we demonstrated that the default uncertainty factor for TKs 
variability (3.16) would be inadequate to protect 99% of the general population for organ-
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specific toxicity of TCE mediated by GSH conjugation metabolites DCVG, DCVC, and 
NAcDCVC (Specific Aim 2).  
We also found that liver disease states (i.e., NAFLD) and the status of a major 
oxidative enzyme (i.e., CYP2E1) could affect metabolism and toxicity of TCE and PCE. 
Specifically, tissue levels of oxidative metabolite TCA were higher in NAFLD mice but 
lower in Cyp2e1(-/-) mice, as compared to the respective wild-type mice. On the other 
hand, tissue levels of GSH conjugation metabolites were lower in NAFLD mice and 
Cyp2e1(-/-) mice for PCE, but higher in Cyp2e1(-/-) mice for TCE. The difference in 
tissue levels of TCA aligned well with the extent of PPARα activation, and that the tissue 
levels of GSH conjugation metabolites concurred with the extent of the PCE-induced 
proximal tubular injury, as indicated in NAFLD mice (Specific Aim 3) and Cyp2e1(-/-) 
mice (Specific Aim 4). 
 The differences in TK of GSH conjugation between TCE and PCE in Cyp2e1(-/-) 
mice are intriguing; therefore, we directly compared the TK of TCE and PCE, and their 
respective metabolites, in multiple organs of male B6C3F1/J, C57BL/6J, and NZW/LacJ 
mice. We found that one chlorine atom replacement in structure led to considerable 
differences in TKs in vivo (Specific Aim 5). In the case of TCE and PCE, significant 
differences were observed in the GSH conjugation pathways, where PCE generated 
approximately 20-fold higher metabolic flux through GSH conjugation compared to TCE. 
In addition, TCOH in which is a TCE-specific metabolite was found in the highest levels 
in the kidney. 
 Collectively, in this dissertation, two LC-MS/MS methods for the simultaneous 
detection of GSH conjugation metabolites at multiple tissues have been developed and 
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validated. With these advancements in the analytical assays, we demonstrated that 
chemical-specific uncertainty factor for TK variability is necessary to protect the 99% of 
the population, especially for the xenobiotics with complex metabolism. Using TCE and 
PCE as model compounds, we concluded that the intrinsic (e.g., genetics) and extrinsic 
(e.g., diet-triggered disease states) factors could introduce inter-individual variability in 
TKs of xenobiotics, which in turn determine the individual susceptibility toward chemical 
exposures. Additionally, one atom replacement in structure could substantially alter the 
metabolism and toxicity of xenobiotics. 
7.2 The significance of this study 
The National Research Council has identified improving the technical analysis as 
one of the future directions for advancing risk assessments (National Research Council, 
2009). Specifically, critical data gaps lie in the uncertainty and variability analyses. 
Uncertainty and variability are inherent properties that are critical to the quality of the risk 
assessment process. Both uncertainty and variability can be better characterized but not 
fully eliminated. Uncertainty results from lack of data; while variability stems from the 
inherent characteristics of a population, from exposure to the adverse effects of exposures 
(National Research Council, 2009).   
Herein, we provide a generalized scheme that improves characterization of the 
variability in metabolism and toxicity of xenobiotics, by using CC mice, a transgenic 
mouse model, and two mouse models for fatty liver disease. The CC is derived from eight 
founder strains, which captures over 90% of the known genetic variability in laboratory 
mice (Churchill, 2007). In addition, this genetic variability is randomly assigned to 
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individual CC lines (Aylor et al., 2011). Combined with the known genetic background, 
CC mice are an ideal animal model to probe the hereditary variability in TKs and TDs of 
xenobiotics in general. In Specific Aim 2, we demonstrated that CC mouse population is 
a useful population-based model to derive the tissue-specific uncertainty factors for TK 
variability.   
Narrowing down to the context of a specific enzyme, transgenic mice can provide 
mechanistic insights into the mode of action of xenobiotics, by knocking in or knocking 
down the gene of interest. Transgenic mouse models have been widely used to study the 
role of specific enzyme in diseases (Agrawal et al., 2015;  Epstein et al., 1987;  Kostic et 
al., 1997;  Langley et al., 2017;  Leissring et al., 2003;  Liu et al., 2001;  Ripps et al., 
1995) and in developing toxicities of xenobiotics (Boverhof et al., 2011;  Gonzalez, 2002; 
Gonzalez and Kimura, 2003;  Reno et al., 2015). If a priori knowledge of the toxicant’s 
mode of action exists, the transgenic mouse model is the most straightforward way to 
investigate how the protein of interest contributes to xenobiotic’s toxicity in vivo. For 
example, with this information, we could determine whether a fast or slow metabolizer 
would increase susceptibility to chemical exposures. Indeed, we found that the PCE-
induced kidney toxicity has been ameliorated in Cyp2e1(-/-) mice, suggesting that 
individuals with higher activity of CYP2E1 may be more susceptible to PCE induced 
kidney toxicity. 
Likewise, the use of mouse models for disease states can also help identifying the 
susceptible individuals toward chemical exposures. Aside from the effects of NAFLD on 
xenobiotic toxicity examined here, the xenobiotic-disease state associations can also be 
evaluated in other disease models, such as diabetes (Kachapati et al., 2012;  Lovati et al., 
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2013;  Mallipattu et al., 2014) and cardiovascular disease (Doggrell and Brown, 1998; 
Hasenfuss, 1998). The data acquired from these disease models would be helpful for 
addressing specific risk-management questions, e.g., the chemical health risk assessment 
for the individual with the hereditary disease. 
The National Academy of Sciences consultation panel has highlighted several key 
scientific issues regarding the MOAs for TCE toxicity, including (i) the toxicological 
importance of TCA and DCA in rodents and humans for liver cancer, (ii) the toxicological 
importance of GSH conjugation metabolites for kidney cancer, and (iii) strength of 
evidence for hypothesized MOAs for liver cancer (e.g., peroxisome proliferation, cell 
replication, selection, and/or apoptosis) and kidney cancer (e.g., genotoxicity, α2µ-
globulin accumulation, peroxisome proliferation, and nephrotoxicity/cytotoxicity) (Chiu, 
et al., 2006a). Our results indicate that the treatment of TCE and PCE could upregulate 
the PPARα responsive genes (i.e., Acox 1 and Cyp4a10). However, the activation of 
PPARα responsive genes did not translate into the cell proliferation in liver and kidney, 
as evidenced by the cell proliferation in liver and kidney of PCE treated mice.  
The work presented in Aim 1&2 has opened up a new horizon for studies regarding 
GSH conjugation and toxicity of TCE and PCE. With these sensitive analytical methods, 
we can study the associations between GSH conjugation metabolites and kidney toxicity 
of TCE and PCE in vivo, especially at a more biologically-relevant tissue level. Our 
findings showed that despite a relatively small flux through GSH pathway, the tissue levels 
of GSH conjugation metabolites aligned well with the extent of proximal tubular injury of 
PCE, as evidenced in CYP2E1 transgenic mice and NAFLD mice. Additionally, the higher 
flux through GSH conjugation pathway also aligned well with the more pronounced 
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transcriptional effects in mouse kidney for PCE, as compared to TCE (Zhou, et al., 2017) 
. These results support the long-lasting hypothesis that metabolites from GSH conjugation 
pathway can contribute to the nephrotoxicity in vivo. However, for chronic kidney 
toxicity, the strength of evidence is stronger for TCE than PCE. Alternative MOAs may 
participate in developing kidney tumors in animals and humans. 
Indeed, we found an unusually high level of TCOH in the kidney as compared to 
the other tissues. TCOH is a TCE-specific metabolite, which is stemming from CH. 
Subject to chronic exposure of TCOH, rodents can develop formic aciduria and manifest 
an elevated level of kidney injury biomarker (Green, et al., 2003). It is known that formic 
acid can lead to histological changes in rabbit kidney (Liesivuori et al., 1987). As this 
MOA is largely uncharacterized for PCE, multiple MOAs, including the contributions of 
GSH conjugation metabolites and TCOH, are plausible for developing kidney tumors for 
TCE.  
In addition, the interconversion of TCOH and TCOG could be a potential source 
of inter-individual variability in TKs of TCE metabolites. We found a higher TK 
variability for TCE metabolites across B6C3F1/J, C57BL/6J, and NZW/LacJ mice, as 
compared to PCE (Specific Aim 5). This finding also concurred with the results in CC 
mice, where the TKs of TCE metabolites are more variable than those of PCE metabolites 
(Cichocki, et al., 2017c).  TCOH and TCOG can be subject to enterohepatic recirculation 
and would be a significant source of TCA (Stenner, et al., 1997). Therefore, UGTs may 
be a critical enzyme to study the inter-individual variability in metabolism and responses 
to TCE exposure. 
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Aside from the metabolism of TCE and PCE, the chemical and physical properties 
of xenobiotic could also be a crucial determinant of the interaction with different disease 
states. For instance, PCE is a lipophilic chemical, which manifests a higher affinity to 
adipose tissues (Cichocki, et al., 2017a). Liver steatosis is anticipated to retain PCE in the 
liver and reduce the delivered dose of PCE in other organs. Indeed, our results showed 
that PCE levels were higher in the liver (Cichocki, et al., 2017b), but lower in the kidney 
and feces of NAFLD mice compared to LFD mice. The higher internal dose of PCE 
increased the production of TCA in the liver of NAFLD mice, which caused more severe 
PCE-induced liver effects (Cichocki, et al., 2017b). This result reveals that chemical and 
physical properties of xenobiotics could be critical factors to identifying susceptible 
individuals, considering the nature of disease states.   
Collectively, this dissertation fills in several data gaps from a broader context of 
risk assessment, to a specific case-scenario of TCE and PCE. With the animal models 
demonstrated in this dissertation, we can better characterize the variability in TKs and TDs 
of xenobiotics and improve the quality of human health risk assessment.   
7.3 Limitations 
Even though the studies from this dissertation have enlightened us on inter-
individual variability in metabolism and toxicity of TCE and PCE, and advanced our 
knowledge in metabolism and toxicity of TCE and PCE, there are several limitations in 
these studies. 
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First, the monitoring metabolites in these studies were confined to the parent 
compounds TCE and PCE, major oxidative metabolites TCA and TCOH, and GSH 
conjugation metabolites D/TCVG, D/TCVC, and NAcD/TCVC. Other minor metabolites 
from oxidative (i.e., CTAC, DCA, and DCVT) and GSH conjugation pathways (i.e., 
DCVCSO and TCVCSO) may also be of interest because of their potential toxicities. 
However, there is little or no analytical capability to detect these minor, but reactive 
metabolites in target organs, partly because these metabolites are too unstable to develop 
analytical methods for targeted analysis. The alternative approach would be using 
untargeted approaches (e.g., NMR, IM-MS, etc.) to compare the differences between 
chemical-exposed and control groups.  
Second, species differences do exist in the metabolism and toxicity of xenobiotics. 
For instance, mice manifest a higher metabolic rate for the oxidative metabolism (e.g., via 
CYPs), but a lower efficiency in GSH conjugative metabolism as compared to rats and 
humans (Chiu, et al., 2009). Other physiological parameters also vary among species. 
Therefore, humanized CYP2E1 mice used in this dissertation would reflect the traits that 
may or may not be found in humans. Besides, the relevance of the animal NAFLD/NASH 
models to human NAFLD remains to be a contentious issue in the field (Maher, 2011;  
Teufel, et al., 2016). Even though HFD- and MCD-fed animals can mimic the 
histopathological phenotypes of human NAFLD and NASH, the degree of injury depends 
on several factors including rodent strains (Lau, et al., 2017;  Tryndyak, et al., 2012a;  
Tryndyak, et al., 2012b). Also, the metabolic profile of MCD-fed mice is different from 
human NASH (Rinella and Green, 2004).  
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Third, we note that the administered dose of TCE and PCE used in these studies is 
relatively high, which may not be correspondent to the exposures to humans. As the 
oxidation of TCE and PCE is even more efficient in mice, tissue levels of oxidative 
metabolites would be several orders of magnitude higher in mice compared to humans. 
However, the GSH conjugation pathway is approximately 100-fold less efficient in mice 
compared to humans, therefore suggesting that tissue levels of GSH conjugates may be 
still close to human exposure of TCE and PCE. In addition, the relationship between TCE 
and PCE dose and GSH metabolites is linear within the dose range used in this study. An 
appropriate PBPK model can help extrapolate the mouse data to humans and provide 
valuable information for the human health risk assessment. 
The limitations described above direct us for the future studies regarding the 
mechanistic toxicology and human health risk assessment of environmental toxicants. In 
the next section, we will discuss the potential directions that would move forward in the 
fields of basic mechanistic toxicology, exposure sciences, to regulatory science and human 
health risk assessment. 
7.4 Future directions 
The advancement in analytical chemistry would improve the characterization 
from exposure to toxicity of xenobiotics in humans 
Unlike the traditional studies using a targeted, hypothesis-driven approach to 
explore the associations between a specific xenobiotic and biological endpoints, exposome 
is a bottom-up approach that represents a life course of environmental exposures (Cui et 
al., 2016). This approach allows for the consideration of multiple chemicals, rather than a 
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single chemical, on the progression of specific biological response (Wild, 2005). 
Accordingly, an untargeted approach is proposed and would be useful to characterize the 
complex exposures that are relevant to the real-life scenario. Recent advances in 
development of analytical chemistry have enable the practice of environment-wide 
association study (EWAS), by using nuclear magnetic resonance (NMR) spectroscopy 
(Beckonert et al., 2007;  Gil et al., 2018;  Maitre et al., 2017), LC/GC coupled with 
Fourier-transformed mass spectrometry (Go et al., 2015;  Johnson et al., 2010;  Soltow et 
al., 2013), hybrid ion-trap-orbitrap MS (Jamin et al., 2014), quadrupole-time-of-flight 
mass spectrometry (Andra et al., 2015;  Diaz et al., 2012;  Fan et al., 2014), or triple-
quadrupole tandem mass spectrometry (Cui et al., 2018;  Hoeke et al., 2015).  
Another technology for characterization of exposome is ion-mobility spectroscopy 
(IMS) coupled with MS-based detectors (Metz et al., 2017). IMS introduces several 
advantages for the untargeted analysis. First, IMS provides additional resolution for 
isobaric ions, because it allows the conformational separation of ions based on the 
electronic field and the drag force from ion-gas collisions (Kyle et al., 2016;  Poyer et al., 
2017;  Williams et al., 2009;  Zheng et al., 2017a). Second, IMS increases the dynamic 
range of existing LC-MS based methods (Metz, et al., 2017). Finally, IMS separations are 
ultra-high throughput, with a single separation occurring in 10-100 ms, as compared to 
LC (~minutes) or GC (~hours) techniques. These advantages make IMS-MS a promising 
tool in EWAS research; however, several analytical and data processing challenges need 
to be resolved for the implementation of IMS in exposome workflow. For instance, 
adducts/dimers annotation need to be distinguished from the principle monoisotopic ion 
as determined by IMS. In addition, as an emerging analytical technique, the database for 
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unknown-known analysis is limited, which requires in-house derivation of experimental 
(i.e., via infusion of known standards) or theoretical (i.e., derived in silico) collision cross 
section (CCS) values. 
Metabolomics can be considered as a subset of exposomics (Athersuch and Keun, 
2015); however, it also shows the perturbed metabolic pathways that potentially associated 
with toxic effects of xenobiotics. The analytical tools discussed above have also been 
widely used for metabolomics (Cajka and Fiehn, 2016;  Ghaste et al., 2016;  Khamis et 
al., 2017). After decades of study, MS-based (Wishart et al., 2009) and NMR-based 
databases (i.e., Biological Magnetic Resonance Data) have been well established for 
human metabolomics. On the other hand, the application of IMS-MS in human 
metabolomics is still at an infant stage. The public-available database generated by Pacific 
Northeast National Laboratory reports the CCS values for approximately 500 primary 
metabolites, secondary metabolites, and xenobiotics (Zheng et al., 2017b). Nevertheless, 
these advanced technologies would be potential tools to characterize the xenobiotic-
associated perturbation in metabolism and toxicity, in an untargeted, high-throughput 
manner.      
Toxicity assessment of metabolite mixtures of TCE and PCE: Insights into the 
observed inter-species variability 
Exposure to a chemical with complicated metabolism creates an exposure scenario 
of mixtures. In the case of chlorinated olefins, the interactions among the parent 
compound, oxidative metabolites, and GSH conjugation metabolites remain unclear. 
Effects of chemical co-exposure have been investigated for TCE and PCE in simple 
mixtures. For instance, TCE has shown a potentiation effect with carbon tetrachloride on 
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hepatotoxicity (Pessayre et al., 1982), and a synergistic effect with di(2-
ethylhexyl)phthalate on developmental toxicity (Narotsky et al., 1995) in rats. 
Additionally, TCE manifested synergistic interactions with methylmercury and benzene 
on liver and kidney transcriptomes in rats, after 14-day exposures at the lowest-observed-
adverse-effect-level (LOAEL) (Hendriksen et al., 2007). The pharmacokinetic 
interactions among TCE, PCE, and 1,1,1-trichloroethane were also examined by using a 
PBPK model (Dobrev et al., 2001).  
However, traditional simple-mixture studies require a considerable amount of time 
and efforts but maybe still too simplified for the real-life conditions. From this 
dissertation, we found that the inter-species and inter-individual differences in toxicity of 
TCE and PCE result from the quantitative differences in their metabolism. The different 
combination of the parent compound, oxidative metabolites, and GSH conjugation 
metabolites creates a different chemical mixture, which in turn may affect the toxicity of 
TCE and PCE. 
Because of the complex nature of chemical mixtures, the simple, in vitro cell-based 
assays would be a good starting point for toxicity assessment of mixtures. Based on the 
results from experimental and PBPK studies, we can create a list of mixtures representing 
the metabolism in mice, rats, and humans. By testing these mixtures and individual 
components in the in vitro assays targeting specific bioactivity, we can understand the 
inter-species difference from a comprehensive view and explore the interactions, if any, 
among the parent compound and its downstream metabolites. 
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Incorporate the tissue-specific data regarding GSH conjugation pathway into PBPK 
models to refine the health risk assessment of TCE and PCE 
PBPK models have been widely used to bridge the animal and human, low and 
high doses for the health risk assessments of xenobiotics. In the case of TCE and PCE, 
several PBPK modeling papers have been published (Abbas and Fisher, 1997;  Allen and 
Fisher, 1993;  Chiu, et al., 2014;  Chiu and Ginsberg, 2011;  Chiu, et al., 2009;  Clewell 
et al., 2000;  Cronin et al., 1995;  Dobrev, et al., 2001;  Evans et al., 2009;  Fisher, 2000;  
Fisher, et al., 1991;  Fisher et al., 1998;  Gearhart et al., 1993;  Greenberg et al., 1999;  
Hissink et al., 2002;  Loizou, 2001;  Reitz et al., 1996;  Stenner et al., 1998). Only a few 
papers included the compartment regarding GSH conjugative pathway of TCE or PCE. 
Because of lack of tissue-specific data, these papers may either use urinary n-acetyl 
cysteine conjugates or serum levels of GSH conjugation metabolites to represent the flux 
through GSH conjugation pathway. However, the tissue levels of GSH conjugation 
metabolites are critical because these GSH metabolites have been postulated as the 
precursors of the nephrotoxic metabolites of TCE and PCE. 
One of the essential findings from this dissertation is that we report the tissue-
specific data regarding GSH conjugates, cysteine conjugates, and n-acetyl cysteine 
conjugates of TCE and PCE in multiple mouse tissues. The incorporation of these animal 
data into an updated PBPK model will be useful to give insights into the role of GSH 
conjugation metabolites in developing kidney toxicity, especially with a more relevant 
scenario to humans.   
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APPENDIX A 
FIGURES 
Figure A-1 Purity of the standards used in this study. Purity of TCVC (A), TCVC* 
(B), TCVG (C), TCVG* (D), and NAcTCVC* (E) was determined using HPLC-UV/Vis 
detection in a full scan mode for the wavelength range from 190 to 600 nm (left image in 
each panel) followed by a detection at the wavelength set at 254 nm (right image in each 
panel).  
A: TCVC 
B: TCVC* 
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C: TCVG 
D: TCVG* 
E: NAcTCVC* 
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Figure A-2 Analysis of the effect of extraction procedures and solvents on recovery 
of TCVG, TCVC, and NAcTCVC in liver and kidney tissue in mice. (A) LC-MS/MS 
chromatogram peak intensity of the neat standards (25 μL of 0.1 μM STD) spiked into 
PBS, methanol/chloroform (M/C) or distilled deionized water. (B) LC-MS/MS 
chromatogram peak intensity of the standards (25 μL of 0.1 μM STD) extracted in 
mouse liver tissue homogenized in PBS, methanol/chloroform (M/C), or in tissue that 
was first homogenized in PBS and then boiled for 10 min at 90oC prior to addition of the 
analytes. (C) Same as B, except mouse kidney tissue was used. Experiments were 
repeated three times and group means with standard deviations are shown. Statistical 
significance (*, p<0.05), as compared to PBS groups for each analyte, was determined 
by one-way ANOVA with Tukey’s post-hoc test. 
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Figure A-3 The LC-MS/MS chromatogram of DCVC in tissue blank and IS blank 
samples of (A) serum, (B) liver, and (C) kidney. 
Figure A-4 Pearson correlation analysis of DCVG, DCVC, and NAcDCVC across 
tissues. Labels indicate statistical significance: * p<0.05, ** p< 0.01, *** p< 0.001. 
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Figure A-5 Gene expression results of Havcr1, Fabp1, and Lcn2 align well between 
qRT-PCR and mRNA sequencing 
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Figure A-6 Comparative analysis of toxicokinetic parameters of TCE (blue) and PCE 
(red) metabolites in male B6C3F1/J (●), C57BL/6J (▲), and NZW/LacJ (■) mice. 
The units of first order rate constants are expressed as h-1. 
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Figure A-7 Toxicokinetic profile of parent compounds (TCE or PCE; red), oxidative 
metabolites (TCA and TCOH; dark and light green), and glutathione conjugation 
metabolites (D/TCVG, D/TCVC, and NAcD/TCVC; blue, brown, and pink) in 
multiple tissues of male B6C3F1/J mice. Each data point represents a single mouse. The 
color matched dash line shows the modeling estimate for individual toxicokinetic profile. 
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APPENDIX B 
TABLES 
Table B-1 Quantifiers and qualifiers for analysis of TCVG, TCVG, and NAcTCVC 
in multiple tissue. 
Analytes Ion transition (m/z) Collision energy (V) Fragmentor (V) 
TCVG 436.0→306.8 13 118 
436.0→203.9 25 118 
438.0→308.8† 13 118 
TCVG* 443.0→313.8† 17 118 
439.0→309.8 13 118 
TCVC 251.9→234.8† 9 90 
249.9→160.8 21 90 
249.9→232.8 9 90 
TCVC* 255.9→237.8† 9 90 
255.9→162.9₸ 21 90 
NAcTCVC 291.9→249.8† 9 90 
291.9→232.8 17 90 
293.9→251.8 9 90 
NAcTCVC* 295.9→235.8† 9 90 
295.9→253.8 17 90 
† Selected quantifier for analysis. ₸ Alternative quantifier of TCVC* in serum. Dwell 
time and cell accelerator voltage were set at 25 ms and 2 V. 
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Table B-2 Optimization of nebulizer gas pressure 
*The values represent the instrumental responses of injected compounds subject to
various conditions of nebulizer gas pressure. a Indicates optimal ionization parameter.
Nebulizer gas pressure 
TCVC 1 2 3 Average STD CV 
10 56904 58104 60691 58566 1935.4 3.3% 
15 80005 79812 78432 79416 857.9 1.1% 
20 91324 88898 91142 90455 1351.2 1.5% 
25 101797 94471 100037 98911 3824.2 3.9% 
30 108307 108587 108771 108756 233.6 0.2% 
35 112670 116330 113840 114579 1869.3 1.6% 
40 116430 117606 119049 117695 1311.8 1.1% 
45 a 119356 120647 118140 119381 1253.7 1.1% 
TCVG 1 2 3 Average STD CV 
10 31674 32350 34581 32868 1521.2 4.6% 
15 50793 50337 49965 50365 414.7 0.8% 
20 60131 60654 61364 60716 618.9 1.0% 
25 68367 63026 67917 66391 2962.3 4.5% 
30 71085 72185 72970 72365 946.9 1.3% 
35 a 74582 73943 74600 74055 374.2 0.5% 
40 69163 70756 73613 71177 2254.7 3.2% 
45 72455 71875 71491 71940 485.3 0.7% 
NAcTCVC 1 2 3 Average STD CV 
10 43022 44392 45915 44443 1447.2 3.3% 
15 60473 60901 60725 60700 215.1 0.4% 
20 69250 69417 70029 69565 410.1 0.6% 
25 75049 73547 73696 74172 827.5 1.1% 
30 a 76599 75993 77821 76929 931.1 1.2% 
35 76105 76478 76472 76486 213.6 0.3% 
40 69497 71811 73568 71625 2041.8 2.9% 
45 71643 73028 71235 71969 939.8 1.3% 
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Table B-3 Optimization of capillary voltage 
Capillary voltage 
TCVC 1 2 3 Average STD CV 
3000 103739 108606 108666 107004 2827.4 2.6% 
3200 109513 111883 112484 111293 1570.8 1.4% 
3400 114497 116304 117587 116129 1552.4 1.3% 
3600 a 117669 120271 117209 118383 1651.2 1.4% 
3800 111324 108803 103991 108039 3725.7 3.4% 
4000 99144 98883 95269 97765 2165.8 2.2% 
TCVG 1 2 3 Average STD CV 
3000 65154 66823 67152 66376 1071.3 1.6% 
3200 70336 71154 72691 71394 1195.7 1.7% 
3400 75595 75221 76151 75656 468.0 0.6% 
3600 a 77739 81310 75644 78231 2864.9 3.7% 
3800 75347 72436 69269 72351 3039.9 4.2% 
4000 68289 67317 63823 66476 2348.7 3.5% 
NAcTCVC 1 2 3 Average STD CV 
3000 71182 74036 75266 73495 2095.1 2.9% 
3200 75596 77311 78382 77096 1405.4 1.8% 
3400 80378 80049 80360 80262 185.0 0.2% 
3600 a 80902 82951 78868 80907 2041.5 2.5% 
3800 76414 75017 71316 74249 2634.3 3.5% 
4000 67493 66438 64990 66307 1256.6 1.9% 
*The values represent the instrumental responses of injected compounds subject to
various conditions of nebulizer gas pressure. a Indicates optimal ionization parameter.
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Table B-4 Optimization of sheath gas temperature 
Sheath gas temperature 
TCVC 1 2 3 Average STD CV 
150 75118 75232 72074 74141 1791.3 2.4% 
200 75153 75820 74122 75032 855.5 1.1% 
250 72878 69316 68149 70114 2463.5 3.5% 
300 74137 73604 71748 73163 1254.1 1.7% 
350a 76631 76293 77726 76883 749.1 1.0% 
400 82172 69410 73559 75047 6509.8 8.7% 
TCVG 1 2 3 Average STD CV 
150 47227 47303 45724 46751 890.5 1.9% 
200 46403 47009 46146 46519 443.1 1.0% 
250 45567 43285 43154 44002 1356.9 3.1% 
300 47249 47256 46068 46858 683.9 1.5% 
350 a 49770 49912 50406 50029 333.8 0.7% 
400 54779 45642 49022 49814 4619.7 9.3% 
NAcTCVC 1 2 3 Average STD CV 
150 43395 44383 42140 43306 1124.2 2.6% 
200 46337 46466 45805 46203 350.4 0.8% 
250 45157 42770 42706 43544 1397.0 3.2% 
300 46856 47911 46427 47065 763.7 1.6% 
350 a 50031 48920 49724 49558 573.7 1.2% 
400 55759 44368 49044 49724 5725.8 11.5% 
*The values represent the instrumental responses of injected compounds subject to
various conditions of nebulizer gas pressure. a Indicates optimal ionization parameter.
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Table B-5 Optimization of nebulizer gas temperature 
Nebulizer gas temperature 
TCVC 1 2 3 Average Std CV 
150 75744 77896 80260 77967 2258.8 2.9% 
200 80482 81424 79237 80381 1097.0 1.4% 
250 82780 82500 82717 82666 146.9 0.2% 
300 a 82304 83912 81747 82654 1124.2 1.4% 
350 61821 62739 60678 61746 1032.5 1.7% 
TCVG 1 2 3 Average Std CV 
150 41434 41864 43360 42219 1011.0 2.4% 
200 45371 45878 45802 45684 273.4 0.6% 
250 48531 46482 48478 47830 1168.0 2.4% 
300 a 48705 51039 49445 49730 1192.8 2.4% 
350 40013 40174 39326 39838 450.4 1.1% 
NAcTCVC 1 2 3 Average Std CV 
150 46060 48183 49188 47810 1597.0 3.3% 
200 50005 51384 49804 50398 860.1 1.7% 
250 52053 52003 52932 52329 522.5 1.0% 
300 a 51857 54556 52430 52948 1422.0 2.7% 
350 41088 40764 39145 40332 1040.9 2.6% 
*The values represent the instrumental responses of injected compounds subject to
various conditions of nebulizer gas pressure. a Indicates optimal ionization parameter.
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Table B-6 Method validation of TCVG, TCVC, and NAcTCVC in liver 
TCVG TCVC NAcTCVC 
Low† Mid High Low Mid High Mid High 
Set 1 1479.1 ± 68.2₸ 10282.9 ± 1516.6 127516.5 ± 12981.4 2096.5 ± 106.5 23103.6 ± 2765.5 288241.1 ± 29730.2 2155.5 ± 329.9 25872.1 ± 2471.6 
Set 2 1816.3 ± 651.2 11829.1 ± 2218.0 134058.1 ± 44461.4 2541.2 ± 580.5 24590.9 ± 1933.8 299887.7 ± 34666.9 1956.8 ± 418.0 22971.5 ± 9114.7 
Set 3 1205.3 ± 243.1 5893.4 ± 2037.0 85114.8 ± 15836.6 1056.3 ± 116.9 7451.8 ± 2146.7 100158.7 ± 17551.9 1136.9 ± 481.9 15070.9 ± 2442.9 
RE (%) 66% 50% 63% 44% 32% 37% 58% 66% 
ME (%) 123% 115% 105% 113% 100% 94% 91% 89% 
PE (%) 81% 57% 67% 50% 32% 35% 53% 58% 
† Method validation in liver was conducted at different levels across the calibration range for TCVG (On-column values, 0.05, 0.5, and 5 pmole), TCVC 
(0.05, 0.5, and 5 pmole), and NAcTCVC (0.5 and 5 pmole). ₸ Values are expressed in area counts as average ± standard deviation. Set 1: Standards were 
prepared in water; Set 2: Samples were post-spiked with standards after extraction; Set 3: Samples were pre-spiked with standards before extraction. 
Recovery, RE (%) = Set 3/Set 2; Matrix effect, ME (%)= Set 2/ Set 1; Process efficiency, PE (%)= Set 3/ Set 1.  
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Table B-7 Method validation of TCVG, TCVC, and NAcTCVC in kidney 
TCVG TCVC NAcTCVC 
Low Mid High Low Mid High Mid High 
Set 1 1831.0 ± 200.7 13170.5 ± 961.1 145267.1 ± 3332.2 2373.0 ± 274.9 25841.3 ± 1900.1 295079.7 ± 6509.9 2490.9 ± 106.8 27367.4 ± 437.6 
Set 2 1687.5 ± 541.8 14126.6 ± 272.4 144654.1 ± 31050.6 2037.6 ± 692.2 26239.7 ± 1180.2 264278.9 ± 47786.1 2117.7 ± 114.6 23085.5 ± 3935.4 
Set 3 1228.9 ± 513.1 7444.2 ± 2220.0 53816.9 ± 19437.2 1399.4 ± 429.1 11404.8 ± 2124.3 92113.5 ± 28440.5 1265.1 ± 224.3 10149.5 ± 3588.8 
RE (%) 73% 53% 37% 69% 43% 35% 60% 44% 
ME (%) 92% 107% 100% 86% 102% 90% 85% 84% 
PE (%) 67% 57% 37% 59% 44% 31% 51% 37% 
Table B-8 Method validation of TCVG, TCVC, and NAcTCVC in Serum 
TCVG TCVC NAcTCVC 
Low Mid High Low Mid High Low Mid High 
Set 1 2103.5 ± 201.4 14829.2 ± 457.4 149155.5 ± 5204.8 2111.9 ± 233.9 23068.3 ± 564.1 239062.6 ± 7017.7 281.3 ± 31.6 2726.9 ± 94.2 28217.7 ± 936.7 
Set 2 2160.9 ± 239.2 13384.0 ± 200.9 138943.8 ± 1926.9 2173.9 ± 189.6 21709.6 ± 185.7 230027.5 ± 3331.6 341.1 ± 50.5 2987.2 ± 152.8 31141.5 ± 1205.8 
Set 3 1827.9 ± 146.5 7543.7 ± 1756.6 80692.8 ± 19993.5 1370.5 ± 145.2 9324.8 ± 2453.4 95905.9 ± 22656.2 319.8 ± 48.3 2025.7 ± 534.7 22237.4 ± 3812.3 
RE (%) 85% 56% 58% 63% 43% 42% 94% 68% 71% 
ME (%) 103% 90% 93% 103% 94% 96% 121% 110% 110% 
PE (%) 87% 51% 54% 65% 40% 40% 114% 74% 79% 
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Table B-9 Method validation of TCVG, TCVC, and NAcTCVC in urine 
TCVG TCVC NAcTCVC 
Low Mid High Low Mid High Mid High 
Set 1 221.6 ± 20.2 1067.4 ± 267.5 11855.4 ± 2023.0 301.4 ± 52.3 2226.9 ± 533.1 25971.6 ± 4297.0 200.1 ± 57.9 2350.8 ± 342.3 
Set 2 196.3 ± 42.8 1349.8 ± 391.7 14389.5 ± 936.9 197.7 ± 25.8 2016.5 ± 550.8 22703.4 ± 895.4 210.9 ± 61.3 1846.0 ± 101.8 
Set 3 174.9 ± 49.4 1087.6 ± 165.5 10195.2 ± 2486.8 189.5 ± 35.2 1838.8 ± 336.0 18514.8 ± 3718.3 214.5 ± 54.0 1532.7 ± 243.6 
RE (%) 89% 81% 71% 96% 91% 82% 102% 83% 
ME (%) 89% 126% 121% 66% 91% 87% 105% 79% 
PE (%) 79% 102% 86% 63% 83% 71% 107% 65% 
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Table B-10 Levels of DCVG, DCVC, and NAcDCVC in liver, kidney, and serum of 
B6C3F1 mice treated with TCE (n=3/group). 
Liver Kidney Serum 
TCE 
(mg/kg) DCVG 
DCV
C 
NAcDCV
C DCVG DCVC 
NAcDCV
C 
DCV
G 
DCV
C 
NAcDCV
C 
24 *0.44 *1.3 *1.0 *0.59 10.8±3.7 *1.2 *0.15
2.9±0.
2 *1.2
240 3.4±1.2 *1.3 4.1±0.8 
†1.8±0.
6 8.5±3.3 *1.2
1.8±0.
4 
4.8±3.
1 3.6±0.4 
800 
65.7±19.
9 
6.4±0.
9 12.8±0.5 4.1±1.4 
34.2±10.
6 4.1±0.5 
4.4±0.
7 
8.7±1.
9 5.8±0.7 
Table B-11 Levels of DCVG, DCVC, and NAcDCVC in liver, kidney, and serum of 
20 CC mice treated with TCE (800 mg/kg). 
Strain Liver Kidney Serum 
DCVG DCVC NAcDCVC DCVG DCVC NAcDCVC DCVG DCVC NAcDCVC 
CC028/Geni
Unc 35.8 5.8 7.4 *0.6 33.2 †2.6 1.9 *0.3 †1.7 
CC027/Geni
Unc 76.3 *1.3 13.0 †2.7 *3.7 4.4 4.0 *0.3 4.1 
CC033/Geni
Unc 70.6 †1.9 6.6 †3.6 27.5 †3.8 5.2 3.0 †2.6 
CC030/Geni
Unc 33.1 †2.1 7.0 †3.1 20.0 7.8 2.0 †0.6 *1.2 
CC008/Geni
Unc 10.1 *1.3 *1.0 †1.8 55.0 *1.2 †0.8 *0.3 *1.2 
CC022/Geni
Unc 21.9 *1.3 4.2 †3.4 27.2 †3.4 1.0 *0.3 †1.9 
CC052/Geni
Unc 20.8 †3.3 †1.9 *0.6 *3.7 7.5 1.3 †1.4 †1.5 
CC056/Geni
Unc 32.0 *1.3 4.9 †2.2 31.9 5.7 2.5 *0.3 †2.2 
CC059/Tau
Unc 4.1 †2.0 †1.6 *0.6 *3.7 *1.2 *0.1 †1.1 *1.2 
CC037/Tau
Unc 75.2 †2.9 12.2 †2.0 27.5 10.8 4.5 †1.3 4.3 
CC055/Tau
Unc †2.7 †3.6 *1.0 *0.6 *3.7 *1.2 *0.1 †0.8 *1.2 
CC007/Unc 37.7 *1.3 7.1 †1.5 27.1 †2.6 1.4 *0.3 †2.0 
CC039/Unc 16.0 *1.3 †3.7 *0.6 *3.7 *1.2 1.2 *0.3 *1.2 
CC021/Unc 13.1 †2.4 8.6 †1.2 8.8 †3.0 1.3 *0.3 †2.3 
CC057/Unc 39.9 *1.3 7.6 †2.2 18.0 †2.7 1.6 †1.6 12.0 
CC036/Unc 4.6 †1.8 4.7 *0.6 *3.7 *1.2 †0.3 *0.3 *1.2 
CC035/Unc 12.3 †2.0 †1.8 *0.6 *3.7 *1.2 †0.8 *0.3 †3.2 
CC046/Unc 3.2 †2.5 *1.0 *0.6 *3.7 †3.2 †0.2 *0.3 *1.2 
CC047/Unc 27.9 *1.3 5.3 5.1 33.6 8.6 1.5 3.5 †2.6 
CC050/Unc 118.9 4.9 30.0 †2.8 11.0 11.4 
missing 
data 
missing 
data 
missing 
data 
* Levels are expressed as pmole/g tissue or mL serum. The data point is shown as ½
LOD if an analyte was non-detected. The background concentration of kidney DCVC
(3.7 pmole/g) is used if the measurement was below the background concentration.
† The values for levels was detectable but lower than LOQ.
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Table B-12 Inter-individual variability of tissue levels of DCVG, DCVC, and 
NAcDCVC in B6C3F1 mice and 20 CC mice (800 mg/kg TCE). 
DCVG 
B6C3F1 study 20 CC study 
Liver Kidney Serum Liver Kidney Serum 
Mean 65.7 6.3 4.4 32.8 1.9 1.7 
Median 63.1 6.5 4 24.9 1.8 1.3 
Std 19.9 1.3 0.7 30.7 1.3 1.4 
CV 30% 21% 15% 94% 68% 86% 
DCVC 
B6C3F1 study 20 CC study 
Liver Kidney Serum Liver Kidney Serum 
Mean 6.4 37.3 8.7 2.3 17.7 0.9 
Median 6.6 34 8.2 1.9 18 0.3 
Std 0.9 5.8 1.9 1.3 15.4 1 
CV 14% 16% 21% 55% 86% 112% 
NAcDCVC 
B6C3F1 study 20 CC study 
Liver Kidney Serum Liver Kidney Serum 
Mean 12.8 5.4 5.8 6.5 4.4 2.6 
Median 12.6 5.3 5.5 5.1 3.2 1.9 
Std 0.5 0.1 0.7 6.5 3.3 2.5 
CV 4% 3% 11% 100% 75% 96% 
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Table B-13 PCR primers used for genotyping CYP2E1 knockout and humanized 
transgenic mice 
Forward sequence Reverse sequence 
129S1/SvlmJ  
(125bp product) 
5'-AGT GTT CAC ACT 
GCA CCT GG-3' 
5'-CCT GGA ACA CAG 
GAA TGT CC-3' 
Cyp2e1(-/-)  
(280bp product) 
5'-CTT GGG TGG AGA 
GGC TAT TC-3' 
5'-AGG TGA GAT GAC 
AGG AGA TC-3' 
hCYP2E1  
(1746 bp product) 
5'-AGA TTC AGC GGT 
TCA TCA CC-3’ 
5'-AGG GCT GAG GTC 
GAT ATC CT-3’ 
hCYP2E1  
(400 bp product)* 
5'-AGA TTC AGC GGT 
TCA TCA CC-3' 
5'-GCC CTA ATC TTC TCA 
CAG GA-3' 
*This revised primer was used for genotyping the mice bred in Texas A&M Institute for
Genomic Medicine.
Table B-14 Number of mice used in TCE study 
Sex Male Female 
Strain 129S1/SvImJ Cyp2e1 (-/-) hCYP2E1 129S1/SvImJ Cyp2e1 (-/-) hCYP2E1 
Treatment TCE 
2h 4 4 2 3 3 3 
5h 4 4 4 4 4 4 
12h 4 3 2 3 3 3 
24h 3 4 3 3 4 4 
Treatment Vehicle 
5h 4 4 4 4 4 4 
Table B-15 Number of mice used in PCE study 
129S1/SvImJ Cyp2e1 (-/-) hCYP2E1 
Total Male Female Male Female Male Female 
V P V P V P V P V P V P 
July, 
2013 4 4 1 2 0 0 0 0 0 1 1 1 14 
July, 
2013 2 2 2 2 1 1 1 1 2 2 2 2 20 
October, 
2013 0 0 1 2 0 1 1 2 2 3 2 2 16 
January, 
2018 0 0 0 0 0 1 2 0 1 0 0 0 4 
March, 
2018 0 0 0 0 3 2 3 3 0 2 1 1 15 
NTK 6 6 3 4 4 4 6 4 3 5 4 4 53 
Total 6 6 4 6 4 5 7 6 5 8 6 6 69 
*V, vehicle group; P, PCE-treated group
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Table B-16 Area under the curve (AUC) of TCE and PCE metabolites in multiple tissues of 
male B6C3F1/J, C57BL/6J, and NZW/LacJ mice. The AUC values were calculated from 
model-predicted concentrations up to 36 hours based on trapezoidal rule.  
TCE treated mice PCE treated mice 
Serum C57BL/6J B6C3F1/J NZW/LacJ Serum C57BL/6J B6C3F1/J NZW/LacJ 
TCE 119.1 202.5 158.5 PCE 522.3 509.3 813.2 
TCA 2011 5175 8106 TCA 4219 3393 5799 
TCOH 1213 2101 2894 
DCVG 0.013 0.004 0.004 TCVG 0.08 0.05 0.09 
DCVC 0.021 0.016 0.016 TCVC 0.11 0.06 0.15 
NAcDCVC 0.014 0.009 0.010 NAcTCVC 0.50 0.14 0.33 
Liver C57BL/6J B6C3F1/J NZW/LacJ Liver C57BL/6J B6C3F1/J NZW/LacJ 
TCE 718.4 1379 809.7 PCE 3478 3140 3760 
TCA 1884 4195 6023 TCA 3701 3612 4951 
TCOH 1880 4877 4088 
DCVG 0.109 0.105 0.096 TCVG 0.54 0.59 1.22 
DCVC 0.045 0.047 0.030 TCVC 0.05 0.03 0.05 
NAcDCVC 0.083 0.063 0.050 NAcTCVC 0.79 0.36 0.87 
Kidney C57BL/6J B6C3F1/J NZW/LacJ Kidney C57BL/6J B6C3F1/J NZW/LacJ 
TCE 70.66 85.53 80.15 PCE 6180 4229 5993 
TCA 1470 2953 5606 TCA 3741 3072 6858 
TCOH 4729 8204 14922 
DCVG 0.041 0.032 0.047 TCVG 0.10 0.10 0.58 
DCVC 0.215 0.245 0.116 TCVC 0.56 0.58 1.59 
NAcDCVC 0.123 0.088 0.094 NAcTCVC 0.27 0.15 0.67 
Brain C57BL/6J B6C3F1/J NZW/LacJ Brain C57BL/6J B6C3F1/J NZW/LacJ 
TCE 287.1 569.8 532 PCE 1592 1961 2413 
TCA 3132 4101 4792 TCA 2572 2444 2743 
TCOH 711.6 1738 2545 
DCVG 0.121 0.111 0.114 TCVG 0.50 0.52 1.11 
DCVC 0.078 0.076 0.063 TCVC 0.10 0.08 0.10 
NAcDCVC 0.085 0.067 0.067 NAcTCVC 0.11 0.06 0.14 
Lung C57BL/6J B6C3F1/J NZW/LacJ Lung C57BL/6J B6C3F1/J NZW/LacJ 
TCE 776.7 1334 923.8 PCE 3788 3682 3860 
TCA 2396 5631 8657 TCA 4787 4271 6545 
TCOH 1647 2806 5612 
DCVG 0.065 0.052 0.062 TCVG 0.17 0.19 0.28 
DCVC 0.077 0.081 0.087 TCVC 0.15 0.11 0.15 
NAcDCVC 0.073 0.077 0.078 NAcTCVC 0.28 0.17 0.35 
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Table B-17 Inter-strain variability of TCE and PCE metabolites in multiple tissues 
of male B6C3F1/J, C57BL/6J, and NZW/LacJ mice. The values show the geometric 
standard deviations (GSD) of metabolite AUCs across strains. 
TCE-treated mice PCE-treated mice 
Serum 
TCE 1.30 PCE 1.30 
TCA 2.04 TCA 1.31 
TCOH 1.25 
DCVG 1.92 TCVG 1.32 
DCVC 1.16 TCVC 1.63 
NAcDCVC 1.26 NAcTCVC 1.91 
Liver 
TCE 1.42 PCE 1.09 
TCA 1.81 TCA 1.19 
TCOH 1.66 
DCVG 1.07 TCVG 1.57 
DCVC 1.28 TCVC 1.22 
NAcDCVC 1.29 NAcTCVC 1.64 
Kidney 
TCE 1.10 PCE 1.23 
TCA 1.95 TCA 1.52 
TCOH 1.78 
DCVG 1.21 TCVG 2.77 
DCVC 1.49 TCVC 1.81 
NAcDCVC 1.19 NAcTCVC 2.13 
Brain 
TCE 1.46 PCE 1.23 
TCA 1.24 TCA 1.06 
TCOH 1.92 
DCVG 1.04 TCVG 1.56 
DCVC 1.12 TCVC 1.12 
NAcDCVC 1.15 NAcTCVC 1.52 
Lung 
TCE 1.32 PCE 1.02 
TCA 1.92 TCA 1.25 
TCOH 1.85 
DCVG 1.12 TCVG 1.29 
DCVC 1.06 TCVC 1.19 
NAcDCVC 1.03 NAcTCVC 1.45 
